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Voor mijn liefsten: 





1O2 = singlet oxygen 
AAM  = alternatively activated macrophages 
AlPcS4 = Tetrasulfonated aluminum 
phthalocyanine 
APC = Antigen presenting cells 
ATCC = American Type Culture Collection 
ATP = Adenosine triphosphate 
BFU-E = Burst forming unit of erythrocytes 
BM = Bone marrow 
BVDV = Bovine viral diarrhoea virus 
CB = Cord blood 
cb = Cytochalasine B  
CBSC = Cord blood stem cells  
CFU = Colony forming unit 
CFU-GEM = Mixed CFU of granulocytes, 
monocytes and erythrocytes 
CFU-GM = CFU of granulocytes and 
monocytes 
CFU-Mk = CFU of megakaryocytes 
CPV = Canine parvovirus 
DAT = Direct gel agglutination test 
DIP = Dipyridamole  
DMMB = Dimethyl-methylene blue 
G- = gram negative 
G+ = gram positive 
GSH = reduced glutathione 
GvHD = Graft-versus-host disease 
Hb = Hemoglobin 
Hct = Hematocrit  
HBV = Hepatitis B virus 
HCV = Hepatitis C virus 
HES = Hydroxy-ethyl starch 
HIV = Human immunodeficiency virus  
HLA = Human leukocytes antigens 
HPC = Hematopoietic progenitor cells 
HTLV = Human T-lymphoma virus 
IAGT = Indirect Antiglobulin Test 
LPS = Lipopolysaccharide 
MB = Methylene blue 
MNC = Mononuclear cells 
MLR = Mixed lymphocytes reaction 
NaP = sodium phosphate buffer 
NAT = Nucleic acid test 
NHFTR = non-hemolytic febrile transfusion 
reactions 
PBS = Phosphate-buffered saline  
PC = Platelet concentrate 
PDT = Photodynamic treatment  
PHA = Phytohemagluttin  
PPV = Porcine parvovirus 
PRV = Pseudorabies virus 
RBC = Red blood cells  
RBCC = Red blood cell concentrate 
ROS = Reactive oxygen species 
SD = solvent/detergent 
SAG-M = Saline Adenine Glucose Mannitol 
T50 = half lifespan 
TCID50 = Tissue Culture Infectious Dose 
(50%) 
Tri-P(4) = mono-phenyl-tri-(N-methyl-4-
pyridyl)-porphyrin chloride  
VSV = Vesicular stomatitis virus 
WBC = White blood cells 
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1. BLOOD TRANSFUSION SAFETY 
Blood product safety is a major priority of blood suppliers. Transmission of viruses 
or other infectious agents can have deleterious effects for the transfused patients. 
To maximize the safety of blood products, various procedures are initiated 
starting as from the moment a person is willing to donate blood.1 
RECRUITMENT AND SELECTION OF VOLUNTEERS 
Before each blood donation, donors must fill a questionnaire as a control of good 
health and faithfulness. The questionnaire is meant to exclude high-risk behavior 
individuals, potential sick donors, and travelers to endemic areas for infections.  
Donors must be willing to give blood without any kind of remuneration. Almost all 
studies have shown that unpaid donors are safer than paid donors.2,3 Indeed, the 
latter failed more frequently than non-remunerated donors to mention illness or 
lifestyle involving risks.4 
SCREENING FOR INFECTION 
The presence of antigens or antibodies against Human Immunodeficiency virus 
(HIV) 1 and 2, Human T-lymphoma virus (HTLV) 1 and 2, Hepatitis C virus (HCV), 
Hepatitis B virus (HBV) and the presence of Treponema pallidum (Syphilis) is 
determined in donor blood samples. A major concern in the determination of 




infection is not detectable yet because the amount of either antibodies and/or 
antigens is below the detection limit. To shorten the window phase, more 
advanced techniques such as nucleic acid test (NAT) are used to detect the 
presence of viral genetic material from HIV, HCV5,6, West-Nile Virus (WNV; In 
North America)7,8 and HBV (Japan)9.  
Furthermore, besides these serological and molecular tests, additional 
precautions are taken. 
Plasma is kept in quarantine for at least 6 months until the donor, coming back for 
a new donation, is tested again for infection.10 If the donor is healthy and testing 
for infectious disease markers is negative, the plasma donation is released for 
transfusion. Platelet concentrates (PC) are cultured to detect bacterial 
contamination.11 
For cellular blood products that are destined to high-risk patients like severely 
immunocompromised patient, pregnant women, or neonates, detection of not 
routinely tested viruses such as Cytomegalovirus (CMV) and human B19 Parvo-
virus is performed to avoid, sometimes even fatal, transfusion complications.  
2. THE PERMANENT THREAT OF PATHOGEN CONTAMINATION   
A wide list of pathogens is permanently threatening the blood supply, whereas no 
screening test is available or readily available.  
New viruses or pathogens are emerging. Since the bird flu virus (H5N1) was 
discovered to be able to infect humans12, with fatal outcome in children and 
elders, increased attention was necessary to ensure the safety of the blood 
supply. Although it is not yet known if this virus can be transmitted through blood 
transfusion, travelers in regions where this virus spread out, were subjected to a 
temporarily deferral for at least 3 weeks as recommended by WHO.13,14 
Another example of an emerging virus is WNV, which emerged in 1999 for the 
first time in North America where it became endemic.15 In 2002, the virus was 
discovered to be transmitted through blood transfusion.16,17 Since 2003, routine 
detection for this virus was implemented for all blood donations in the USA.18,19 In 
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UK, the National Blood Service performs a test for this virus in donors who 
donates within 28 days of a visit to the USA or Canada.  In the Netherlands, such 
donors are temporarily suspended for donation during 60 days.  
Another potential danger for blood transfusion is prions. Prions are pathogenic 
proteins which can lead to Creutzfeldt-Jakob disease and its variant (CJD or 
vCJD).20. It is still unclear if prions are transmissible through blood transfusion.21,22 
Direct evidences were only obtained in animal experiments.23 In addition, no test 
is available to detect contamination of an individual with prions. To counterpart a 
potential epidemic, leukodepletion of blood components was implemented, as 
prions may be associated to leukocytes24; although this declaration was denied by 
other researchers.25 A deferral strategy was introduced to exclude blood donors 
who had received blood transfusion before 1980 or who resided in UK for longer 
than 6 months. 
New viruses are still discovered, thanks to advanced molecular techniques. 
SenV26, TTV27, and Hepatitis G virus28 were found to be transmissible through 
blood transfusion; however, no disease is associated with these infections.29 
HTLV-3 and HTLV-4 were recently discovered in rural Cameroon but it is not 
known yet if they can cause diseases.30 
People travel more, especially from western countries to developing countries 
where some diseases are endemic such as malaria-like diseases caused by 
infection with parasites Plasmodium or Babasia and Chagas disease caused by 
infection with parasite Trypanosoma cruzi. Infections with these pathogens are 
mostly asymptomatic, and blood donors which have journeyed in these regions 
are temporarily deferred for donations.31 However, a case of a very long 
incubation period before the appearance of detectable anti-Plasmodium 
antibodies was reported.32 Moreover, parasites carriers such as mosquitoes can 
be transported to other, non endemic-countries by plane, exposing airport 
workers to infection risks.33 
Besides the efforts made to minimize risks for virus and tropical parasite 




About 17-22% of all reported transfusion-related fatalities in USA were caused by 
transfusion of contaminated blood products with bacteria.34 The frequency of 
clinical apparent sepsis through transfusion amounts 1 in 15.000 platelet units34 
and 1 in 10.4 million red blood cell (RBC) units35. Only PCs are cultured for bacteria 
but the standard techniques available to detect the presence of bacteria last 
several days. If the post-donation cultured sample is negative, PC can be released 
with the mention “negative to date”. However, if the cultured sample appeared to 
be positive after that time, hospital employees are informed of the bacterial 
contamination and asked to inform about transfusion reactions. In addition, the 
red blood cell concentrate (RBCC) originated from the same donor is recalled and 
discarded.  
However, this strategy cannot completely prevent the transfusion of a 
contaminated product and served rather to determine the frequency of bacterial 
contamination in related blood products. Other attempts to reduce 
contamination by diversion of the first 20 ml of blood withdrawal and 
improvement of skin disinfection at time of donation have been introduced. As 
the majority of contaminating bacteria were shown to originate from skin flora36, 
this new regulation has been shown to reduce the frequency of bacterial 
contaminated blood products.37 
In summary, stringent selection of donors, deferral strategies and the use 
of highly sensitive tests make that blood transfusion has never been so safe. In 
industrialized countries, residual risks of infection through blood transfusion 
amount lower than 1 in 205.000 for HBV, 1 in 270.000 units for HCV and 1 in 3.1 
million units for HIV, and almost inexistent for HTLV and Treponema pallidum.38-40 
However, the safety of blood products is not only challenged by the well known 
viral infections mentioned above, but also by increased donor travel, patients 
health conditions, and the time of infection of the blood donor. Emerging 
pathogens raise the concern as tests are either not available or supplementary 
tests must be required to ensure a pathogen-free product for high-risk patients. 
Infection can develop in an unexpected way (long incubation period). Bacterial 
contamination tests last too long. Considering the wide range of pathogens, it 
may be unrealistic to implement test for each of them. Increased costs and time 
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consuming leading to longer storage of labile blood cells prior to release may have 
enormous consequences on the blood supply. Finally, it is clear that, even though 
blood transfusions are presently considered to be very safe, continuous efforts 
are necessary to keep it safe. 
3. UMBILICAL CORD BLOOD: A PARTICULAR BLOOD PRODUCT 
Umbilical cord blood cells can be used for hematopoietic stem cell transplantation 
and tissue engineering e.g. megakaryocyte and RBC expansion. 
Normally, during the gestation, placenta acts as a filter that protects the fetus 
from opportunistic infections. That is why cord blood is in principle considered as 
free from infections.41 However, this filter does not always work perfectly and 
contamination from mother to child occurs.42-47 
To ensure the safety of cord blood transplants, routine viral detection is 
performed in maternal blood. Tests for the detection of HIV1/2, HCV, HBV, 
HTLV1/2, Treponema pallidum are standard. A recall after 6 months helps to 
determine if the umbilical cord blood donor (the baby) has not developed any 
congenital diseases [source Eurocord]. A major problem with umbilical cord blood 
donation is the high rate of bacterial contamination. Contamination takes 
principally place at delivery and during the cord blood collection. Depending on 
the sample size and the method of testing, up to 13% of cord blood stem cell 
(CBSC) products have been found to be positive in bacterial cultures.48,49 No case 
of sepsis or bacterial contamination related complications were reported after 
stem cell transplantation. This is probably due to the low bacteria titers (1-10 
CFU/ml) contaminating cord blood product. As cord blood products are stored at 
very low temperature (-190°) until transplantation purposes, bacteria cannot 
grow to clinically significant levels. However, bacterial contamination of cord 
blood products may limit expansion protocols. Cord blood hematopoietic 
progenitor cells culture and expansion may create conditions in which low 
numbers of contaminating bacteria may reach levels of clinical significance, 




risks of infection. Therefore for such purposes, pathogen-free cord blood products 
are required.  
Efforts to minimize the risks of bacterial contamination, for example by stringent 
disinfection and intensive monitoring of clean areas, did not reduce the rate of 
microbial contamination.50 In addition, the addition of antibiotics in vitro 
appeared to be unsuccessful and gave a new opportunity for contamination.51 In 
general, the use of antibiotics is preferably avoided, considering the development 
of bacteria resistance to this kind of antimicrobial agents.52 Recently, the FDA 
guidelines and Netcord FACT Standards requested the release of pathogen-free 
CBSC products for unrelated transplantation.53 In case of contamination, the 
product should be discarded. This may be a problem in case the cord blood is 
from a related donor, intended for transplantation e.g. to a diseased sibling and 
for patients from ethnic minorities. Indeed, the cord blood bank has an advantage 
on bone marrow donations because it may help to reduce the shortage in stem 
cell products for non-Caucasian patients. Mothers originating from immigrant 
populations are easily reachable through regular maternity controls whereas 
those persons are largely less represented among blood and bone marrow 
donation institutions. Some of the cord blood donations from ethnic minorities 
may have a particular HLA typing. The discard strategy because of contamination 
may lead to the loose of these valuable products. As for common blood products, 
pathogen inactivation may represent an approach to circumvent the problem of 
microbial contamination.  
4. PATHOGEN INACTIVATION  
Since pathogens involved in transfusion-transmitted infection are very 
heterogeneous, a non-specific approach of inactivation of a broad range of 
pathogens would be desired.  The ideal method to ensure the production of 
pathogen-free blood products should be a method that inactivates at once a 
broad range of pathogens in blood products. Such method of decontamination is 
commonly but often wrongly referred to as sterilisation. Sterilisation is a process 
that destroys or removes all microorganisms (pathogenic or not) from an object or 
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a solution. A sterilized item cannot support life in any form. Despite platelets and 
RBCs do not contain a nucleus and thus are not able to reproduce themselves, 
they anyway have an active respiratory metabolism thereby they are living cells, 
forming the essential therapeutic components of the blood products. Treatment 
of cellular blood products to inactivate pathogens must be applied in such a way 
that the therapeutic effect of the blood cells such as platelets and RBCs remain 
intact. Therefore, the common sterilization procedures are not suitable for PC and 
RBCC. However, pathogen inactivation procedures that will have a broad 
antimicrobial activity while preserving all blood components will represent a 
proactive approach to blood safety. The challenge of pathogen inactivation is to 
reduce maximally the greatest number of potential pathogens in blood without 
significantly compromising the cellular or protein constituents or introducing 
some new toxicity, carcinogenicity, or teratogenicity.54 
PRINCIPLES OF PATHOGEN INACTIVATION TECHNIQUES 
I. METHODS OF EVALUATION 
The key requirement in the evaluation of the efficacy of pathogen inactivation 
strategies is to show that the procedure is effective in reducing the risk of 
infection by pathogens.  
Potential infectivity is determined by several measures. Genomic equivalents refer 
to the number of viral particles detected by molecular techniques. The tissue 
culture infectious dose (50%) TCID50 refers to the dose of viral particles in a tissue 
culture assay capable of infecting 50% of susceptible cells or animals. The term 
TCID50 log10 reduction is usually used to define the degree of pathogen reduction. 
Although the “acceptable” log10 reduction number for a given organism is not 
standardized, experience suggests the fewer than 4 log reductions may be 
insufficient and greater than 6 log10 reduction is ordinarily sufficient.
54 However, 
in practice a 6 log10 reduction order is not always possible to demonstrate 
because of the limitations in inocula for some specimens; thereby a maximal of 5 
log10 reduction can be demonstrated. As no all conceivable organisms can be 




pathogens. Model viruses are used in place of pathogens that cannot be cultured 















Duck Hepatitis B virus 
(DHBV) 
Hepadnaviridae Lipid-env.  
RNA 
40-45 HBV 
Bovine viral diarrhorea 
virus (BVDV) 




Porcine Parvovirus (PPV) 








Rhabdoviridae Lipid-env.  
RNA 
100 HIV 
 Table 1: Viruses, their properties and their use as model 
II. CHEMICAL TREATMENTS 
The combination of organic solvent and detergent (SD) is widely used for 
pathogen inactivation. The combination most often used is TNBP (tri-(n-butyl)-
phosphate) with Triton-X100.55  TNBP acts as an organic solvent which removes 
lipids from the membranes, while Triton X-100 is a non-ionic detergent which 
stabilizes TNBP and disrupts lipid bilayers for easier extraction of lipids. Solvent 
and detergent must be removed because the chemical reaction is non-selective. 
The detergent keeps the lipids from the membranes in suspension in order to be 
removed before the final product is transfused.  
Lipid-envelop viruses as HIV, HBV and HCV or bacteria are sensitive to this 
treatment and are inactivated in an irreversible way. Non-lipid enveloped viruses 
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like Hepatitis A virus (HAV) and human B19 parvo-virus are insensitive to the SD-
treatment. This chemical treatment is only suitable for pathogen inactivation in 
plasma products. As the SD treatment disintegrates plasma membranes, it is not 
suitable for pathogen inactivation of cellular blood components. Therefore, 
alternative methods to inactivate pathogens without affecting the therapeutic 
blood cells were developed. For the treatment of RBC, Pen 110 and Frangible 
Anchor Linker Effector compounds S-303 are under investigation. 
Pen 110 is an alkylating ethyleneamine oligomer of low-molecular weight, highly 
water-soluble, and positively charged, diffusing readily through cell membranes 
and having a high selectivity for nucleic acid guanine bases. The disruption of 
nucleic acid replication forms the biochemical basis for pathogen reduction by the 
Inactine Pen 110 process.56,57 Pen 110 is capable of inactivating a broad spectrum 
of viruses, bacteria, protozoa, and mycoplasma in RBCC56,58-62 RBC membrane 
integrity seems to be maintained in Pen 110-treated RBCs. Hemolysis was less 
than 1% after 42 days of storage at 4°C. In vivo RBC recovery after autologous 
transfusion of treated RBCs in healthy subjects was comparable with the 
untreated control group.62 Alteration of RBC surface antigens was not detected 
and neoantigens formation was not identified during subsequent testing. 
However, phase III clinical trials were halted when antibody formation was 
reported in repeatedly transfused patients. All other clinical studies have been 
suspended.54 
S-303 (N,N-bis(2-chloroethyl)-2-aminoehtyl-3-[(acridin-9-yl)amino] propionate 
dihydrochloride) is an alkylating agent derived from a quinacrine mustard and 
belongs to a class of compounds called frangible anchor-linked-effectors (FRALE). 
The molecule consists of three components: an acridine ring, a planar compound 
that reversibly intercalates with double-stranded and single-stranded DNA and 
RNA; a bi-functional alkylating moiety that crosslinks DNA and RNA strands; and 
an alkyl ester linker that hydrolyses when exposed to neutral pH.63 The compound 
is rapidly taken up by cells, bacteria and viruses. S-303 molecule becomes active 
as a result of pH change attendant upon admixture with the blood component 
and induces DNA and RNA cross-linkage inhibiting pathogen replication and 




glutathione quenching agent. The alkyl ester linker spontaneously degrades 
releasing S-303 that diffuses outside of cell and is absorbed by an appropriate 
compound.64 S-303 binds to other proteins and cell membranes as well as to 
nucleic acids, and up to 20% can potentially remain bound to the surface or 
contained within the RBCs.54 S-303 has demonstrated pathogen inactivation of a 
wide range of viruses, bacteria, and protozoa.65 No unexpected toxicities have 
been described. Assays for RBC storage lesions (extracellular potassium (K+) 
leakage, plasma free hemoglobin (Hb), adenosine triphosphate (ATP), 2,3-
diphosphoglycerate (2-3 DPG), glucose, and lactate) are comparable to control 
RBCs. The RBC function appears to be normal, and in-vivo survival studies with 
radioactive chromate labeling comply with the required standard of at least 75% 
recovery at 24 hours. However, as seen with Inactine Pen110 treatment, phase III 
clinical trials were halted when antibodies to residual RBC bound S-303 were 
discovered in 2 subjects.66 Additional studies have revealed that 1% of patients 
and healthy donors that had never been exposed to S-303 had naturally occurring 
antibodies that reacted with S-303 treated RBC. Modifications have been made to 
the S-303 treatment process to reduce the amount of RBC bound S-303 in 
attempts to eliminate immunoreactivity and immunogenicity. Preliminary finding 
indicate that RBCs from the modified S-303 treatment process were crossmatch-
compatible with the anti-S-303 antibodies formed after exposure to the original S-
303 formulation as well as the anti– S-303 antibodies found in the patients and 
donors never exposed to S-303. The antibodies do not appear to impair RBC 
survival or to pose any clinical problem.67  
PHOTOCHEMICAL TREATMENT  
In photochemical treatment, light is used as a source of energy for intermolecular 
reactions, which consists of a reaction between the light-excited molecule and a 
different non-excited molecule. A good example of intermolecular reaction is the 
photoaddition of furocoumarins to pyrimidines.68 By the use of psoralens (family 
of furocoumarins), photochemical treatment can be applied in cellular blood 
components. Psoralens are molecules that can intercalate into DNA base pairs. 
Upon activation by UVA-light (320 – 400 nm), formation either of monofunctional 
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adducts (single strand) or bifunctional adducts (interstrand cross-links) with DNA 
takes place. These adducts block the replication and transcription machinery and 
cause cell death.69  
INTERCEPT, the S-59 amotosalen system, can currently be applied in PC.70 It has 
been evaluated in clinical trials which, albeit not unequivocally, demonstrated 
comparable platelet transfusion requirements and posttransfusion platelet 
increments between photochemically treated platelets and control platelets.71 
Application in plasma is currently under investigation.70 Functional quality of 
plasma proteins (factor VII, factor VIII, von Willebrand factors, metalloprotease, 
fibrinogen, protein C, protein S, and antithrombin) decreased slightly but  were 
considered still sufficient for therapeutic use.72 Antibodies against neo-antigens 
have not been detected thus far. Clinical trials are ongoing.54 
Platelet and plasma are substantially transparent above 300 nm, but hemoglobin 
present in RBC has several absorption bands in the range 300-630 nm. Therefore 
photoactivated compounds for use in RBCC should exhibit significant absorption 
outside this spectrum (i.e. at longer wavelengths) and for this reason psoralens 
like S-59 cannot be used for pathogen inactivation in RBCC treatment.  
PHOTODYNAMIC TREATMENT 
A special form of photochemical reactions is photosensitization.  Photosensitized 
reactions can occur when a mixture of at least two compounds is irradiated: one 
compound absorbs the light but the other is chemically altered. The term 
photodynamic refers to oxygen-requiring photosensitized reactions in biological 
systems.73  
In photodynamic reactions, oxygen (O2) acts as an intermediate transporting 
electrons or energy between the light-absorbing molecule and the altered 
molecule.73 Figure 1 shows a schematic overview of the successive reactions 
involved in a photodynamic process. The light absorbing molecule is referred to as 
the photosensitizer (P). The altered molecule is termed a substrate (S). After 
absorption of light, the photosensitizer is transformed from its singlet electronic 
ground state (1P0) to an electronically excited state (




intersystem crossing, the short-lived singlet excited stated is converted to the 
triplet excited state (3P*) (equation 2) which has lower energy than the singlet 
excited state, but the lifetime of the triplet excited state is much longer (typically 
> 500 ns).74 
There are two mechanisms by which the triplet excited state photosensitizer can 
react with biomolecules: type I and type II reactions.  
In a type I reaction, 3P* can either abstract an electron from, or donate an 
electron to a substrate molecule (S). This reaction produces radical forms of both 
the photosensitizer and the substrate (equations 3). The substrate radicals (S1
- ) 
can react with other oxygen, to give oxidized forms of the substrate (equation 4). 
The photosensitizer radicals (P+ ) can react with oxygen to give superoxide radical 
(O2
- ; equation 5) which can rapidly oxidize cellular targets (S2) (equation 6).  
Type II reaction can occur when the energy difference between the triplet excited 
state and the ground state of the photosensitizer exceeds 94.5 kJ/mol.  3P* can 
then directly transfer its energy to ground state oxygen (3O2), thereby generating 
the highly reactive singlet oxygen (1O2) (equation 7). 
The photosensitizer returns to its ground state without being chemically altered 
and is able to repeat the process of energy transfer to oxygen many times. Singlet 
oxygen can react with a variety of cellular components such as amino acids 
(cysteine, histidine, tryptophan, tyrosine and methionine), nucleoside (mainly 
guanine) and unsaturated lipids.75 Because of the short lifetime of 1O2, damages 
are induced at, or close to, the sites where the photosensitizer is activated. 
Figure 1: Schema of type I and type II photodynamic reactions 
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5. PHOTOSENSITIZERS USED FOR PATHOGEN INACTIVATION OF RBC  
OPTIMAL PHOTOSENSITIZER PROPERTIES 
Photosensitizers used for pathogen inactivation should have a high selectivity for 
the pathogens so that the pathogens are inactivated without altering the quality 
of cells. For RBC containing blood products, the sensitizer should absorb light of a 
long wavelength (> 600 nm) to avoid absorption by hemoglobin. An extra 
advantage of the use of long wavelength light is the greater penetration of the 
light in tissues and cell containing suspensions. During the past 15 years, a 
number of photosensitizers have been studied for their ability to inactivate 
pathogens in cellular blood products.  
PHENOTHIAZINES 
Phenothiazinium photosensitizers are efficient producers of singlet oxygen. The 
Phenothiazinium dye Methylene Blue (MB) is positively charged and planar 
molecule with affinity for nucleic acids and the surfaces of viruses.76,77 Upon UV 
light exposure, most enveloped viruses are inactivated; however, non-enveloped 
viruses are more resistant to treatment. As the photosensitizer is easily reduced 
by biological systems to a neutral species MB has a low antibacterial and 
antiprotozoa activity.78,79 Because of its virucidal activities, MB has been used in 
Europe for approximately 15 years for pathogen inactivation of single unit plasma. 
Millions of MB single units of plasma have been transfused without unexpected 
adverse outcome.80  
Methylation of this dye results in Di-Methyl-Methylene Blue (DMMB) which is 
considerably more bactericidal in-vitro than MB and less susceptible to 
reduction.77 DMMB (Fig.3) is a more hydrophobic dye with a permanent positive 
charge and can pass through the cellular plasma membrane.81 The photosensitizer 
intercalates into DNA82 and is a highly efficient photobactericide against a wide 
range of bacteria and against both extra- and intracellular viruses and non-
enveloped species upon light activation at wavelength >600 nm.83,84 However, up 




for the photoinduced hemolysis.76. The use of quinacrine which inhibits 
photosensitizer binding to RBC membranes was shown to enhance VSV 
inactivation and to diminish hemolysis of photo-treated RBCs.82 However, DMMB 
exhibited (dark) toxicity85 and post-treatment removal of the molecules e.g. by 
filtration is required before transfusion.  
RIBOFLAVIN 
Riboflavin is a natural compound, a proven and accepted non toxic agent known 
as vitamin B2 an essential dietary requirement in humans. The Riboflavin 
molecule is a polycyclic planar molecule with a sugar side chain that confers water 
solubility. The planar portion of the molecule is capable of intercalating into the 
bases of DNA and RNA of pathogens, and absorbing visible light (max absorption 
at 475 nm and 444 nm) or UV light. Light-activated, intercalated riboflavin oxidizes 
guanine in nucleic acids, a process preventing replication of the pathogen’s 
genome.86 Especially type I reaction (formation of radicals through electron 
transfer) are involved in the photoreaction of Riboflavin.87  
Upon light activation, the photosensitizer breaks down to secondary 
photosensitizers Lumichrome and Lumiflavin.88,89 The advantages of these 
photoproducts are that they are also naturally generated in situ by light 
transmitted through the skin and eyes and are naturally excreted by the human 
body.90 
The particularity of Riboflavin is that this photosensitizer is sensitive to UV light 
and blue light (250 - 500 nm) and not to red light (> 600 nm), therefore Riboflavin 
seems not very, suitable for pathogen inactivation of RBCC. In contrast, Riboflavin 
was shown to be effective in inactivating pathogens in this blood product. A 
reduction of 4 to 7 log10 of extra- and intracellular HIV, BVDV, and PRV was 
obtained after treatment with Riboflavin. The non-enveloped PPV which has a 
tight-capsid, was more resistant. The antibacterial efficacy of Riboflavin was 
demonstrated with the inactivation of S. aureus, E. coli, K. pneumoniae, and Y. 
enterocolitica.91 However, for this, it was necessary to reduce the RBCC 
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hematocrit to 30-37% instead of normally used 60% before the suspension was 
subjected to visible light (  = 450 nm).64,86,91 92,93 
PORPHYRINS 
Porphyrins are a class of deeply colored red or purple pigments, of natural or 
synthetic origin, which vary in their substituent around the same basic skeleton. 
The latter is an aromatic macrocyclic ring consisting of four pyrrole rings, linked 
together by four methane bridges (Fig.2). Porphyrins are probably the most 
important class of compounds in biological systems because of their central role 
in photosynthesis, biological oxidation and reduction, and oxygen transport.74,94  
The interest for porphyrins in clinical use rose when a mixture of porphyrin, called 
Hematoporphyrin derivatives (HpD), and later a purified form of HpD known as 
Photofrin was found to localize in tumour cells, making it useful in detecting and 
treating cancers.95-97To improve therapies and diminish side effects, in particularly 
long lasting skin photosensitivity, the development of new photosensitizers was 
necessary. In photodynamic treatment of cancer, red light (>600 nm) is usually 
used because long wavelength enter deeper in tissue. Since porphyrins have only 
a small absorption band in this region, research was focused on the synthesis of 
new photosensitizers with a strong absorption in the red.98 This resulted to a 
second generation of photosensitizers, among which phthalocyanines and meso-
substituted porphyrins appeared to be promising for RBCC decontamination. 
 





Phthalocyanines are porphyrin derivatives with an increased aromatic structure. 
They absorb intensively in the visible region with a maximum absorption around 
670-680 nm and to a lesser extend in the near-ultraviolet region (see spectrum, 
Fig.4).74 Therefore phthalocyanines are suitable for application in RBCC. The most 
effective molecules in inactivating pathogens were silicon phthalocyanine (Pc4) 
and chloro-aluminium sulfonated phthalocyanine (AlPcS4) (Fig.3).  
Pc4 is a hydrophobic molecule which targets the lipid envelope of pathogens. 
Formulated into liposomes to maximize delivery into viruses with minimum 
distribution to RBCs, Pc4 was able to inactivate HIV-1 is three forms:  cell-free 
virus, cell-associated virus and virus in latency infected cells, and to inactivate 
both enveloped and non-enveloped viruses.99,100 AlPcS4 is a water-soluble 
derivative which is efficient in cell-free lipid-enveloped virus inactivation, but not 
capable of inactivating intracellular virus.101,102 However, with both 
phthalocyanines RBC damage was apparent which required the addition of 
antioxidant such as vitamin E or a mixture of antioxidants containing either 
tocopherol succinate and carnitine or Trolox, Mannitol and glutathione to 
diminish the extensive hemolysis, K+ efflux and binding of IgG to phototreated 
RBCs.100,103-105 
II. Meso-substituted porphyrins 
The growing interest in the meso-substituted porphyrins began when besides 
their photosensitizing properties106, their capacity to intercalate into DNA was 
discovered.107 Their potential antimicrobial effect was shown by Merchat et 
al.108,109; especially cationic meso-substituted porphyrin were able to inactivate 
both Gram-positive and Gram-negative bacteria. 
Meso-substituted porphyrins absorb radiant energy intensively in the UV region, 
at their Soret band (400-410 nm) and to a lesser extent in the long visible bands 
called the Q bands (580 – 650 nm) (see spectrum, Fig.4).74 Again their capacity to 
absorb red light make these porphyrins suitable for application in RBCC. 
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In this thesis, 5 different meso-substituted porphyrins, from which the most 
powerful was the mono-phenyl-tri-(N-methyl-4-pyridyl)-porphyrin chloride (Tri-


































Figure 4. Absorption spectrum in Methanol of Hemoglobin and photosensitizers Tri-
P(4) and AlPcS4. 
 
6. CURRENT STATUS OF PATHOGEN INACTIVATION OF RBC 
Many different techniques were studied to inactivate microorganisms in RBCC. 
Most of the treatments are able to induce a considerable reduction of viable 
pathogens. However, too much damage to the RBCs, such as hemolysis, RBC 
aggregation105, K+ leakage, enhanced transbilayer mobility of lipids110 and IgG 
binding111 are induced by pathogen inactivation techniques, especially the one 
based on the use of light. To reduce the damage to the RBCs, various antioxidants 
had to be added to the RBC suspension before treatment.100,104,105 Such additives 
may have side-effects and may have to be removed before transfusion.  
Besides the direct damage to RBCs, several treatments have shown to induce 
antibodies against either the agent added to the suspension or to the treated 
RBCs.  Despite encouraging in-vitro results concerning the efficacy of S-303 and 
P110 treatments to inactivate a broad spectrum of pathogens while preserving in-
vitro RBC qualities (Hb, ATP, 2-3 DPG level and storage time) and in-vivo survival, 
unexpected results in clinical trials showed up which resulted to their suspension. 
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The future of both S-303 and PEN110 as pathogen inactivation methods for RBCC 
is uncertain until the immunogenicity is understood and resolved.54  For 
Riboflavin, extended animal studies are required to ensure the absence of 
neoantigenicity to Riboflavin and its breakdown product before proceeding 
clinical studies.64 
7. OUTLINE OF THIS THESIS 
This thesis describes different studies regarding the photo-decontamination of 
RBC and Cord-blood-derived stem cell products. Besides the inactivation of 
pathogens, major efforts were taken to preserve the therapeutic quality of the 
treated blood products. By using the photosensitizer DMMB, we tried to identify 
the target for RBC damage induced by photodynamic treatment (PDT). Based on 
this, we evaluated the possibility to protect the RBCs against photo-damage 
without reducing the virucidal capacity of the photo-treatment (Chapters 2 and 
3). A series of meso-substituted porphyrins were tested for their potential to 
inactivate viruses in RBCC. From the series, one photosensitizer Tri-P(4) stood out 
as a very promising compound to be applied in pathogen inactivation in RBCC  
(Chapters 4 and 5). Photosensitization with Tri-P(4) was further tested in Cord-
blood derived stem cell products (Chapter 6). Since the treatment did not seem to 
affect the viability of leukocytes, the potential immunomodulatory effect on 
leukocytes was investigated (Chapter 7).  
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Potassium (K+) leakage is one of the first events that appear after 
photosensitization of RBCs. This event may subsequently lead to colloid osmotic 
hemolysis. The aim of our study was to determine which photodynamically 
induced damage is responsible for increased membrane cation permeability. This 
was done by studying the effect of DMMB-mediated PDT on different membrane 
transport systems. Inhibition of band 3 activity (anion transport) showed a 
comparable light dose dependency as PDT-induced K+ leakage, whereas glycerol 
transport activity was inhibited only at higher light doses. Dipyridamole (DIP), an 
inhibitor of anion transport, protects band 3 against DMMB-induced damage, and 
prevents the increase in cation permeability of the membrane. Damage to 
glycerol transport was partially reduced when PDT was performed in the presence 
of DIP. Because DIP has no affinity for the glycerol transporter, this protection 
might result from the reduced photodamage to band 3. These results support the 
hypothesis that band 3 might be involved in glycerol transport. Glucose transport 
was not affected by DMMB-mediated PDT. The present results are the first to 
show a causal relationship between DMMB-mediated photodamage to band 3 
and increased cation permeability of RBCs.  
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INTRODUCTION 
In spite of continuing improvement in laboratory tests to decrease the window 
phase and so to reduce the possibility of viral transmission, viral and bacterial 
contamination remains a major problem of the blood transfusion services.1 The 
increasing costs cannot be met by many countries outside the western world. It is 
therefore necessary to investigate new strategies to improve the safety of blood 
component transfusion. Inactivation of the infectious pathogens may present an 
alternative method of ensuring pathogen-free blood. A heating or solvent–
detergent treatment is already included in the processing of plasma products. 
These approaches have been shown to reduce the risk of virus transmission2,3; 
however, because of the fragility of the cells, they are not applicable to cellular 
blood products. The use of PDT as a method for pathogen inactivation in cellular 
blood products such as RBCC is being explored because various lipid-enveloped 
and non-enveloped viruses, gram-positive and gram-negative bacteria can be 
inactivated.4-9 PDT is based on the use of light-activated agents, photosensitizers. 
The photosensitizers studied for pathogen inactivation in RBCC usually belong to 
the group of phthalocyanines10 or to the group of phenothiazine dyes, such as 
MB11 and DMMB.12 On light activation, these molecules generate reactive oxygen 
species such as singlet oxygen (1O2), which are able to react rapidly with 
substrates present in their environment. Pathogens can be inactivated completely 
by PDT, but all photosensitizers tested so far also induce damage to RBCs.13-17 A 
better understanding of the molecular mechanisms behind photodynamically 
induced damage is needed to improve the selectivity of the photodynamic 
decontamination technique and to reduce, or if possible to avoid, damage to 
RBCs. Increased permeability of the membrane to cations, as measured by K+ 
leakage, is one of the first events that appear after photosensitization of RBCs. It 
is believed that this increased permeability will lead ultimately to colloid 
osmotic.9,14-17 It is as yet unclear which photodynamically induced damage is 
responsible for the increased membrane permeability. Dubbelman et al.18 have 
shown that inhibition of several carrier-mediated transport systems for glucose, 
glycerol and sulfate precedes K+ leakage after protoporphyrin-mediated PDT. 




has been suggested that hemolysis results from damage to the anion transport 
protein of the RBC, band 3.19 Recently, VanSteveninck et al. 20  have shown that 
the band 3 ligand dipyridamole (DIP) protects RBCs against DMMB-mediated PDT. 
This protection was selective for RBCs; DIP had no effect on the virucidal efficacy 
of DMMB.  The aim of the present study was to gain a better insight into the 
molecular mechanisms behind DMMB-mediated photodynamically induced K+ 
leakage in RBCs. As it is likely that damage to a membrane-spanning protein could 
be involved in K+ leakage, the kinetics of photodynamically induced K+ leakage and 
inhibition of carrier-mediated transport of glucose, glycerol and sulfate were 
compared. Because DIP is known to protect against DMMB-mediated K+ leakage, 
the effect of DIP on the photoinhibition of the various transport systems was also 
investigated. Based on both the kinetics of inhibition and the effect of DIP, an 
attempt was made to identify the critical target for DMMB induced K+ leakage. 
MATERIALS AND METHODS 
MATERIALS 
RBCC were provided by the Red Cross Blood Bank Leiden-Haaglanden (Leiden, The 
Netherlands) after consent of human volunteer donors. The erythrocytes were 
centrifuged shortly after collection, washed three times with phosphate-buffered 
saline (PBS) containing 30 mM sucrose and resuspended at 10% hematocrit (Hct) 
in the same buffer. Sucrose was added to prevent photohemolysis.21 DMMB was 
obtained from Sigma-Aldrich, Zwijndrecht, the Netherlands. Stock solutions of 1 
mM were made in 50 mM sodium phosphate buffer (NaP), pH 7.4, and stored at 
4°C. DIP (2,6-bis(diethanolamino)-4,8-dipiperidino-[5,4-d] pyrimidine) (Sigma-
Aldrich) was stored as a 200 mM stock solution in dimethylsulfoxide (DMSO) at 
4°C. Sodium [35S] sulfate (Na2
35SO4) and D-[U-14C-glucose] were obtained from 
Amersham, ’s-Hertogenbosch, the Netherlands. All other chemicals were also 
purchased from Sigma-Aldrich. 
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PHOTODYNAMIC TREATMENT 
Illumination was performed with a 300 W halogen lamp (Philips, Brussel, 
Belgium). The light passed a water and red filter to transmit only light with  
above 600 nm and to avoid heating of the sample. RBC suspensions were 
illuminated in 3 cm diameter culture dishes (Greiner, Alphen a/d Rijn, the 
Netherlands) containing 1 mL of RBC suspension (10% Hct). Irradiance was 10 
mW/cm2, as measured with an IL400A photometer equipped with an SEL033/F/U 
detector (International Light, Newbury, MA). 
RBC suspensions were incubated with 100 μM DIP in the dark. After 5 min, 15 μM 
DMMB was added to the suspension. After another 5 min of incubation in the 
dark, illumination was started. All treatments were performed at a constant 
temperature of 20°C under continuous shaking (150 cycles/min). In control 
experiments, the same volumes of DMSO and NaP were added, without DIP and 
DMMB, respectively. These samples were illuminated as described previously.  
POTASSIUM LEAKAGE AND HEMOLYSIS 
K+ leakage from RBCs was determined immediately after illumination, by means of 
a flame photometer (Clinical Flame Photometer 410C; Corning, Halstead, UK). 
Hemolysis was determined by measuring the optical density of the supernatant at 
540 nm using a Novaspec II spectrophotometer (Pharmacia Biotech, Weesp, the 
Netherlands). Both K+ and Hb release were expressed as a percentage of the total 
efflux evoked by lysis of the cells in distilled water.  
BAND 3 ACTIVITY 
Band 3 activity was measured by the influx of Na2
35SO4 as described previously.22 
Briefly, after PDT, cells were centrifuged and resuspended (10% Hct) in PBS plus 1 
mM Na2SO4. The suspensions were incubated with 0.5 μCi/mL Na2
35SO4 at 37°C. 
After 0, 10, 20 and 30 min of incubation, samples were taken and washed twice 
with PBS to remove free Na2
35SO4. After precipitating the Hb with 5% 
trichloroacetic acid, radioactivity in the cells was determined by means of liquid 




Band 3 activity of PDT-treated cells is expressed as percentage of control (cells 
without DIP or DMMB). Because DIP inhibits band 3 activity strongly, it must be 
removed before anion uptake can be measured. Therefore, cells incubated with 
DIP were centrifuged and resuspended to a 2% Hct solution in PBS containing 30 
mM sucrose. After overnight incubation at 4°C, the cells were washed twice and 
resuspended in PBS plus 1 mM Na2SO4. Band 3 activity was determined as 
described previously.  
GLUCOSE TRANSPORT 
Efflux of glucose was measured as described by Harris23 and Sen and Widdas24, 
with slight modifications. After illumination, cells were resuspended in buffer 
containing 135 mM NaCl, 10 mM KCl, 10 mM Tris and 100 mM glucose 
(Trisbuffered saline [TBS]–glucose), pH 7.4, at 10 % Hct. Cells were loaded with 
0.25 μCi/mL D-[U-14C-glucose] for 5 min at room temperature. The labeled cells 
were washed twice with TBS–glucose to remove free 14C-glucose. After 
resuspension of the 14C-glucose–loaded cells in 180 mM  NaCl plus 12.5 mM 
glucose at 10% Hct, the efflux of 14C-glucose was determined. For this, samples 
were taken every 30 s and centrifuged immediately for 10 s at 13.000 rpm. The 
amount of radioactivity in the supernatant was determined by means of liquid 
scintillation counting. Efflux was calculated as percentage of the total amount of 
14C-glucose taken up. Glucose transport activity is expressed as percentage of the 
activity of control (cells without DIP and sensitizer). The specificity of the glucose 
transport activity after DMMB-PDT was evaluated by incubating cells with the 
glucose transport inhibitor Cytochalasine B (cb; 50 μM) for 10 min prior to loading 
with 0.25 μCi/mL D-[U-14C-glucose]. After washing, cells were resuspended in 
buffer plus 50 μM cb to maintain the inhibition during the measurement. 
GLYCEROL TRANSPORT 
Glycerol transport was measured by the hemolysis technique as described by 
Naccache and Sha’afi.25 Briefly, RBCs were centrifuged and resuspended in 300 
mM glycerol (2% Hct). Hemolysis was followed by the decreased scattering of the 
suspension, as measured at 620 nm (DU-64 spectrophotometer; Beckman, 
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Fullerton, CA). Nonspecific glycerol transport was measured in the presence of 2 
mM CuSO4, which completely inhibits the facilitated diffusion of glycerol.26 Active 
glycerol transport of the treated cells is expressed as percentage of the activity in 
control (cells without DIP and sensitizer). 
STATISTICS 
All experiments were performed three to five times with blood from different 
donors. Paired t-tests were used to determine the significance of differences 
between two groups. A p-value < 0.05 was considered significant. Means and 
standard deviations are reported. 
RESULTS 
EFFECT OF DMMB-MEDIATED PDT ON MEMBRANE PERMEABILITY 
Photo-oxidation of human RBCs with DMMB resulted in increased permeability of 
the membrane toward cations, as measured by the leakage of K+. This effect was 
detected already at low light doses. At 3 J/cm2, the leakage amounted to 20% (Fig. 
1). None of the light doses used induced any hemolysis. The K+ leakage was 
inhibited by 80% when DIP was present in the cell suspension during the PDT with 
DMMB.  
 
Figure 1. Effect of DIP on DMMB-mediated 
photodynamically induced K+ leakage.  
Ten percent erythrocyte suspensions in PBS and 30 
mM sucrose were incubated in the dark with ( , ) 
or without ( , ) 100 μM DIP. After 5 min, DMMB 
(15 μM) was added ( , ) and the cells were 
incubated in the dark for another 5 min. In control 
cells ( ), neither DIP nor DMMB was present. The 
RBC suspensions were exposed to light doses of 0 to 
9 J/cm2. K+ leakage is expressed as percentage of the 




EFFECT OF DMMB-MEDIATED PDT ON BAND 3 ACTIVITY 
DIP is known to inhibit band 3 activity strongly. To study the effect of PDT on band 
3 activity, DIP should be removed from the cells before the transport of anions 
can be measured. Therefore, cells containing DIP were subjected to extensive 
washing. This washing procedure resulted in complete restoration of anion 
transport activity in DIP-treated cells. The washing procedure had no effect on the 
band 3 activity of control cells (without DIP). Band 3 activity was inhibited strongly 
by DMMB-mediated PDT (Fig. 2). At 3 J/cm2, a 30% inhibition of anion transport 
was observed, which increased to over 60% at 9 J/cm2. When phototreatment was 
performed in the presence of DIP, even at a light dose of 9 J/cm2, band 3 activity 
was not inhibited, and was maintained at the level of control cells (cells without 
DMMB or DIP). 
Figure 2. Protective effect of DIP against DMMB-
induced inhibition of band 3 activity. 
Ten percent erythrocyte suspensions in PBS and 
30 mM sucrose were incubated in the dark with 
( , ) or without ( ) 100 μM DIP. After 5 min, 
DMMB (15 μM) was added ( , ), and the cells 
were incubated in the dark for another 5 min. 
The RBC suspensions were exposed to light 
doses of 0 to 9 J/cm2. Samples treated with DIP 
were washed before band 3 activity was 
measured. Band 3 activity is given as percentage 
of control cells in which neither DIP nor DMMB 
were present. 
 
EFFECT OF DMMB-MEDIATED PDT ON GLUCOSE TRANSPORT ACTIVITY 
Incubation of the RBCs with DIP, which is known to bind with low affinity to the 
erythrocyte glucose transporter27, has a small, but significant (P< 0.05), inhibitory 
effect on the glucose transport activity. In contrast to the results obtained with 
protoporphyrin, DMMB-mediated photosensitization of red cells did not affect the 
activity of the glucose transporter (Fig. 3). Even at light doses that induced 90% 
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leakage of K+ (9 J/cm2), glucose transport activity was not inhibited significantly. 
The efflux as measured at this high light dose was not because of nonspecific 
leakage of glucose. Cytochalasine B, an inhibitor of the Glut-1 glucose 
transporter28, inhibited glucose exchange in treated cells to an extent comparable 











Figure 3. Effect of DMMB-PDT on the glucose transport of RBCs.  
Ten percent erythrocyte suspensions in PBS and 30 mM sucrose were incubated in 
the dark for 5 min with DIP only (DIP), with DIP and DMMB (DIP & DMMB) or with 
DMMB only (DMMB). [DIP] = 100 μM, [DMMB] = 15 μM. Glucose transport of the 
treated cells was measured immediately after light exposure of 9 J/cm2. Control for 
specificity of the activity measurement was performed with the use of 50 mM 
Cytochalasine B (cb) after incubation with DMMB in the dark or exposed to a light 
dose of 9 J/cm2. Glucose transport activity is given as percentage of control in which 
neither DIP nor DMMB were present. ** P < 0.05. 
EFFECT OF DMMB-MEDIATED PDT ON GLYCEROL TRANSPORT ACTIVITY 
After an initial lag phase, glycerol transport was inhibited rapidly by DMMB-
mediated photosensitization (Fig. 4). In contrast to what was observed with band 
3 activity, DIP only partially protected against DMMB-mediated photodamage to 




measured transport activity after DMMB-PDT was carrier mediated, as checked 
with the use of CuSO4, a specific blocker of the carrier. Passive transport was 
measured in this case and was negligible in comparison with the active transport. 
After 6 J/cm2, the active transport was equal to the passive transport, suggesting a 
total inhibition of the carrier by DMMB-PDT (data not shown).  
Figure 4. Partial protective effect of DIP  against 
DMMB-induced inhibition of glycerol transport.  
Ten percent erythrocyte suspensions in PBS and 30 
mM sucrose were incubated in the dark with ( , ) 
or without ( , ) 100 μM DIP. After 5 min, DMMB 
(15 μM) was added ( , ) and the cells were 
incubated in the dark for another 5 min. In control 
cells ( ), neither DIP nor DMMB were present. The 
RBC suspensions were exposed to light doses of 0 to 
9 J/cm2. Measurement of glycerol transport activity 
occurred immediately after light exposure from 0 to 
9 J/cm2. Glycerol transport activity is given as 
percentage of control. 
 
DISCUSSION 
A damaged band 3 has been suggested as being responsible for various forms of 
RBC lysis, including immunolysis29, hyperthermic lysis30, glycerol lysis31 and 
osmotic lysis.32,33 Based on the observation that photohemolysis obeys a second-
order power dependence on light dose, and on the great potency of eosin 
isothiocyanate to sensitize photohemolysis, Pooler suggested a role in 
photohemolysis of band 3 protein, which exists as a dimer in the membrane.19 
Recently, VanSteveninck et al.20 showed that the band 3 ligand DIP could protect 
RBCs against photodynamically induced K+ leakage and delayed hemolysis. This 
again suggested an involvement of damage to band 3 in increased cation 
permeability and photohemolysis. Based on the comparable light dose 
dependency and response to DIP, we were able to show a direct correlation 
between DMMB-mediated damage to band 3 and K+ leakage. Already, at a light 
dose of 3 J/cm2, there was considerable K+ leakage and inhibition of band 3 
K+ leakage and damage to Band 3 in red cells 
47 
activity, as measured by decreased sulfate transport. Both K+ leakage and 
inhibition of band 3 activity were completely prevented when illumination was 
performed in the presence of DIP. These results suggest strongly that DMMB-
mediated photodamage to band 3 is indeed a causal factor in inducing K+ leakage. 
The study of the transport systems for glucose and glycerol showed that they 
were not involved in the onset of DMMB-photodynamically induced K+ leakage. 
Glucose transport was not affected by the PDT. Neither the rate of glucose efflux 
nor the ability of cytochalasin B to inhibit glucose transport was decreased. The 
facilitated diffusion of glycerol was inhibited by DMMB-mediated PDT. However, 
an involvement of this transport system in K+ leakage is highly unlikely because of 
the difference in light dose dependency. At a light dose of 3 J/cm2, K+ leakage was 
already initiated, whereas glycerol transport was not affected. Notwithstanding 
the fact that DIP has no known preference for the glycerol transporter, 
photoinhibition of glycerol lysis was prevented partially by the presence of DIP in 
the illumination mixture. This was not caused by a general stabilization of the red 
cell membrane, because addition of DIP after the PDT had no effect on the 
inhibition of glycerol transport (data not shown). An alternative explanation for 
the protective effect of DIP could be the involvement of band 3 in glycerol 
transport as previously suggested.31,34,35 Indeed, it has been observed that 
erythrocytes from patients suffering from systemic lupus erythomatosus have a 
decreased glycerol transport activity, which correlated with a decreased quantity 
of band 3 protein in the membrane.34 Further evidence for the involvement of 
band 3 in glycerol transport is provided by the observation that the classical band 
3 transport inhibitor 4.49-diisothiocyanostilbene-2,29-disulfonate also inhibits 
glycerol transport.31,35 Not all band 3 inhibitors influence glycerol transport 
activity. 
From our results it is clear that DIP has no effect on the glycerol transport activity 
(Fig. 3), which is in agreement with the finding that phenylglyoxal and 4.49-
dinitrostilbene-2,29-disulfonate, which bind at the same location in band 3 as 
DIP36, also had no effect on glycerol transport activity.35 We hypothesize that the 
observed inhibition of glycerol transport activity by DMMB-mediated PDT is, at 
least partly, because of damage to band 3, and that DIP prevents such damage. In 




mediated photodamage to band 3 and K+ leakage. It remains to be elucidated 
whether this is specific for DMMB or is a general phenomenon for all 
photosensitizers, and whether band 3 is the only critical target. Also, it has to be 
established which photodamaged residues in band 3 are responsible for the 
leakage of potassium.  
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BACKGROUND: All studied photosensitizers for virus inactivation impair RBCs. To 
reduce damage to the RBCs without affecting virucidal activity, selective 
protection of the RBCs is necessary. The ability of the band 3 ligand, dipyridamole 
(DIP), to react with singlet oxygen and to increase the selectivity of 
photodecontamination was investigated.  
STUDY DESIGN AND METHODS: Solutions of DIP were illuminated in the presence 
of AlPcS4 and DMMB. Solutions of amino acids, RBCs, and vesicular stomatitis 
virus (VSV) in RBC suspensions were photodynamically treated in the presence or 
absence of DIP. 
RESULTS: Illumination of a solution of DIP in the presence of AlPcS4 or DMMB 
resulted in changes in the optical spectrum of DIP. The photooxidation of DIP was 
inhibited by azide and augmented by deuterium oxide, which suggests the 
involvement of singlet oxygen. Photooxidation of amino acids and photodamage 
to RBCs was strongly reduced in the presence of DIP. In contrast, 
photoinactivation of VSV in RBC suspensions was only slightly affected by DIP. 
CONCLUSION: DIP can improve the specificity of photodynamic decontamination 
of RBCC, thereby increasing the practical applicability of this 
photodecontamination method. 
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INTRODUCTION 
The safety of blood transfusion components is a major issue in transfusion 
medicine practice. Improved donor screening and the implementation of 
diagnostic screening of blood samples have substantially reduced the risk of virus 
transmission by transfusion. However, mainly because of window-period 
donations, residual risk exists.1 For plasma components, the risk has been reduced 
considerably by the application of virucidal treatments such as heating or 
solvent/detergent (SD) treatment.2,3 These procedures, however, are not 
applicable to cellular blood components, because of the fragility of the cells. The 
use of light-activated agents, photosensitizers, is widely studied for the 
inactivation of viruses in cellular blood components, especially RBCC.4-6 Upon 
activation of the photosensitizer with visible light, various reactive oxygen species 
are formed. Although photosensitizers can mediate both type I (charge transfer, 
radicals) and type II (energy transfer, singlet oxygen [1O2]) reactions, most 
photosensitizers are considered to act mainly via 1O2. It is able to inactivate a 
broad range of enveloped viruses.4 However, as 1O2 is not selective and can be 
generated in all locations where sensitizer molecules are present, phototreatment 
can also damage RBCs. This means that photosensitizers with high affinity for virus 
particles must be used to protect the RBCs from photodynamic damage. 
Promising results have been obtained with phenothiazine dyes, such as MB and 
DMMB6,10,11 , and with certain phthalocyanines.12-14 However, all photosensitizers 
tested so far also induce damage to the RBCs, as detected by an increased 
permeability of the membrane to cations. To minimize the damage to RBCs 
induced by photodynamic pathogen inactivation, we searched for chemicals that 
bind preferentially to the RBC membrane and react readily with 1O2. An obvious 
way to achieve effective binding of candidate scavengers is the use of band 3 
ligands. Band 3 constitutes the anion transporter of the RBC, and, with about a 
million copies per cell, it is the most abundant protein on the RBC membrane. An 
additional argument for using scavengers that bind to band 3 is the proposed 
involvement of band 3 damage in photohemolysis.15 Band 3 is widely studied and 




of one molecule of DIP per band 3 dimer. The inhibition of anion transport is not 
due to binding of DIP to the anion-binding side, but to blocking of the anion 
channel.16  Besides its use as ligand for band 3, DIP is widely used in the treatment 
of cardiovascular diseases because of its vasodilating activity and its ability to 
inhibit platelet aggregation.17 It has previously been reported that DIP also exerts 
an inhibitory effect on lipid peroxidation18,19 and possesses activity as a scavenger 
of superoxide anion, hydroxyl radical, and peroxyl radical.18,20 These properties 
make DIP a promising candidate for selective protection of RBCs against 
photodynamic damage. The aim of the present study is to investigate whether DIP 
is able to react with photodynamically formed 1O2, thereby protecting substrates 
against photodynamic damage. In addition, the possibility of using DIP for 
selective protection of RBCs against virucidal PDT was investigated. For this we 
used AlPcS4 and DMMB, both of which are photosensitizers whose role in virus 







MATERIALS AND METHODS 
MATERIALS  
DIP (2,6-bis(diethanolamino)-4,8-dipiperidino-[5,4-d]pyrimidine) was purchased 
(Sigma-Aldrich BV, Zwijndrecht, the Netherlands). Stock solutions (20 mM) were 
prepared in ethanol. AlPcS4 was obtained from Porphyrin Products (Logan, UT). 
VSV (San Juan strain) and the host cells A549 were provided by the departments 
of Virology and Lung Diseases respectively (Leiden University Medical Center, 
Leiden, the Netherlands). A549 cells were cultured in medium (RPMI 1640) 
Figure 1. Structure of dipyridamole 
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supplemented with 10-percent fetal bovine serum (Gibco BRL, Breda, the 
Netherlands). All other chemicals were obtained from Sigma-Aldrich and were of 
the highest purity available. Heparinized human blood, provided by the regional 
Red Cross Blood Bank (Leiden-Haaglanden, the Netherlands), was centrifuged 
shortly after collection. The RBCs were washed three times with 150 mM NaCl and 
20 mM HEPES, pH 7.6, and resuspended at 2-percent Hct in the same buffer. 
PHOTODYNAMIC TREATMENT 
For all illuminations, the light source used was a slide projector with a 150 W lamp 
(HLX 64640, Xenophot, Osram, Germany).21 To avoid light absorption by Hb and 
DIP, a cutoff filter, transmitting only light with a wavelength above 590 nm, was 
used in all experiments. Both AlPcS4 (maximum absorption at 675 nm) and DMMB 
(maximum absorption at 652 nm) strongly absorb in this region. The irradiance 
was 350 W per m2, as measured with a photometer (IL1400A, International Light, 
Newburyport, MA) equipped with a detector (SELO33, International Light). All 
illuminations were performed at a constant temperature of 20°C under 
continuous mixing. 
Solutions of DIP M M AlPcS4. 
Absorption spectra of DIP after different illumination times were recorded with a 
spectrophotometer (DU-64, Beckman, Fullerton, CA). Suspensions of RBCs (2% 
Hct) either with or without VSV (105 infectious particles/mL) were incubated with 
100 M DIP M AlPcS4 or DMMB was added 
to the suspension. After another 5 minutes of incubation, the suspensions were 
illuminated for different periods. 
OXYGEN CONSUMPTION 
Oxygen consumption during illumination was measured with an oxygen monitor 
(YSI, Yellow Springs, OH) equipped with a Clark-type electrode. A 3-mL sample of 
histidine (2 mM in 150 mM NaCl/1% Triton-X100/20 mM HEPES, pH 7.6) was 
M AlPcS4 M DMMB plus various 
amounts of DIP at a constant temperature of 20°C under continuous mixing. The 




POTASSIUM LEAKAGE AND DELAYED HEMOLYSIS 
K+ leakage from RBCs was determined immediately after illumination by means of 
a flame photometer (Clinical Flame Photometer 410C, Corning, Halstead, UK). To 
study delayed hemolysis, RBCs were treated with a light dose inducing minimal K+ 
leakage. The light dose used with DMMB was 75 kJ per m2, and that used with 
AlPcS4 was 200 kJ per m
2. After treatment, the cells were centrifuged, 
resuspended in fresh buffer, and stored in the dark at room temperature. After 
different storage times, released Hb was determined by measuring the OD of the 
supernatant at 540 nm using a DU-64 spectrophotometer. Both K+ and Hb release 
were expressed as a percentage of the total efflux evoked by lysis of the cells in 
distilled water. 
VSV INFECTIVITY ASSAY 
Assay of the infectivity of VSV by an endpoint dilution assay was performed as 
described previously.14 In short, VSV samples were serially diluted (10 times), 
inoculated into A549 cell cultures in 96-well microtiter plates (Greiner, Alphen a/d 
Rijn, the Netherlands), and incubated for 72 hours. The cytopathology of the cells 
was scored in eight well replicates for each dilution. Quantification of the virus 
titer was performed according to the Spearman-Karber method.22 
STATISTICS 
All experiments were performed at least four times with blood from different 
donors. Values are expressed as mean ± standard error. 
RESULTS 
PHOTOOXIDATION OF DIP 
It has previously been shown that oxidation of DIP with hydroxyl radicals results in 
a changed optical spectrum of DIP.23 To investigate whether 1O2 also can induce 
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oxidation of DIP, a solution of DIP M) was illuminated in the presence of 10 
M AlPcS4. 
After application of different light doses, the optical spectrum of DIP was 
recorded. The characteristic yellow color of DIP (absorption maximum at 410 nm) 
disappeared gradually upon illumination, while at 270 nm a new absorption 
maximum appeared (Fig. 2). Illumination, also with white light, in the absence of 
AlPcS4 had no effect on the optical spectrum of DIP, which indicates that DIP does 
not act as a photosensitizer. The photodynamically induced degradation of DIP 
was slowed by the addition of 1 mM sodium azide (Fig. 3). When the buffer was 
made in deuterium oxide (D2O) instead of in H2O, photodynamic degradation was 
strongly augmented (Fig.3). Comparable results were obtained with DMMB (2 
M) as photosensitizer (results not shown). 
Figure 2. Effect of photooxidation on the spectral properties of DIP. 
A solution of DIP (10 μM in 150 mM NaCl/10 mM Hepes, pH 7.6) was illuminated in 
the presence of 10 μM AlPcS4. After 0 ( ), 20 ( ), 40 ( ), 60 ( ) and 100 ( ) 







Figure 3. Effects of sodium azide and deuterium oxide on the photooxidation of 
dipyridamole. 
A solution of DIP (10 μM in 150 mM NaCl/10 mM Hepes, pH 7.6) was illuminated in 
the presence of 10 μM AlPcS4. ( ): no extra additions, ( ): 1 mM sodium azide 
added, ( ): H2O replaced by D2O.  
 
EFFECT OF DIP ON THE PHOTOOXIDATION OF HISTIDINE 
Illumination of a 2 mM solution of histidine in the presence of AlPcS4 M) or 
M) resulted in a rapid decrease in the oxygen content of the buffer. 
The rate of oxygen consumption in the absence of DIP M of 
O2 per minute for AlPcS4 and to M of O2 per minute for DMMB. The 
inclusion of increasing amounts of DIP in the illumination mixture resulted in a 
decreasing rate of photooxidation of histidine (Fig. 4). Comparable results were 
obtained when the amino acids tryptophan, methionine, and tyrosine or the DNA 
base guanosine was used as substrate. Illumination in the absence of substrate, in 
either the presence or absence of DIP, induced no significant oxygen 
consumption. In addition, no changes in the optical properties of DIP were 
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observed, which indicates that, under these conditions of low sensitizer 
concentration and high DIP concentration, DIP was not significantly oxidized. 
Figure 4. Effect of dipyridamole on the photooxidation of histidine. 
A histidine solution (2 mM in 150 mM NaCl/10 mM Hepes/1% Triton-X100, 
pH 7.6) was illuminated in the presence of 2.5 μM AlPcS4 ( ) or 0.5 μM 
DMMB ( ) with increasing concentrations of DIP. The initial oxygen 
consumption during illumination was recorded using a Clark-type electrode. 
The oxygen consumption rates obtained in the absence of DIP were 
normalized to 100%.  
 
EFFECT OF DIP ON PHOTODYNAMICALLY INDUCED DAMAGE TO RBCS 
To investigate whether the presence of DIP can protect RBCs against 
photodynamic damage, RBC suspensions (2% Hct) were incubated in the dark for 
5 minutes with DIP before photosensitizer was added. As can be seen from Fig. 5, 
both AlPcS4 and DMMB induced damage to the RBCs upon illumination, as 
reflected by the increased concentration of extracellular K+. Neither illumination 
without photosensitizer nor incubation in the dark with photosensitizer induced 




photodynamically induced K+ leakage (Fig. 5). However, the magnitude of this 
reduction differed strongly with the photosensitizer used. The protection factor, 
defined as the ratio between the light doses needed to induce 50-percent K+ 
leakage in the presence and in the absence of DIP, for AlPcS4 amounted to 1.5, 
while that with DMMB was 4.5. The effect of DIP on delayed hemolysis induced by 
PDT is depicted in Fig. 6. In the absence of DIP, both PDTs induced complete 
hemolysis 10 hours after their use. When illumination was conducted in the 
presence of DIP, hemolysis was strongly delayed. With AlPcS4 as sensitizer, 
complete hemolysis was obtained 24 hours after PDT. With DMMB, the protective 
effect of DIP was even more pronounced: 30 hours after PDT, hemolysis 
amounted to less than 10 percent. Because of its lipophilic nature, DIP can be 
inserted between phospholipids.24 The insertion of molecules in the membrane 
results in membrane expansion, which can result in protection of the RBC against 
osmotic hemolysis.25,26 To investigate the involvement of membrane expansion in 
the protection, DIP was added to the RBC suspension after the PDT. In this case, 
DIP had no effect on delayed hemolysis (not shown). These results imply that it is 
very likely that the protective effect of DIP is due to its scavenging properties.  
 
Figure 5. Effect of dipyrida-
mole on photodynamically 
induced potassium leakage 
from RBCs. 
Two percent-erythrocyte sus-
pensions were incubated in 
the dark without (open sym-
bols) or with 100 μM DIP 
(closed symbols). After 5 min, 
the suspensions were ex-
posed to light in the presence 
of 1 μM AlPcS4 ( , ) or 1 M 
DMMB ( , ). 
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Figure 6. Effect of dipyridamole on photodynamically induced delayed hemolysis. 
Two percent-erythrocyte suspensions were incubated in the dark without (open 
symbols) or with 100 μM dipyridamole (closed symbols). After 5 min, the 
suspensions were exposed to light in the presence of 1 μM AlPcS4 ( , ) or 1 M 
DMMB ( , ). After a light dose of 200 kJ/m2 or 75 kJ/m2 respectively, the cells were 
washed, resuspended in fresh PBS (without dipyridamole or sensitizer) and stored at 
room temperature in the dark. 
EFFECT OF DIP ON THE PHOTOINACTIVATION OF VSV IN RBC 
SUSPENSIONS 
From the above, it is clear that DIP strongly protects RBCs against photodamage. 
To investigate whether DIP can increase the specificity of a photody-namic 
virucidal treatment, the effect of DIP on the photoinactivation of VSV was 
investigated. For this, VSV was spiked (105 infectious particles/mL) in 2 percent 
RBC suspensions. The suspensions were incubated in the dark for 5 minutes with 
DIP before the photosensitizer was added. After different light doses, samples 
were taken to assay for viral infectivity. As can be seen from Fig. 7, both AlPcS4- 
and DMMB-mediated photoinactivation of VSV was only slightly affected by DIP. 
When measured directly after the treatment, the light doses needed for 5 log 
inactivation of VSV induced only very limited leakage of potassium out of the 
RBCs; this indicated the potential use of these photosensitizers for 




Figure 7. Effect of dipyri-damole on photodynamic inactivation of VSV. 
VSV (105 infectious particles / mL) in 2 % erythrocyte suspensions, were incubated 
without (open symbols) or with 100 μM DIP (closed symbols). After 5 min, the 
suspensions were exposed to light in the presence of 1 μM AlPcS4 ( , ) or 1 M 
DMMB ( , ).  
DISCUSSION 
The cardiovascular drug DIP is known to be a scavenger of superoxide anions, 
hydroxyl radicals, and peroxyl radicals.18,20 The present study is the first to show 
that DIP can also react with 1O2, the most important reactive oxygen species 
formed upon PDT. With illumination of a solution of DIP M) in the presence 
of AlPcS4 M M) as photosensitizer, the optical spectrum of DIP 
changes (Fig. 2), and this indicates a chemical reaction between DIP and a 
photogenerated reactive species. The involvement of 1O2 in this reaction was 
demonstrated by both the inhibitory effect of the 1O2 scavenger azide and the 
faster oxidation in D2O (Fig. 3). Because of the much longer lifetime of 
1O2 in D2O 
than in H2O, reactions involving 
1O2 are strongly accelerated in D2O.
27 The changes 
in the optical spectrum of DIP differ from those obtained with DIP exposed to 
hydroxyl radicals, which indicates the formation of different reaction products.23 
The exact nature of the reaction product(s) and the possible intermediates 
remains to be elucidated. DIP is able to protect various substrates (histidine, 
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tryptophan, methionine tyrosine, and guanosine), which are known to be oxidized 
by 1O2,
28,29 against photooxidation (Fig. 4). Under the conditions used in these 
experiments, no change in the optical spectrum of DIP could be observed. This 
suggests that, under certain circumstances; that is, a high concentration of DIP 
and a low concentration of 1O2; DIP reacts with 
1O2 without being chemically 
changed. This physical interaction can most likely be attributed to the amine 
groups present in DIP, which are well known physical quenchers of 1O2.
30 The 
following mechanism for the reactions of DIP with 1O2 is suggested:  
 
DIP + 1O2     [DIP---O2]    DIP + O2 
       + 
1O2 
      oxidized DIP 
The present study proposed to investigate whether the cardiovascular drug DIP is 
able to selectively protect RBCs against damage induced by virucidal PDT. DIP 
binds with high affinity to the anion transport protein, band 3, the most abundant 
protein on the RBC membrane. This means that the concentration of 1O2 
scavengers in the vicinity of the RBC is higher than in the rest of the solution, 
which makes feasible the selective protection of RBCs against PDT. It was shown 
that DIP strongly protects RBCs against damage induced by PDT. The conditions 
used in these experiments are quite similar to those used in the photooxidation of 
histidine, which suggests that the protection of RBCs is due to the physical 
quenching of 1O2 by DIP. The extent of RBC protection by DIP strongly depends on 
the sensitizer used to induce the RBC damage. With DMMB as photosensitizer, 
the protection by DIP was much stronger than with AlPcS4. A feasible explanation 
for these differences in protection by DIP could be the localization of the 
photosensitizers. For effective scavenging, the activated photosensitizer and DIP 
should be in proximity to each other. DIP is known to bind in the hydrophobic 
interior of band 3.16 Because of its hydrophilic nature it is very unlikely that AlPcS4 




DMMB is much more hydrophobic and possibly is located in the same 
microenvironment as DIP, which makes effective 1O2 scavenging feasible. To study 
the effect of DIP on the inactivation of viruses, we used the model virus, VSV, 
which was shown to be as sensitive to photoinactivation as HIV.10 In contrast to 
the very strong protection found with RBCs, DIP caused hardly any decrease in the 
AlPcS4- or DMMB-mediated photoinactivation of VSV. Because it has been shown 
that DIP binds with low affinity (950-1150 M–1) to lipid bilayers,24 the binding of 
DIP to VSV cannot be excluded. But because DIP does not interfere with the 
photoinactivation of VSV, it must be concluded that the binding of DIP is not in 
the proximity of the critical target for virus photoinactivation. The present results 
were obtained by illumination of a model virus in a severely diluted RBC 
suspension (2% Hct). Further research is focused on the effect of DIP on the 
photoinactivation of other viruses, including HIV-1/2 and HCV, in a more 
concentrated RBC suspension. In addition, the effect of DIP on the shelf-life of 
photodynamically decontaminated RBCC must be investigated. Thus, the present 
study shows that DIP has the potency to become a very valuable tool to increase 
the specificity of the pathogen inactivation of RBCC, thereby increasing the 
practical applicability of this photodecontamination method. 
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BACKGROUND: PDT could be a way to inactivate pathogens in RBCC. The 
objective of this study was to characterize the virucidal activity and RBC-
damaging activity of a series of cationic porphyrins. Using the most efficacious 
photosensitizer, various in-vitro human RBC quality parameters and in-vivo RBC 
survival in Rhesus monkeys were evaluated.  
STUDY DESIGN AND METHODS: RBCC, spiked with 5 log10 of extracellular VSV, 
were treated with porphyrins (25 μM) and red light (100 W/m2) and essayed for 
virucidal activity. In-vitro RBC quality variables were assessed during 5 weeks of 
storage in various additive solutions. In-vivo survival was investigated with 
autologous RBCs in Rhesus monkeys. 
RESULTS: Tri-P(4) was by far the best sensitizer of a series tested, giving the least 
hemolysis under conditions that resulted in 5 log10 kill of extracellular VSV. Under 
our experimental conditions, the percentage hemolysis in treated cells was 5.1% 
± 1.1% after five weeks of storage in SAG-M compared to 1.9% ± 1.1% in the 
untreated control. Storage in AS-3 resulted in hemolysis of 2.3% ± 1.9%. With the 
exception of IgG binding and potassium leakage, quality parameters of RBCs 
remained unchanged after photodynamic treatment. Addition of reduced 
glutathione (GSH) during treatment reduced IgG binding. The 24-hour recovery 
and the half-life span T50 of treated RBCs in Rhesus monkeys were satisfactory.  
CONCLUSION: Porphyrin Tri-P(4) may be a suitable photosensitizer for 
decontamination of RBCC. However, further exploration to optimize the method 
is necessary to reach clinically acceptable goals. 
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INTRODUCTION 
Blood transfusions in developed countries are generally considered to be safe, 
however recent reports revealed that maximal vigilance is still needed and that 
considerable efforts are required to maintain optimal safety of blood transfusion 
practices.  
The emergence of new viruses, such as the WNV in the North American continent 
or TTV in Asia,1,2 the potential risk of transmission of variant PrPsc,3,4 the bacterial 
contamination of blood products responsible for sepsis,5,6 the reduction but not 
the elimination of the window-periods with increasing sensitivity of viral and 
bacterial testing,7,8 and in less developed countries, the lack of adequate and 
systematic viral and bacterial screening4 promote the development of new 
strategies to increase the safety of the blood products.9 
Chemical and photodynamical pathogen inactivation technologies are the most 
recent developments for the reduction of pathogen transmission via blood 
transfusions. The chemical Pen 11010,11 and Frangible Anchor Linker Effector 
compounds S-30312  are under investigation for the decontamination of RBCC. 
These compounds cause irreversible alkylation of nucleophilic groups in 
macromolecules, including nucleic acids, rendering pathogens noninfectious and 
inhibiting white blood cells (WBC) proliferation.13,14 However, both chemicals are 
toxic and must be removed before transfusion of the RBCC. PDT relies on the 
activation of a light-sensitive agent (photosensitizer) in an oxygen-rich 
environment, resulting in the generation of reactive oxygen species of which 
singlet oxygen is the most important. Singlet oxygen can react with proteins, lipids 
and nucleic acid. Because of its short lifetime, damage is localized at the binding 
site of the photosensitizer. The efficacy and selectivity of the photodynamic 
treatment depend on the physical and chemical properties of the photosensitizers 
used. Various photosensitizers, including phenothiazines DMMB and MB15-17, 
phthalocyanines18-21, merocyanines20, riboflavin (vitamin B2)22, benzoporphyrin 
derivative monoacid ring A BPD-MA and, photofrin23 have been tested for their 
virucidal and bactericidal activities and, their abilities to preserve the functional 
integrity of the therapeutic RBCs. All dyes tested so far induced considerable RBC 




damage, scavengers such as dipyridamol, and vitamin E derivatives (Trolox, 
vitamin E succinate),15 reduced glutathione (GSH), mannitol, or cremophore19,21 
were added to the RBCC.  
The aim of our study was to find a photosensitizer that efficiently inactivates 
viruses without RBC damage. We focused on a series of positively charged 
porphyrin derivatives which have been shown to have a strong photo-bactericidal 
potential.24,25 From this series, mono-phenyl-tri(N-methyl-4-pyridyl) porphyrin, Tri-
P(4), gave the most promising results and was investigated in more detail. Various 
RBC variables were investigated after storage in various additive solutions. In 
addition, to evaluate the in-vivo survival of Tri-P(4)-treated RBCs, a limited study, 
not meant as a formal preclinical study, was performed using two Rhesus 
monkeys. 
MATERIAL AND METHODS 
STORAGE SOLUTIONS 
 AS-3 (Haemonetics Co, Braintree, MA) contains 70 mM NaCl, 61.1 mM glucose, 
2.22 mM adenine, 2 mM citric acid, 20 mM Na3citrate and 15.5 mM Na2HPO4. 
SAG-M (Baxter, Utrecht, the Netherlands) contains 150 mM NaCl, 1.25 mM 
adenine, 50 mM glucose and 29 mM mannitol. SAG-S and SAG-D have the same 
composition as SAG-M, except that mannitol is replaced by 29 mM sucrose or by 
29 mM dextran-1000, respectively. These two storage solutions were 
experimental. The chemicals were purchased from Sigma-Aldrich (St. Louis, MO).  
OTHER CHEMICAL 
Stock solution of 1 mM GSH (Boehringer-Mannheim, Germany) was made in PBS 
and stored at 2-6°C. Dipyridamol (DIP; 2,6-bis(diethanolamino)-4,8-dipiperidino-
[5,4-d] pyrimidine) (Sigma-Aldrich, St. Louis, MO) was stored as a 200 mM stock 
solution in dimethylsulfoxide (DMSO) at 2-6°C. Radioactive disodium-51chromate 
(51Cr) was purchased from NEN, Boston, MA.  
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DISPOSABLES 
EDTA- and serum- tubes were purchased from Vacuette, Greiner Bio-One, Austria. 
Polystyrene culture dishes with a diameter of 9 cm and 11-mL sterile polystyrene 
test tubes were obtained from Greiner, Alphen a/d Rijn, the Netherlands.  
MODEL VIRUS AND HOST CELLS 
VSV (San Juan strain) was kindly provided by the Department of Virology at the 
Leiden University Medical Center (LUMC, Leiden, the Netherlands). A549 cells for 
the VSV infectivity assay were kindly provided by the department of Lung 
Diseases, LUMC.  
SENSITIZERS 
The following porphyrins (Fig. 1) (obtained from Mid-Century, Posen, IL, USA), 
were studied: meso-tetra-(N-methyl-4-pyridyl)-porphyrin chloride (Tetra-P(4)), 
trans-diphenyl-di-(N-methyl-4-pyridyl)-porphyrin chloride (Trans-P(4)), cis-
diphenyl-di-(N-methyl-4-pyridyl)-porphyrin chloride (Cis-P(4)), triphenyl-mono-(N-
methyl-4-pyridyl)-porphyrin chloride (Mono-P(4)), tetra-(N-2-hydroxy-ethyl-4-
pyridyl)-porphyrin chloride (TNH-P(4)), tetra(4-N, N, N-trimethylanilinium)-
porphyrin chloride (TAP). Photosensitizer mono-phenyl-tri-(N-methyl-4-
pyridyl)-porphyrin chloride (Tri-P(4)) was obtained from Porphyrin Systems, 
Luebeck, Germany. Aluminum phthalocyanine tetrasulfonate (AlPcS4) was 
purchased from Porphyrin Products (Logan, Utah, USA). Stock solutions (1 mM) 
were prepared either in 50 mM sodium-phosphate buffer (NaP) pH 7.4 
(Tetra-P(4), Tri-P(4), TAP, TNH-P(4) and AlPcS4) or in DMSO (Trans-P(4), Cis-P(4), 
Mono-P(4)). Solution in Na-phosphate buffer were sterilized by filtering through a 
0.22 μm filter and stored at 4 oC. Sensitizer concentration, after a 10-fold dilution 
in absolute ethanol, was measured fluorimetrically with a Perkin Elmer LS50B 
Luminescence Spectrometer. The concentration was determined using a linear 










+-CH3, R4= CH 
Trans-P(4): R1=R3= N
+-CH3, R2=R4= CH 
Cis-P(4): R1=R2= N
+-CH3, R3=R4= CH 
Mono-P(4): R1= N





Figure 1: Structures of the positively charged 
porphyrins used. 
 
RED BLOOD CELL CONCENTRATES 
After written consent blood from volunteer donors (500 ± 50 mL) was collected in 
73 mL citrate-phosphate-dextrose adenine (CPDA) in quadruple polyvinylchloride 
bags (NPBI, Emmer-Compascuum, the Netherlands). After extraction of the buffy-
coat, the Hct of the RBCC was adjusted to 60 ± 4% with the storage solution SAG-
M.26  In Europe, the allowed maximum shelf life of CPDA-RBCC in SAG-M is limited 
to 35 days. 
PHOTODYNAMIC TREATMENT OF RBCC 
Porphyrins were added to RBCC to give a final concentration of 25 μM. Where 
indicated, DIP or GSH were added to RBCC before illumination. The RBC 
suspensions were thoroughly mixed. Samples of 6 mL were transferred to 9 cm-
polystyrene culture dishes and agitated at room temperature on a horizontal 
reciprocal shaker (60 cycles/min, GFL, Burgwedel, Germany) for 5 min in the dark. 
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from above with a 300 W halogen lamp (Philips, Eindhoven, the Netherlands). To 
avoid heating of the samples, the light passed through a 1-cm water filter. A cut-
off filter (Kodak, wratten nr. 23A, Rochester, NY), only transmitting light > 600 nm, 
was used in all experiments. The irradiance at the cell layer was 100 W/m2, as 
measured with an IL1400A photometer equipped with a SEL033 detector 
(International Light, Newburyport, MA, USA).  
Cells illuminated without sensitizer were used as control because illumination 
alone was shown to have no effect on RBC function or virus inactivation. Cells 
with sensitizer kept in the dark were used as dark control.   
VSV INFECTIVITY ASSAY 
Stock solutions of VSV were added to RBCC so that the volume of the spike was 
less than 10% of the total volume of RBCC. The number of extracellular virus 
particles was approximately 105/mL and was our maximum starting titer of 
inoculum. PDT was performed as described above.  
Infectivity of VSV was assayed as previously described.27 In short, RBC samples 
taken after various light doses were centrifuged for 5 min at 500 x g. The 
supernatants were serially diluted (10x) and added to A549 cell cultures in 96 well 
microtiter plates. After 72-hours incubation the cytopathology of the cells was 
scored in 8-well replicates for each dilution. Quantification of the virus titer was 
performed according to the Spearman-Karber method,28 expressing the quantity 
of virus infecting 50% of the cells (TCID50). Results are expressed as percentage of 
the control. 
RBC QUALITY VARIABLES 
Hemolysis was determined by measuring the absorbance of free Hb at 540 nm. 
Cell supernatants were obtained by centrifugation of diluted (10x) RBCs (in PBS) at 
12000 x g for 3 min. Absorbance was measured using a DU-64 spectrophotometer 





Potassium leakage from RBCs was measured using a flame photometer (Model 
410C, Corning, Halstead, UK). Both K+ leakage and hemolysis were expressed as a 
percentage of the total concentration. 
ATP content of the cells was determined by adding firefly lantern extract after 
lysis of the cells in H2O, and dilution with a glycine buffer (25 mM gly-gly, 20 mM 
MgCl2, pH 7.5). The luminescence was measured using a Model 1251 luminometer 
(Bio-Orbit, Turku, Finland), as described before.21 
Measurement of RBC lactate and glucose content of the medium were performed 
according to the manufacturer’s instructions (Procedure 735 and 16-UV 
respectively, Sigma Diagnostics, St. Louis, MO).  
Lipid peroxidation was essayed by measuring the generation of thiobarbituric acid 
reactive species as described by Miller et al.30 Intracellular GSH was measured 
according to Sedlak and Lindsay.31 RBC deformability was measured as described 
previously.32  
Anion transport through band 3 was measured by the influx of Na2
35SO4 as 
described previously.33 Briefly, after PDT, cells were centrifuged and resuspended 
(10% Hct) in PBS plus 1 mM Na2SO4 and 0.5 μCi/mL Na2
35SO4 at 37°C. After 0, 5, 
10, 15, 20 and 30 min incubation at 37°C, samples were washed twice with ice-
cold PBS to remove free Na2
35SO4. After precipitating the Hb with 5% 
trichloroacetic acid, radioactivity in the cells was determined by means of liquid 
scintillation counting (Tri-Carb 4000, Packard Instrument Co., Downers Grove, IL).  
AGGLUTINATION AND IGG BINDING 
The direct gel agglutination test (DAT) was performed on human RBCs and 
monkey RBCs using DiaMed-ID micro typing system LISS/Coombs (DiaMed SA, 
Cressier sur Morat, Zwitserland) according to manufacturer’s instructions. The 
test includes antibodies against the four human IgG sub-classes and C3d.  
IgG binding to human-RBCs was analyzed by flow cytometry. Briefly, RBCs were 
washed twice with PBS / 0.5% Bovine Serum Albumin (BSA) and resuspended to 
5% Hct in the same buffer. A 50 μL sample was incubated with 50 μL of diluted 
(20x) FITC-conjugated F(ab’)2 fragment of rabbit anti-human IgG (gamma-chains) 
or FITC-conjugated F(ab’)2 fragment of rabbit Ig (negative control) (DAKO, 
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Glostrup, Denmark) for 30 min at 4°C. Labeled cells were washed with PBS/0.5% 
BSA before analysis on the Epics XL (Beckman Coulter, Mijdrecht, the 
Netherlands). A total of 20.000 events were analyzed, and mean fluorescence 
intensity (MFI) of the FITC signal (FL1) was determined. The indirect antiglobulin 
test (IAT) was performed using plasma-free RBCs (washed 6 times in SAG-M)  and 
autologous plasma, which was photodynamically treated separately. IgG binding 
was analyzed macroscopically and by flow cytometry.  
STORAGE OF HUMAN RBCC AFTER PHOTODYNAMIC TREATMENT 
After illumination of RBCC, Hct 60% in SAG-M, 5-mL samples were transferred to 
11-mL sterile polystyrene test tubes. After centrifugation at 500 x g for 10 min the 
supernatant was removed. Cells were resuspended to 60% Hct in SAG-M, SAG-S, 
SAG-D or AS-3. The RBC suspensions were stored in tubes in the dark at 2-6°C. 
These conditions were chosen for convenience when working with small samples. 
RBC quality was assayed after 1, 7, 21 and 35 days of storage. 
STATISTICS 
All in-vitro experiments were performed at least 4 times with blood from different 
donors. Values are expressed as mean ± standard deviations (SD). The p values 
were calculated using student’s t-tests. A p value less than 0.05 were defined as 
significant. 
RHESUS MONKEY SURVIVAL STUDIES 
All procedures were performed in accordance with the guidelines of the Animal 
Care and Use Committee installed by Dutch law. In a pilot study, the effect of PDT 
on monkey RBCs was determined with respect to VSV kill, RBC quality (K+ leakage 
and hemolysis) and 51Cr uptake. In-vivo survival studies were carried out using two 
Rhesus monkeys (Macaca mulatta). Monkey RBCs were prepared from 20 mL of 
freshly drawn blood, collected after ketamine-anaesthesia in 2.5 mL CPDA. CPDA 




were discarded. The RBCs were resuspended in SAG-M to a Hct of 60 ± 4% and 
photodynamically treated as described above.   
In-vivo survival was investigated after autologous transfusion of either fresh or 35 
days stored RBCC. (Table 1). RBCs were stored in AS-3 in polystyrene tubes at 4°C 
during 5 weeks. Twenty four hours before transfusion, RBCs were labeled with 
51Cr. Unbound radioactivity was removed by washing in excess volume with AS-3. 
A 1-mL sample was removed before transfusion and used to determine the 
labeling efficiency and the remaining Tri-P(4) concentration (excitation 424 nm, 
emission 659 nm). Labeling efficiency was shown to be 87 ± 9% in both untreated 
and PDT-treated RBCs. Freud et al.34 have shown that until RBCs are committed to 
hemolysis, 51Cr leakage does not occur during storage of PDT-treated RBCs. For 
parallel in-vitro analysis during storage, control and Tri-P(4)-treated monkey RBCs 
were washed and resuspended to 60% Hct in AS-3.  
To determine the 24-hour recovery, blood samples in EDTA were drawn 30 min 
and 1, 2, 4, 8 and 24 hours after transfusion. To determine the life span of the 
transfused RBCs, samples were drawn at Day 2 and Day 3 after transfusion and 
thereafter twice a week until the radioactivity was decreased to less than 45% of 
the initial value.  The Hb, Hct, Mean cell volume (MCV), RBC, WBC and platelet 
numbers, creatinin, total bilirubin, LDH and haptoglobin were measured before 
and after transfusion by standard procedures. Urine samples were recovered 
during 24 hours after transfusion. The 24-hour recovery and the RBC survival, 
expressed as T50, were calculated according to the ICSH guidelines.
35  
All radioactivity counts were corrected for Hct, decay and elution of 51Cr, which 
was taken to be 1% per day.  
Exp nr. Monkey A   Monkey B                 Storage time
 
1 RBC, non-treated (control)  RBC, PDT-treated     < 24 hrs  
 
2 RBC, PDT-treated   RBC, non-treated (control)   < 24 hrs  
 
3 RBC, non-treated (control)  RBC, PDT-treated        35 days  
 
4 RBC, PDT-treated   RBC, non-treated (control)    35 days  
 
Table 1: Experimental design of the in-vivo RBC survival studies  




INITIAL SCREENING OF PHOTOSENSITIZERS  
VSV inactivation. All sensitizers tested were capable of inactivating extracellular 
VSV. However, the light dose needed for 5-log10 VSV kill varied strongly (Fig. 2A). 
Tri-P(4) appeared to be the most efficient sensitizer, requiring a light dose of 90 
kJ/m2 (15 min at 100 W/m2). The dose required for Mono-P(4) was fourfold 
higher. All other sensitizers required an intermediate light dose varying from 120 
to 240 kJ/m2.  
RBC damage. A light dose needed to kill 5-log10 VSV was used to study the effect 
of the different porphyrins on RBC integrity. Figure 2B shows the RBC hemolysis 
after storage of treated cells in SAG-M. Virucidal treatment with Tri-P(4) induced 
the least hemolysis,  5.1 ± 1.1% after 35 days of storage. Virucidal treatment with 
TAP, TNH and Tetra-P(4) induced intermediate levels of hemolysis (mean 16.13 ± 
0.81% ), whereas Trans-P(4), Cis-P(4) and Mono-P(4) induced very high levels of 
hemolysis. Further experiments were restricted to Tri-P(4). RBCs were 
photodynamically treated with 25 μM Tri-P(4) and a light dose of 90 kJ/m2 (15 
min, 100 W/m2). RBCs were stored for 5 weeks at 4-6°C. 
HEMOLYSIS AND POTASSIUM LEAKAGE: COMPARISON OF VARIOUS 
ADDITIVE SOLUTIONS 
After 35 days of storage in tubes, hemolysis of control cells amounted to 1.9 ± 
1.1% and was independent of the additive solution used. Storage of Tri-P(4)-
treated RBCs in SAG-S or SAG-D resulted in lower hemolysis as compared to SAG-
M (Fig. 3). Hemolysis was the lowest after storage in AS-3 (2.3 ± 1.9%). After 
storage in SAG-S, SAG-D and AS-3, there was no significant difference between 
treated cells and controls. When stored in SAG-M, SAG-S, and SAG-D, Tri-P(4) 




Potassium leakage during storage was substantially higher for Tri-P(4)-treated 
cells than for  the controls and was independent of the storage solution (Fig. 4). 
We observed a rapid increase in extracellular K+ 1 day after illumination, followed 
by a gradual increase to about 60% after 35 days of storage. In the controls, K+ 
leakage was around 40% after 35 days. The presence of the scavengers GSH (32 





Figure 2: (A) Infectivity of VSV after 
PDT. RBCC spiked with 5-log10 
extracellular VSV were illuminated 
with red light (light intensity: 100 
W/m2) in the presence of 25 μM 
Tetra-P(4) ( ), Tri-P(4) ( ), TNH-P(4) 
( ), TAP ( ), Trans-P(4) ( ), Cis-P(4) 
( ), Mono-P(4) ( ). Results are ex-
pressed as percentage of un-treated 
control. (B) RBC hemolysis after 
virucidal treatment. RBCC with 25 μM 
porphyrins were illu-minated with a 
light dose giving 5-log10 kill of VSV. 
After treatment, the cells were stored 
for 35 days at 4 to 6°C. Control (red 
light only; +), Tetra-P(4), 240 kJ/m2 
( ), Tri-P(4), 90 kJ/m2 ( ), TNH-P(4), 
120 kJ/m2 ( ), TAP, 180 kJ/m2  ( ), 
Trans-P(4), 150 kJ/m2  ( ), Cis-P(4), 
190 kJ/m2 ( ), Mono-P(4), 360 kJ/m2 
( ). Results are expressed as 
percentage of total Hb. Error bars 
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Figure 3. Role of the storage solution on RBC hemolysis.  
RBCC, Hct 60% in SAG-M, were treated with red light only (+), 25μM Trip-(4) only ( ) or with 25μM 
Tri-P(4) plus red light (90 kJ/m2, ). After treatment, cells were resuspended in SAG-M, SAG-S, SAG-
D or AS-3 and stored for 35 days at 2-6°C. Hemolysis is expressed as percentage of total Hb. Data 
presented are the average ± SD of 4 to 6 experiments. Significant differences are indicated with * (p 









Figure 4: Potassium leakage after PDT with Tri-P(4).  
RBCC, Hct 60% in SAG-M, were treated with red light only (90 kJ/m2; open symbols) 
or 25 μM Tri-P(4) plus red light (90 kJ/m2, filled symbols). After treatment cells were 
resuspended in SAG-M ( ; ), SAG-S ( ; ), SAG-D ( ; ) or AS-3 ( ; ) and 
stored for 35 days at 4 to 6°C. Data presented are average ± SD of four to six 




OTHER RBC VARIABLES 
RBC quality variables after storage in SAG-M are summarized in Table 2. After 35 
days of storage, the cellular ATP content and extracellular glucose levels 
decreased and the lactate concentration increased to comparable levels in both 
control and Tri-P(4) treated cells. The GSH concentration in treated cells was 
slightly decreased after 35 days of storage. The photodynamic dose used in these 
experiments did not induce any detectable lipid peroxidation, changes in 
deformability of the cells or changes in anion transport through band 3. The use of 
different additive solutions had no effect on any of the mentioned variables (data 
not shown).  
         ATP  Glucose  Lactate  GSH 
                Week (μmol/g Hb) (mg/mL)  (mol/L)  (μmol/g Hb)  
 
Control      1 3.8  0.4  4.1  0.5  12.3  2.2 1.5  0.3 
      5 1.8  0.3  2.3  0.5  23.0  4.0 1.5  0.2 
Tri-P(4)      1 4.0  0.5  3.5  1.5  12.1  3.9 1.6  0.1 
      5 1.6  0.3  2.4  0.5  23.9  1.4 1.2  0.3 
Table 2: RBC quality after photodynamic treatment with Tri-P(4) and red light * and stored in SAG-M 
during 5 weeks (mean ± sd).  
* Light dose of 90 kJ/m2 which corresponds to an illumination time of 15 min at 100 W/m2 
IgG BINDING AND AGGLUTINATION  
Virucidal treatment of RBCC, Hct 60% in SAG-M with Tri-P(4) resulted in binding of 
IgG to RBCs. The extent of the binding was light dose dependent and increased 
with illumination time. IgG binding after treatment at 90 kJ/m2 was very low, 
sometimes undetectable by DAT (Table 3) and flow cytometry (Fig. 5A). The MFI 
of untreated cells was 4.7 ± 0.6, that of treated cells with 90 kJ/m2 was 5.1 ± 0.7 
and with 360 kJ/m2 the MFI was 8.2 ± 2 (Fig. 5A). PDT with AlPcS4 (2.5 μM, 360 
kJ/m2) was previously described to induce IgG binding19 and was used as a positive 
control. Both Tri-P(4)-induced IgG binding measured by flow cytometry and 
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agglutination in the DAT could be prevented by the presence of GSH (32 mM) 
during the illumination. Addition of GSH after PDT did not reduce or prevent IgG 
binding or agglutination (Fig. 5B and Table 3). The presence of the singlet oxygen 
scavenger DIP (125 μM) during illumination did not prevent IgG binding or 
agglutination.  
Figure 5: (A) Binding of IgG to RBCs after PDT with Tri-P(4). RBCC were treated in the presence of 25 
μM Tri-P(4) with a light dose of 90 kJ/m2 or 360 kJ/m2. RBCC treated with AlPcS4 (2.5 μM, 360 kJ/m
2) 
served as positive control. One representative experiment of a total of seven experiments is shown. 
(B) Effect of GSH on the Tri-P(4)-induced binding of IgG to RBCs. RBCC were treated with 25 μM Tri-
P(4) with a light dose of 360 kJ/m2. GSH (32 mM) was added to the RBCC either before or after the 
illumination. After treatment cells were analyzed for IgG binding by flow-cytometry, as described in 
Material and Methods. One representative experiment of a total of three experiments is shown. The 
untreated sample is shown in solid gray.  
To unravel the process of the photodynamically induced IgG binding, plasma and 
plasma-free RBCs were treated with Tri-P(4) (light dose 360 kJ/m2) separately. No 
IgG binding was detectable after phototreatment of the plasma-free RBCs. Using a 
cross-match reaction (IAT), i.e. plasma added to RBCs, it was shown that both Tri-
P(4)-treated plasma and Tri-P(4)-treated plasma-free-RBCs were required for IgG 
binding and to induce agglutination. The IAT remained negative when a single 
treated component, RBCs or plasma, was added to an untreated one (Table 3).  
 





























DAT Untreated 90 kJ/m2               360 kJ/m2 + GSH* during PDT         + GSH* after PDT  
 
RBCC†  0 (n = 7)               0 / + (n = 4 / 3)      4+ (n = 7)       0 (n = 3)              4+ ( n = 3)  
 
IAT      Washed RBCs‡   
             Untreated        PDT (360 kJ/m2)              PDT (360 kJ/m2) + GSH* 
 
Plasma        
Untreated          0  0   0 
PDT (360 kJ/m2)   0  2+   0 
PDT (360 kJ/m2) + GSH*   0  0   0 
 
* [GSH ] = 32 mM 
†RBCC, Hct 60% in SAG-M 
‡ Washed 6 times in SAG-M (= plasma-free RBCs) 
Table 3: DAT and IAT score after PDT with Tri-P(4) and red light 
MONKEY RBCS 
IN VITRO QUALITY  
Tri-P(4) treatment of monkey RBCC spiked with VSV, using the same conditions as 
for human RBCC, resulted also in a 5-log10 kill of VSV. RBC hemolysis was assayed 
after 35 days of storage in AS-3. AS-3 was selected because it was shown to 
maintain human RBC integrity better than SAG-M (Fig. 3). After 35 days of 
storage, the hemolysis of untreated monkey RBCC was 2.7%, 1.5-fold higher than 
with human RBCC. After PDT with Tri-P(4), hemolysis amounted to 4.2% after 35 
days of storage. This was twofold higher than observed with human RBCC in AS-3. 
After 1 week of storage, the level of photodynamically induced K+ leakage was as 
high as in human-RBCC after 35 days of storage. After PDT with Tri-P(4) at 90 
kJ/m2, no IgG binding was found on monkey RBCs in the DAT using anti-Hu-IgG 
and C3.  
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IN VIVO SURVIVAL 
The 24-hr recovery of autologous RBCs is shown in Table 4. After PDT, the 24-hr 
recovery of fresh RBCs was in the same range as for non-treated cells (85%). After 
5 weeks of storage, the 24-hr recovery of treated RBCs was approximately 11% 
lower than that of untreated stored cells. The values for T50 showed a large 
variation, which was independent of the treatment. The residual Tri-P(4) 
concentration in the transfusion products was about 1-2 μM. No clinical 
symptoms suggesting transfusion-related adverse effects were observed. 
Blood samples taken 30 min, 1 hour and 24 hours after transfusion were analysed 
for chemical and hematological values. Values for number of WBC, RBC and 
platelets, serum creatinin, total bilirubin and LDH were all in the normal range and 
there were no differences between PDT-treated and untreated transfusions (data 
not shown). Haptoglobin concentration was increased in some samples 24 hours 
after transfusion, but this was not associated with the treatment method of RBCs.  
Twenty-four hours after transfusion, urine analysis (51Cr, bilirubin, protein) 
showed no change with the values obtained before the RBC infusions (data not 
shown).  
 
Transfusion product            Fresh RBCC       Stored RBCC 
   Monkey A          Monkey B         Monkey A            Monkey B 
 
24-hr recovery (%)             
Untreated               82  87                 81        73 
PDT          90  80                 62                      68 
T50 (days) 
Untreated               16                  18                             23        26 
PDT           22                  19                             15        20 








Positively charged porphyrins are known to inactivate bacteria.24,36 Our study has 
shown that they are also able to inactivate extracellular VSV. VSV is a lipid 
enveloped, single stranded RNA virus which has been found to be as sensitive to 
PDT with Pc4 and red light as HIV and is therefore a useful virus to study PDT.37 All 
positively charged porphyrins tested were able to inactivate extracellular VSV 
spiked in RBCC (Fig. 2a), however the compounds differed greatly by their 
potential to preserve RBC integrity during storage. Under conditions that induced 
a 5-log10 inactivation of extracellular VSV, the hydrophobic compounds Trans-P(4), 
Cis-P(4) and Mono-P(4) caused a very high percentage of  cell lysis after 35 days of 
storage. Because of their hydrophobic nature, these compounds most likely 
penetrated the bilayer of the RBCs. The hydrophilic compounds Tetra-P(4), TAP 
and TNH-P(4) showed a moderate percentage of lysed cells. The amphiphilic Tri-
P(4) showed the least hemolysis and could therefore be a suitable photosensitizer 
for pathogen inactivation in of RBCC. 
Tetra-, Tri- and Di-P(4)’s have been shown to intercalate in isolated calf thymus 
DNA.38,39 Although this property may contribute to the selective killing of viruses, 
the exact mechanism by which the porphyrins inactivate viruses still remains to be 
explored.  
RBC integrity after Tri-P(4)-mediated phototreatment was influenced by the 
composition of the storage solution. Storage of treated cells in SAG-S, SAG-D or 
AS-3 resulted in much less hemolysis as compared to storage in SAG-M. 
Comparable results were recently obtained by Besselink et al. 40 using the 
photosensitizer DMMB. The presence of high concentrations of impermeable 
macromolecules in SAG-S (29 mM sucrose), SAG-D (29 mM dextran 1000) and AS-
3 (22 mM citrate) compensate for the osmotic activity of intracellular Hb.41-42  
RBC metabolic function and deformability remained intact after PDT with Tri-P(4), 
whereas K+ leakage during storage was increased. We have previously shown that 
K+ leakage induced by PDT with DMMB was related to damage to band 3 and that 
both band 3 damage and K+ leakage could be reduced by scavenger DIP.43  Tri-P(4) 
seems to have a different mechanism, since K+ leakage is induced without 
affecting band 3 activity, and the addition of DIP did not reduce K+ leakage. The 
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mechanism underlying K+ leakage induced by Tri-P(4) phototreatment remains 
unclear. Further investigations focusing on channels involved in K+  concentration 
regulation such as the Na+-K+ pump, Gàdos channel and the K+Cl- co-transporter 
might help to unravel the mechanism behind the K+ leakage.  
IgG binding was induced by PDT with Tri-P(4). However the extent of IgG binding 
at virucidal light dose (90 kJ/m2) was very low and was sometimes not detectable 
(Table 3). IgG binding induced by PDT is a known phenomenon which can be 
prevented by the addition of the scavenger GSH during illumination. GSH can 
prevent IgG binding by prevention formation of disulfide bridges.19 In agreement 
with previous findings of Rywkin et al.19 the addition of GSH after the 
phototreatment was unable to reverse IgG binding or agglutination. Addition of 
DIP did not prevent IgG binding. To ensure cell survival and to avoid problems 
with compatibility testing, it may be necessary to add GSH or cysteine during the 
PDT with Tri-P(4). Both GSH and cysteine are natural constituents of the blood and 
therefore might not have to be removed before transfusion. 
The cross-match IAT showed agglutination only when both plasma-free RBCs and 
plasma were photo-treated. This suggests that both the RBC membrane and 
plasma proteins were modified by PDT. Remarkably, there was no agglutination 
when Tri-P(4)-treated plasma-free RBCs were incubated with untreated plasma. 
This indicates that Tri-P(4) does not induce formation of neoantigens reacting 
with naturally occurring auto-antibodies. This however does not preclude that 
phototreated RBC membrane alterations may cause new antibody formation 
upon transfusion.  
Based on the promising in-vitro results on one side and the considerable efforts to 
translate our experimental set-up for application in humans on the other, we 
evaluated the in-vivo survival of Tri-P(4) treated RBCs in 2 Rhesus monkeys. The 
number of animals was kept to a minimum by performing a cross-over study. The 
study was not meant to obtain statistic relevance but to evaluate whether 
proceeding with Tri-P(4) was worthwhile. Both the 24-hour recovery and the long 
term survival were satisfactory after transfusion of phototreated fresh RBCs. In 
accordance with previous reports,44 we found monkey RBCs to be more fragile 
than human RBCs.  Storage of monkey RBCC resulted in higher hemolysis as 




experimental conditions storing RBCC in tubes were suboptimal compared to the 
Blood Bank conditions in which RBCC are stored in bags. After 5 weeks of storage, 
the 24-hour recovery was lower compared to fresh RBCs and recovery was 
approximately 10% reduced by Tri-P(4)-mediated PDT (Table 4). The T50 however, 
varied in our study from 15 to 26 days, and was not clearly associated with either 
the storage or the PDT. The true impact of PDT on in-vivo survival after storage is 
difficult to interpret as suboptimal storage condition, using tubes instead of bags, 
were used.  
Recent publication by Vitex and Cerus45,46 have reported the formation of 
autoantibodies in patients receiving Pen-110- or S-303-treated RBCs and Phase III 
clinical trials have been abandoned. These results were unexpected and not 
foreseen despite extensive animal studies. Our study showed that treatment with 
Tri-P(4) preserved the structure and functionality of RBCs but resulted in a slight 
elevation of hemolysis after 5 weeks of storage, an acceleration of  K+ leakage, 
and a weak induction of IgG binding, which  could be prevented by GSH. Although 
it seems that neoantigens reacting with naturally occurring IgG antibodies are not 
formed after Tri-P(4)-mediated PDT,  to predict the immunogenicity of Tri-P(4)-
treated RBCs in human trials in-vivo, further research is required to elucidate the 
cause of this event.  
The results obtained in this study form an acceptable basis for further 
investigations on the use of Tri-P(4) for pathogen inactivation in RBCC. Further 
research will focus on the inactivation of viruses more relevant to transfusion 
medicine, such as HIV and hepatitis viruses. Also the inactivation of intracellular 
viruses has to be studied. It might well be possible that for inactivation of other 
more resistant viruses, a more stringent photoinactivation is needed, which might 
result in more RBC damage. Therefore, more insight in both the mechanism of 
pathogen inactivation and RBC damage after phototreatment with Tri-P(4) is of 
utmost importance.  
In conclusion, although we realize that the step from “bench” experiments to a 
functioning pathogen inactivation system in a blood-bank setting is a big one, Tri-
P(4)-mediated phototreatment might become a suitable method to inactivate 
pathogens in cellular blood products. 
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Background and Objectives: PDT with the cationic porphyrin Tri-P(4) was 
previously shown to effectively inactivates VSV in RBCC with limited damage to 
RBC. The aim of this study was to determine the pathogen inactivating capacity of 
PDT with Tri-P(4) for a broader range of pathogens and the associated effect on in 
vitro red blood cell quality. 
Materials and methods: A series of viruses and bacteria were spiked in 60% RBCC. 
Pathogen inactivation were determined after PDT with 25 μM Tri-P(4) and red 
light up to 360 kJ/m2. Human immunodeficiency virus (HIV)-infected cells were 
evaluated for cell death induction, and treated RBCs for induction of hemolysis 
and ATP content. 
Results: For the lipid enveloped viruses bovine viral diarrhoea virus (BVDV), HIV 
and pseudorabies virus (PRV), the gram positive (G+) bacterium Staphylococcus 
aureus and the gram negative (G-) bacteria Pseudomonas aeruginosa and Yersinia 
enterolitica, 5 log10 or more inactivation was measured after 60 min of PDT with 
Tri-P(4). The required treatment time to achieve this level of inactivation was four 
times longer than required for VSV in the previous study. For cell-associated HIV 
only 1.7 log10 of inactivation was found, despite clear induction of cell death of 
HIV-infected cells. The non-enveloped virus canine parvovirus (CPV) was 
completely resistant to the treatment. PDT with Tri-P(4) for 60 min of RBCC and 
subsequent storage in AS-3 resulted in 4% of hemolysis after 35 days of storage. 
ATP content of untreated and treated RBCs declined with similar kinetics during 
storage. 
Conclusion: PDT with Tri-P(4) for 60 min of RBCC inactivates a wide range of 
pathogens, but not cell-associated HIV and a non-enveloped virus and 
compromises RBC quality. This impairs PDT with Tri-P(4) as a suitable method for 
pathogen inactivation in RBCC. Therefore, further improvements of the treatment 
to potentiate pathogen inactivation and to preserve RBC integrity will be required 
to generate an effective treatment to decontaminate RBCC.  
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INTRODUCTION 
Risks associated with blood transfusion have dramatically decreased by the 
implementation of careful donor selection and sensitive tests. Since the 
introduction of nucleic acid tests (NAT) for Hepatitis C virus (HCV) and HIV, the risk 
of transfusion-associated transmission of these viruses has decreased to less than 
one in a million donations, although low levels of viraemia were missed in a 
recent case of HIV transmission through transfusion of RBCC.1,2 Furthermore, 
there is a residual risk of transmission of viruses that are not regularly screened, 
such as human parvovirus B19 and human cytomegalovirus.3,4 The emergence of 
new viruses and increased donor travel has resulted in an increased awareness of 
the risks associated with blood transfusion.5-7 
The safety of cellular blood products is not only challenged by emerging viral 
infections, but also by common bacterial infections, as RBCC are not routinely 
tested for bacterial contamination. The prevalence of bacterial transmission 
through RBC transfusion is reported by the French Hemovigilance network to 
amount to 1.6% (73 / 4706).8 Also reports from the British Serious Hazards of 
Transmission and the US FDA indicate that bacterial contamination of RBCC, 
mainly with Yersinia Enterolitica and Pseudomonas spp, is a major cause of 
morbidity and mortality.9,10 
Implementation of individual tests to detect a wider range of pathogens 
responsible for morbidity and mortality seems unrealistic. A strategy involving 
pathogen inactivation technologies may offer better perspectives, further 
improving the safety of transfusion products. Pathogen inactivation technologies 
based on the use of UV-light, as developed for platelets are very promising 11. 
However, this technology is not applicable to RBCC, as the technologies based on 
the use of light are hampered by the fact that hemoglobin (Hb) strongly absorbs 
between 300-600 nm. Therefore, pathogen inactivation technologies for RBCC can 
use either light-independent chemical compounds or photodynamic compounds 
that can be activated with light at wavelengths above 600 nm. The chemical 
approach uses S-30312 or Inactine 13, which have a high affinity for nucleic acid, 




acceptable in-vitro quality and in-vivo survival. However, transfused patients 
unexpectedly produced antibodies against the treated RBCs, resulting in the 
postponement of the initiated clinical trials.14,15 
The photodynamic approach relies on the use of light-absorbing molecules which, 
upon activation with light at the appropriate wavelength, produce singlet oxygen, 
causing oxidative damage to target cells. The resulting damage occurs in the close 
vicinity of the photosensitizer and can lead to inactivation of the micro-
organism.16 Several photosensitizers have been investigated for their ability to 
inactivate pathogens in RBCC; however most of them caused unacceptable RBC 
damage.17-21 
Recently, we showed that PDT of RBCC with the positively charged porphyrin Tri-
P(4) resulted in 5 log10 reduction of the model virus VSV with only limited damage 
to subsequently stored RBCs.22 This was considered worthy of further 
investigations. In this article, we extend the previous study by investigating the 
effect of PDT with Tri-P(4) on a series of viruses and bacteria. HIV-infected cells 
were used to study the inactivation of cell-associated HIV and to study the effect 
of the treatment on infected cells. Finally, we evaluated the effect of PDT dosage, 
needed for optimal pathogen inactivation, on in-vitro RBC quality. 
MATERIAL AND METHODS 
REAGENTS AND PHOTOSENSITIZER 
Photosensitizer Mono-phenyl-tri-(N-methyl-4-pyridyl)-porphyrin chloride (Tri-P(4)) 
was kindly provided by Buchem N.V. (Apeldoorn, the Netherlands). Stock 
solutions of 1 mM were prepared in PBS pH 7.4 (Leiden University Medical Center 
(LUMC) pharmacy, Leiden, the Netherlands) and stored in the dark at 2-6 °C. RBC 
storage solutions SAG-M and AS-3 were obtained from Baxter Fenwal (Utrecht, 
the Netherlands) and Haemonetics Co. (Braintree, MA), respectively. SAG-M 
contains 150 mM NaCl, 1.25 mM adenine, 50 mM glucose, and 29 mM mannitol. 
AS-3 contains 70 mM NaCl, 61.1 mM glucose, 2.22 mM adenine, 2 mM citric acid, 
20 mM Na3citrate, and 15.5 mM Na2HPO4.  
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PREPARATION OF RBCC 
Whole blood was collected using a quadruple CPD / SAG-M blood bag system 
(Compoflex; Fresenius Hemocare, Emmer Compascuüm, the Netherlands). After 
overnight storage at room temperature, the whole blood unit was centrifuged at 
2900 x g for 8 min and separated into RBC, plasma, and buffy coat with 
Compomat G4 (Fresenius Hemocare). SAG-M was transferred from one of the 
satellite bags to the RBC. The RBC suspension was leucodepleted by passage over 
a BioR leucocyte-reduction filter (Fresenius Hemocare, Cavezzo, Italy). The volume 
of the resulting suspension was 270-320 mL with a hematocrit (Hct) of about 60%.  
BACTERIA 
Pseudomonas aeruginosa (G-, isolated from a patient) was kindly provided by the 
Central Bacteriological Laboratory (Haarlem, the Netherlands). Yersinia 
enterolitica (G-, ATCC #9610) and Staphylococcus aureus (G+, ATCC #2593) were 
kindly provided by the Department of Medical Microbiology of the LUMC, Leiden, 
the Netherlands. Bacteria were grown in 10 mL of brain heart infusion broth 
(Oxoid Ltd., Hampshire, UK) at 35 °C. After 18 hours, bacteria were harvested by 
centrifugation at 2000 x g for 10 min, washed twice with PBS and finally 
resuspended in PBS to an optical density of 0.7 at 650 nm corresponding to 
approximately 108 CFU/mL.  
VIRUSES AND CELL LINES 
A series of lipid-enveloped and non-lipid enveloped viruses were used as models 
for the major blood-borne viruses (Table 1). Pseudorabies virus (PRV), strain 
Aujeszki Bartha K61 (Duphar, Weesp, the Netherlands), was cultivated and 
titrated on PD5 swine kidney cells (Duphar). Bovine viral diarrhoea virus (BVDV), 
strain NADL (VR-534, ATCC, Manassas, VA, USA), was cultivated on MDBK cells 
(CCL-22, ATCC) and titrated on EBTr cells (Animal Sciences Group, Lelystad, the 
Netherlands). HIV, strain HTLV-IIIB (National Cancer Institute, Bethesda, MD, 
USA), was cultivated on H9 cells (National Cancer Institute) and titrated on MT2 




(State University Rotterdam, Rotterdam, the Netherlands), was cultivated and 
titrated on A72 cells (State University Rotterdam). For BVDV and PRV non-
concentrated-serum containing culture supernatants served as inocula for spiking 
studies. For CPV and extracellular HIV (E-HIV) concentrated serum-free inocula 
were used. For cell-associated HIV (CA-HIV) chronically HIV-infected H9 cells 
(National Cancer Institute, Bethesda, MD) were used. CA-HIV contains all forms of 
the virus present during its life cycle: provirally infected cells, and intracellular, 
membrane bound and cell-free virus particles. 
 
Table 1: Viruses, their properties and use as model 
 
LIGHT SOURCE AND EXPERIMENTAL SET-UP 
A 300 W halogen lamp (Philips, Eindhoven, the Netherlands) combined with a cut-
off filter (Kodak, wratten nr. 23A, Rochester, NY) only transmitting light > 600 nm, 
was used as source of red light. To avoid heating of the samples, the red light was 
passed through a 1-cm thick water layer. RBCC was treated in tissue culture grade 
Petri dishes (Greiner, Alphen a/d Rijn, the Netherlands) placed under the red light 
 Virus  Virus family  Virus group  Genome type  Size [nm]  Model for 
 PRV  Herpes  Lipid enveloped  dsDNA  100-200 
 Large lipid env. dsDNA viruses 
(Hepatitis B virus, 
Cytomegalovirus) 
 BVDV  Flavi  Lipid enveloped  ssRNA  37-50 
 Hepatitis C virus, 
 West-Nile virus 
 HIV  Retro  Lipid enveloped  2 ssRNA  100  (Relevant virus) 
 CPV  Parvo 
 Non-lipid 
enveloped 
 ssDNA  18-26  Human parvovirus B19 
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source on a shaker. The fluence rate at the level of the Petri dish was adjusted to 
100 W/m2 as measured with an IL1400A radiometer with a SEL033 detector 
(International Light, Newburyport, MA, USA). 
PHOTODYNAMIC TREATMENT 
Stock solutions of bacteria and viruses were 10-fold diluted in the RBCC. To 
maintain the original Hct, RBCC were centrifuged at 2000 x g for 10 min. 
Subsequently, 10% of the total RBCC volume was removed from the supernatant 
and the same volume of solutions containing pathogens was added to RBCC. Tri-
P(4) was added to the spiked RBCC to a final concentration of 25 μM. The 
suspension was incubated in the dark for either 5 min (for viruses) or 30 min (for 
bacteria) under continuous mixing. Subsequently, the suspensions were 
transferred to Petri dishes (Greiner). The resulting thickness of the cell layer was 1 
mm. The dishes were illuminated, under continuous agitation (100-120 RPM) for 
various periods of time to determine pathogen inactivation kinetics. For each 
sample, a separate Petri dish was used.  The maximum illumination time was 60 
min, corresponding to a light dose of 360 kJ/m2. As a negative control (or light 
control), RBCC were illuminated without addition of pathogens and 
photosensitizer for the maximum illumination time tested. As a positive control 
(or dark control), RBCC were spiked with pathogens and photosensitizer and 
subsequently were kept in the dark for the maximum illumination time tested. 
INACTIVATION OF BACTERIA 
The number of viable bacteria in samples collected was determined with limiting 
dilution assays, according to a modified version of the method described by Miles 
and Misra.23 Samples were serially 10-fold diluted in PBS. Each dilution was plated 
on an iso-sensitest agar (Oxoid Ltd, Hampshire, UK) plate. Staphylococcus aureus 
and Pseudomonas aeruginosa were incubated at 35°C for at least 18 h and 
Yersinia enterolitica was incubated at room temperature (20-25°C) for at least 36 
h. After the incubation, the colonies on the agar plates were counted and colony 
forming units (CFU) were calculated for each sample tested. Clearance factors (CF) 




derived from the inoculum sample / total amount of bacteria recovered from the 
treated sample). 
INACTIVATION OF VIRUSES 
Infectivity was measured with TCID50 assays and bulk culture tests. For TCID50 
assays, three-fold serial dilutions of samples were prepared in culture media and 
50 μL (or 0.5 mL for HIV) volumes were tested in eight replicates. To detect small 
amounts of virus, samples were tested in duplicate bulk culture tests using 175 
cm2 flasks. BVDV, CPV, and PRV cultures were inspected microscopically for 
cytopathic effects at 6, 7, and 5 days post-infection (dpi), respectively. HIV 
cultures were inspected microscopically twice a week for formation of syncytia 
until 21 dpi. Prior to testing the samples were 27-fold diluted with culture 
medium and centrifuged at 1000 x g for 10 min to remove the RBCs. HIV-infected 
H9 cells were isolated from the RBCC with Ficoll-Paque density gradient 
centrifugation and tested in a co-culture assay with MT2 cells as previously 
described.24 Virus titres were calculated by the Spearman-Kärber method, and 
expressed as TCID50 / mL which define the reciprocal dilution that is able to infect 
50% of the inoculated cultures. If all cultures were negative, the titre was 
considered to be less than 1/total test volume (mL). Reduction factors (RF) were 
calculated by the formula: RF = log10 (total amount of virus spiked as derived from 
the reference sample / total amount of virus recovered from the treated sample).  
APOPTOSIS OF CHRONICALLY HIV INFECTED H9 CELLS 
HIV-infected H9 cells were isolated from the RBCC samples using Ficoll-Paque 
density centrifugation, diluted with culture medium and incubated at 37°C. After 
24 h, the cells were resuspended in HEPES binding buffer (20 mM HEPES, 132 mM 
NaCl, 6 mM KCl, 1 mM MgSO4, 1.2 mM KHPO4, 0.5% albumin, and 1 mM CaCl2, pH 
7.4). The cells were labelled with AnnexinV and propidium iodine (PI) (ApoptestTM-
Fitc kit, VPS Diagnostics, Hoeven, the Netherlands) during 10 min on ice, washed 
once with binding buffer and analysed in BD flow cytometer (Facscan) (Becton 
Dickinsons, Erembodegem, Belgium). As a positive control for apoptosis induction, 
incubation with 200 μM etoposide (Sigma-Aldrich, Saint-Louis, MI) for 16 h was 
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used; as a negative control, untreated HIV-infected H9 cells and non-infected H9 
cells incubated in culture medium only were used. 
RBC QUALITY ASSESSMENT 
Photodynamically treated RBCC, without pathogens, were washed twice and 
resuspended in AS-3 to a final Hct to 60%. The washed RBCs were stored in 15 mL 
tubes (Greiner) at 2-6°C for 35 days. Total Hb was measured with a Coulter Act 10 
instrument (Beckman Coulter, Mijdrecht, the Netherlands). Free Hb in the 
supernatant was measured with an Anthos SHT3 spectrophotometer (Anthos 
Labtec b.v., Heerhugowaard, the Netherlands) at 415 nm. From these values, the 
percentage hemolysis was calculated after correction for Hct. ATP content of the 
cells was determined using enzymatic reaction with hexokinase and glucose in 
neutralized perchloric acid extracts. NADPH production was measured at 340 nm 
in an Anthos SHT3 spectrophotometer and the concentration was calculated 
based on the absorption coefficient of NADPH. 
RESULTS 
PDT INDUCED BACTERIAL INACTIVATION 
Photodynamic treatment with Tri-P(4) for 60 minutes resulted in > 6.4 log10 
inactivation of  the G+ bacteria  S. aureus (Table 2). High levels of inactivation (5 - 
6 log10, but not complete) were obtained for G- bacteria P. aeruginosa and Y. 
enterolitica.  No inactivation (<1 log10) of the bacteria tested was observed in the 
dark controls. 
PDT INDUCED VIRUS INACTIVATION 
Photodynamic treatment with Tri-P(4) for 60 minutes resulted in 10 
inactivation of PRV and > 5.5 log10 inactivation of BVDV and extracellular (E)-HIV 
(Table 3). In contrast to these cell-free lipid-enveloped viruses, the inactivation of 
cell-associated (CA)-HIV was limited to approximately 2 log10, while the non-




no inactivation (<1 log10) of viruses was observed in the dark controls, indicating 
that the observed viral inactivation was due to the combined effect of Tri-P(4) and 







Mean clearance factor ± standard deviation (log10)* 
10 min 15 min 30 min 60 min Dark§ 
S.aureus 7.4 ± 0.2 2.8 ± 1.2 NA 5.8 ± 0.8 >6.4 ± 0.2† 0.2 ± 0.4 
P.aeruginosa 7.8 ± 0.4 NA 1.2 ± 0.9 3.5 ± 1.1 4.8 ± 0.6 0.1 ± 0.6 
Y.enterolitica 7.8 ± 0.2 NA 1.5 ± 0.3 2.7 ± 0.2 5.9 ± 0.4 0.3 ± 0.5 
Table 2: Inactivation of bacteria by photodynamic treatment with 25 μM Tri-P(4) and red light 
* The mean ± standard deviation of 2 - 4 independent experiments with RBCC units from different 
donors is presented. † No bacteria were detected in all replicates tested. The limit of detection used 
was 1 log10 CFU/mL. 
§ Dark controls: RBCC units were inoculated with bacteria and 25 μM Tri-P(4), 
and subsequently incubated for 60 min in the dark. NA: Not applied 
PDT INDUCED CELL DEATH OF HIV-INFECTED H9 CELLS  
To further investigate the resistance of CA-HIV to PDT, we determined by FACS 
analysis Annexin V and PI straining of the HIV-infected H9 cells treated with PDT. 
No increase of Annexin V and PI straining of HIV-infected H9 cells was observed 
after 15 min of treatment (Fig. 1). However a clear increase of Annexin V and PI 
staining was observed after 30 min of treatment (p=0.001 as compared to 15 
min), and approximately 90% of the cells stained positive after 60 min of 
treatment. The staining of the untreated and dark controls of HIV-infected H9 
cells was similar. HIV infection by itself already causes a certain degree of cell 
death. Comparing uninfected and HIV-infected H9 cells, we found 12.5% and 35 % 
positive for Annexin V and PI, respectively, while both type cells were even 
sensitive to etoposide (88% and 74% positive for Annexin V and PI, respectively) 
(data not shown).  





(Total TCID50 ) 
Reduction factor ± standard deviation (log10) 
15 min 30 min 60 min § Dark † 
PRV 
A 108.15   
 
 
1.4 ± 0.3 
B 107.86   
 
1.1 ± 0.4 
BVDV 
A 106.13 1.5 ± 0.4  >5.5 ± 0.3 -0.4 ± 0.4 
B 106.25 1.7 ± 0.3  >5.6 ± 0.2 -0.1 ± 0.4 
E-HIV 
A 106.80 3.0 ± 0.4  
 
0.1 ± 0.3 
B 106.62 2.7 ± 0.4 >5.0 ± 0.2 >6.0 ± 0.2 -0.2 ± 0.3 
CA-HIV 
A 108.22 1.1 ± 0.4   0.4 ± 0.4 
B 108.12     
CPV 
A 107.56 0.1 ± 0.4 0.0 ± 0.4 0.1 ± 0.4 0.1 ± 0.4 
B 107.14 -0.4 ± 0.3 -0.4 ± 0.3 -0.2 ± 0.4 -0.4 ± 0.3 
Table 3: Inactivation of viruses by photodynamic treatment with 25 μM Tri-P(4) and red light 
* Each virus was tested in duplicate using RBCC units derived from two different donors. § These 
samples were also tested in 175 cm2 culture flasks. † Dark controls: RBCC units were inoculated with 
viruses and 25 μM Tri-P(4), and subsequently incubated for 60 min in the dark. 
 
RBC IN VITRO QUALITY 
We studied the in-vitro quality of RBCs after PDT. After PDT with the highest 
tested light dose (60 min of illumination) of 60% RBCC in SAG-M, the treated cells 
were washed twice and subsequently stored in AS-3 for a total period of 35 days. 
After 0, 7, 21, and 35 days samples were collected and tested for hemolysis and 




to 4 ± 2.6% after 35 days of storage (Fig. 2A). The hemolysis in untreated and dark 
controls however remained below 1% after 35 days of storage. The ATP content of 
untreated, treated RBCs, and dark controls declined with similar kinetics during 
storage (Fig. 2B). 
 
Figure 1. Induction of cell death of HIV-infected H9 cells by photodynamic treatment 
(PDT) with 25 μM Tri-P(4) and red light.  
HIV-infected H9 cells were spiked in RBCC and illuminated for 0, 15, 30, or 60 
minutes. A dark control was collected after incubation of spiked RBCC with 25 μM 
Tri-P(4) for 60 minutes, but not illuminated. Cells were analyzed for Annexin V 
expression and PI uptake after incubation at 37°C for 24 h. % of cell death expressed 






































Figure 2. Hemolysis (A) and ATP content 
(B) of RBCs stored in AS-3 for 35 days.  
After PDT with Tri-P(4) and illumination 
with red light for 60 min, samples were 
washed and suspended in AS-3 as 
described in Material and Methods. (o) 
Untreated samples; ( ) dark controls; 
( ) photodynamically treated samples. 
Mean with standard deviation of 4 











To extent our previous study which showed few damage to RBCs after 
photodynamic inactivation of VSV with Tri-P(4) 22, a broader range of bacteria and 
viruses were tested and the subsequent damage induced to RBCs was evaluated.  
We showed that both G+ and G- bacteria were sensitive to PDT with Tri-P(4). The 
clearance factors obtained – approximately 5 log10 – is likely to be sufficient to 
significantly increase the safety of RBCC for bacterial contamination, because 
treatment will be performed directly after production and before storage; and the 
initial contamination of blood products is very low, at the sensitivity level of 




We found that the viruses tested vary widely in their sensitivity to PDT with Tri-
P(4) of RBCC. To reach 5 log10 of inactivation of cell-free HIV, we had to use a 
fourfold higher light dose than required for 5 log10 of inactivation of VSV.
22 VSV 
has been used as a model virus for HIV, because both viruses are lipid-enveloped 
RNA viruses of medium size and are equally sensitive to PDT with the 
phthalocyanine Pc4.25 As the virucidal spectrum of PDT is dependent on the 
selected photosensitizer, the illumination system, and the treatment solution, it is 
not surprising to encounter in our study differences in sensitivities between VSV 
and HIV. Cell-associated HIV was clearly less sensitive to PDT with Tri-P(4) than 
cell-free HIV. This difference can be explained by a lack of diffusion of Tri-P(4) into 
cells and the notion that HIV can be shedded into endosomes in a infectious 
form.26 Tri-P(4) is positively charged photosensitizer and it is known that charged 
photosensitizers are in general less effective in intracellular inactivation than 
neutral photosensitizers.27 From preliminary data we know that Tri-P(4) does not 
enter the cell, indicating that intracellular HIV is probably not exposed to the PDT-
mediated reactive oxygen species.  
To further understand the difference in sensitivity to PDT with Tri-P(4) between 
cell-free and cell-associated HIV, we determined whether the treatment induce 
cell death in HIV-infected H9 cells. Although the treatment clearly induces cell 
death, this is not enough to stop effectively the virus production. While the cells 
undergo the process cell death – measured after 24 h 90% of the cells stain 
positive for Annnexin V and PI -  the virus already produced in the cells and not 
reached by the PDT with Tri-P(4), can still be excreted and subsequently 
contaminate the RBCC. 
The sensitivities of BVDV and PRV to PDT with Tri-P(4) of RBCC were similar to that 
of cell-free HIV. In dark controls no inactivation was found, except for PRV, 
indicating that there was no direct inactivating effect of Tri-P(4). For PRV a mean 
inactivation of 1.2 log10 was observed. This inactivation is probably due to anti-
alpha-galactosyl natural antibodies present in normal human serum - 10 to 15% of 
human plasma is still present in RBCC - resulting in neutralization of PRV, which 
was produced on swine kidney cells.28  
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In contrast to the lipid-enveloped viruses tested, no inactivation after PDT with 
Tri-P(4) of RBCC of the non-enveloped Canine parvovirus (CPV) was found. Within 
the Parvoviridae family, however, various sensitivities to PDT were reported. 
Porcine parvovirus (PPV) was found to be resistant to PDT with MB, while human 
parvovirus B19 was found to be sensitive.29 This remarkable difference in 
sensitivity might be explained by differences in the composition of the capsid of 
PPV and human-B19. In our study, we used CPV that like PPV belongs to the 
parvovirus genus, while human-B19 belongs to erythrovirus genus.30 Possibly, by 
using CPV as model for human-B19, the inactivation of human-B19 after PDT with 
Tri-P(4) of RBCC is underestimated. 
The PDT with Tri-P(4) results in more than 5 log10 reduction of the lipid-enveloped 
viruses extracellular-HIV, BVDV and PRV. Assuming that these data are relevant 
for the major blood-borne infections HIV, HBV and HCV, the treatment may be 
particularly useful for preventing viral transmission of RBCC derived from window 
blood donations. To illustrate the contribution of PDT with Tri-P(4) to viral safety 
of RBCC, a simple calculation of the residual risk can be made. The 95% detection 
limit for viral screening in RBCC donations is estimated to be 183 gEq/mL for HIV 
NAT, 126 gEq/mL for HCV NAT and 10000 IU/mL for HbSAg test.31,32 Assuming that 
RBCC contain 15 mL of plasma and all virus is present in the plasma fraction of the 
RBCC, the maximal viral load in RBCC is  3.103 gEq of HIV, 2 .103 gEq of HCV and 
1,5.105 IU of HBV. Assuming that the genome-equivalent (or IU) to infectious-
particle ratio is 1000 for HIV and 10 for HCV and HBV33, we can estimate the 
presence of maximally 3 infectious particles of HIV, 200 infectious particles of HCV 
and 15000 infectious particles of HBV per RBCC. A 5 log10 reduction would result 
in a residual infectivity per RBCC of 0.00003 infectious particle of HIV, 0.002 
infectious particle of HVC and 0.15 infectious particle of HBV. This calculation 
illustrates that the risk of transmitting the infection by transfusion of a treated 
RBCC in case of a window donation is significantly reduced compared to untreated 
RBCC. However, considering the titers of non-routinely tested viruses, which may 
amount to 106 to 1012 IU/mL, it is clear that the conditions used in our study to 




Recent studies investigating the mechanism of pathogen killing found that, with 
the yeast C. albicans, the addition of 10% PBS enhanced influx of the 
photosensitizer into the yeast, potentiating the photosensitizing effect.34 This 
mechanism might also be applicable for bacteria as suggested by Merchat et al.35 
It would be interesting to investigate the conditions upon which bacteria, 
leukocytes, and viruses, but not the RBCs, are permeable to the photosensitizer, 
increasing the Tri-P(4)-photoinactivation efficiency. 
In our previous studies, we showed that PDT with Tri-P(4) for 15 min was sufficient 
for 5 log10 inactivation of VSV inducing only a slight increase in hemolysis of 
subsequently stored RBCs.22 However, treatment up to 60 min was required to 
inactivate substantially bacteria and viruses tested in this study, and this clearly 
increased RBC damage. The hemolysis in treated RBCC remained below 0.8% after 
8 days of storage, but increased to 4% after 35 days of storage. The relatively high 
values for hemolysis can partially be explained due to suboptimal storage of the 
treated RBCs in tubes and lower values would be expected when the samples 
would be stored in bags. The latter was for practical reasons not possible. The 
hemolysis in untreated samples and dark controls was about 3-4 times higher 
than during storage under optimal conditions in bags. In contrast to the 
hemolysis, PDT with Tri-P(4) did not appeared to induce more ATP loss in AS-3 
stored RBCs.  
In conclusion we showed that PDT with Tri-P(4) of RBCC inactivates a wide range 
of pathogens, potentially closing the window period for routinely tested viruses. 
In Western countries, however, incidence of window donation is so rare that the 
benefit for increasing the blood safety is very small. Further research must include 
the use of particular incubation media, which could enhance the virucidal and 
bacterial effect of the photodynamic treatment, the protection of the RBCs as well 
as the improvement of storage media to better preserve RBC integrity. These 
many problems must be solved before Tri-P(4)-mediated PDT can be considered 
as a feasible approach to inactivate pathogens in RBC products. 
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Background: Hematopoietic stem cell transplants and culture of hematopoietic 
progenitor cells (HPC) require pathogen free conditions. The application of a 
method of pathogen inactivation in RBCC using PDT was investigated for the 
decontamination of cord blood stem cell (CBSC) products. 
Study design and methods: CBSC products, spiked with G+ and G- bacteria, were 
treated with PDT using Tri-P(4) and red light. After PDT, in-vitro and in-vivo 
evaluation of the CBSC functions were performed. 
Results: PDT of CBSC products resulted in the inactivation of the bacteria, with 
Staphylococcus aureus being the most resistant. Complete decontamination was 
achieved when CBSC products were contaminated with low titers of bacteria. PDT 
had no effect on leukocyte viability, the ex-vivo expansion potential of the 
progenitor cells and their capacity to differentiate to various hematopoietic cell 
lineages. However, PDT reduced the engraftment of human CBSC in NOD-scid 
mice; affecting particularly the B-cell lineage engraftment.  
Conclusion: Pathogen inactivation of CBSC with Tri-P(4)-mediated PDT is feasible 
at contamination level up to 10-20 cfu/mL and can be considered when ex-vivo 
expansion culture is anticipated. However this treatment is not recommended for 
transplantation purposes at this time. Further investigations may elucidate why 
engraftment is diminished. 
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INTRODUCTION 
The use of HPC products is increasing and expanding from hematopoietic 
transplantation to tissue engineering. To overcome the current limitations of the 
use of cord blood transplantation in adult patients, such as delayed hematopoietic 
reconstitution because of the low number of stem cells, ex-vivo expansion of CBSC 
is widely explored.1-4 
HPC products can harbor microorganisms, which in low levels (< 20 cfu/mL) may 
not be of clinical relevance in transplantation. However, HPC culture and 
expansion may create conditions in which low numbers of contaminating bacteria 
may reach levels of clinical significance. The contamination rate of HPC products 
varies with the graft source. Bacterial contamination of mobilized peripheral 
blood HPCs is lower compared to bone marrow harvests (2.1 % and 3.5 % 
respectively)5, while up to 13% of CBSC products has been found positive in 
bacterial cultures, depending on the sample size and the method of testing.6,7   
Recently, the FDA guidelines and Netcord FACT standards requested the release 
of pathogen-free CBSC products for transplantation.  All contaminated products 
are discarded, what may form a serious problem in case of cord blood 
transplantation with a family donor. To minimize the risks of bacterial 
contamination at the time of cord blood collection, efforts were made, i.e. by 
stringent disinfection and intensive monitoring of clean areas. However, these 
efforts did not reduce the rate of microbial contamination.8 The addition of 
antibiotics in-vitro appeared to be unsuccessful and even introduced new 
contamination.9 In general, the use of antibiotics is discouraged because of the 
risk of development of bacterial resistance.10  
To overcome these problems, we evaluated whether pathogen inactivation by 
PDT with a cationic porphyrin, mono-phenyl-tri-(N-methyl-4-pyridyl)-porphyrin 
(Tri-P(4)) could be suitable for CBSC products.  This method was originally 
developed for RBCC, where it successfully inactivates non-cell bound lipid-
enveloped viruses, G+ and G- bacteria.11,12 Based on RBCC experiments, we first 




studied the potency of PDT to inactivate the G+ bacterium Staphylococcus aureus 
and the G-bacteria Pseudomonas aeruginosa and Streptococcus agalactiae, since 
especially this latter bacterium is frequently found in CBSC products (6.25 %).6 
Furthermore, we evaluated the effect of PDT on the CBSC viability and HPC 
functions.  
MATERIAL AND METHODS  
MATERIALS 
Photosensitizer Tri-P(4) was kindly provided by Buchem b.v., Apeldoorn, the 
Netherlands. Stock solutions of 1 mM were prepared in PBS and stored in the dark 
at 2-6°C. 
PBS (pH 7.4), Polymixin-B, Ficoll gradient and Hydroxy-ethyl starch (HES) were 
provided by the Leiden University Medical Center (LUMC) Pharmacy, Leiden, the 
Netherlands.  
Cipoxin and Fungizone were provided by Bristol-Meyers-Squibb, Woerden, the 
Netherlands. 
IMDM medium was purchased from Invitrogen, Breda, the Netherlands. Penicillin 
and streptomycin (pen/strep) were purchased from Bio-Whittaker (Verviers, 
Belgium). Human serum albumin Cealb® and AB heparin plasma were provided by 
Sanquin, Amsterdam, the Netherlands. Thrombopoietin was kindly provided by 
Amgen, Thousand Oaks, CA, USA. DNAse, Human transferring saturated with 
FeCl3.H2O were purchased from Sigma-Aldrich (Saint-Louis, MI, USA).  
Phycoerythrin-conjugated (PE) anti-human CD3, CD14, CD15, CD19, CD33, CD34, 
CD41, CD56 and isotype-matched mouse IgG2a monoclonal antibodies and 
fluorescein-conjugated (FITC) anti-human CD45, CD61, CD62p and isotype-
matched mouse IgG1 monoclonal antibodies, apoptosis detection kit containing 
Annexin V-FITC and binding buffer, IOTest3 lysis solution and the Flow-count 
fluoropheres were purchased from Beckman Coulter, Mijdrecht, the Netherlands. 
Rat anti-mouse CD45-FITC and rat IgG2b-FITC were purchased from PharMingen, 
San Diego, CA, USA.   
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StemSep CD34 positive selection kit, Methocult GF H4434, MegaCult and alkaline 
phophastase detection system were provided by StemCell technologies, Grenoble, 
France. 
MICROORGANISMS 
VSV, St Juan strain, cultivated in baby hamster kidney cells and the host cells A549 
were kindly provided by the departments of Virology and Lung diseases 
respectively, LUMC, Leiden, the Netherlands. 
Pseudomonas aeruginosa (isolated from a patient) was kindly provided by the 
Central Bacteriological Laboratory, Haarlem, the Netherlands. Staphylococcus 
aureus (ATCC #2593) and Streptococcus agalactiae (ATCC #13813) were kindly 
provided by the department of Medical Microbiology, LUMC, the Netherlands. 
Bacteria were grown in 10 ml of brain heart infusion broth (Oxoid Ltd, Hampshire, 
UK) at 35°C, 5% CO2. After 18 hours, bacteria were harvested by centrifugation at 
20000 gmin, washed twice with PBS and resuspended in PBS to an optical density 
of 0.7 at 650 nm, corresponding to about 108 colony forming units (CFU) per mL.  
Aerobic hemo-cultures bottles were provided by Organon Teknika, Boxtel, the 
Netherlands. 
CORD BLOOD PROCESSING  
After consent cord blood (CB) was collected in-utero before delivery of the 
placenta. All newborns had a gestational age > 36 weeks. Blood was drawn from 
the umbilical vein into a closed system (MacoPharma, Tourcoing, France) 
containing 25 mL citrate-phosphate-dextrose anticoagulant solution and 
processed within 36 hours. HES was added to the CB at a volume ratio of 1:5. 
After a soft spinning at 500 gmin the stem cell-rich supernatant was separated 
from the residual erythrocyte fraction and subsequently the leukocytes were 
concentrated by spinning at 4000 gmin. The supernatant HES-plasma and 
erythrocyte fraction were used to dilute the concentrated cells to a final white 
blood cell concentration of 20.106 cells per mL and a Hct of 15-20 %. These values 





For all illuminations, the light source was a 300 W halogen lamp (Philips, 
Eindhoven, NL) combined with a cut-off filter (Kodak, wratten nr. 23A, Rochester, 
NY) only transmitting light > 600 nm. The fluence rate at the level of the Petri dish 
was adjusted to 100 W per m2, as measured with an IL1400A radiometer with a 
SEL033 detector (International Light, Newburyport, MA). To avoid heating of the 
samples, the light was passed through a 1-cm thick water layer. The temperature 
did never exceed 25°C. 
PHOTODYNAMIC TREATMENT 
Tri-P(4) was added to the spiked CBSC to a final concentration of 50 μM, unless 
otherwise indicated. Six mL of CBSC samples were transferred into 9 cm diameter 
Petri dishes (tissue culture grade, Greiner, Alphen a/d Rhijn, the Netherlands), 
resulting in a cell layer thickness of 1 mm. The dishes were illuminated under 
continuous agitation (100-120 rpm) for various periods to determine pathogen 
inactivation kinetics. The maximum illumination time was 60 min, corresponding 
to a light dose of 360 kJ/m2. Two controls for the treatment were used, a light 
control and a dark control. The light control corresponded to CBSC illuminated 
without addition of photosensitizer and pathogens. The dark control 
corresponded to CBSC spiked with photosensitizer and pathogens but kept in the 
dark. 
VIRAL INACTIVATION 
Stock solutions of VSV were diluted 10-fold in CBSC to obtain approximately 105 
extracellular viral particles per mL. Prior to PDT, samples with virus and 
photosensitizer were incubated in the dark for 5 min under continuous mixing.  
Infectivity of VSV was studied using Tissue Culture Infectious Dose 50% (TCID50), as 
described before.13 The TCID50 is defined as the reciprocal dilution that is able to 
infect 50% of the inoculated cultures. Briefly, CBSC samples spiked with VSV were 
centrifuged at 2500 gmin. Subsequently, supernatants were 10-fold serially 
Pathogen inactivation in cord blood stem cell products 
119 
diluted, inoculated into A549 cell cultures in 96-wells microtiter plates (Greiner) 
and incubated for 72 hours. The cytopathology of the cells was scored in 8 well 
replicates for each dilution. Quantification of the virus titer was performed 
according to the Spearman-Karber method13. Virus survival is expressed as 
percentage of inocula. 
BACTERIAL INACTIVATION 
Bacterial suspensions were 10-fold diluted in CBSC to obtain a high titer of 
contamination (107 cfu per mL). Low titer contamination (0.1-20 cfu per mL) was 
obtained by a 107 and 108 fold dilution in PBS before the 10-fold dilution in the 
CBSC. Prior to PDT, samples with bacteria were incubated with Tri-P(4) in the dark 
for 30 min under continuous mixing. 
The number of viable bacteria was determined with limiting dilution assays, 
according to a modified version of the method described by Miles and Misra.14 
Samples were 10-fold serially diluted in PBS. Each solution was plated on iso-
sensitest agar and incubated at 35°C, 5% CO2. After at least 18 h, the colonies on 
the agar plates were counted and the numbers of cfu were calculated for each 
sample tested. Bacterial survival is given as percentage of inocula. 
Contamination of whole CBSC samples (6 mL) spiked with low titer of bacteria (< 
20 CFU/mLl) was tested in 2 standard aerobic hemo-culture bottles. The bottles 
were incubated up to 7 days at 35°C using the BacT/Alert continuous monitoring 
blood culture system (Organon Teknika, Boxtel, the Netherlands). 
FLOW CYTOMETRIC ANALYSIS  
After PDT application of CBSC, samples were washed 4 times with PBS at 1500 
gmin to remove the photosensitizer. Cells were incubated with anti-human 
monoclonal antibodies for 20 min at room temperature. After red cell lysis with 
lysis solution IOTest3, samples were analyzed on a four-laser cytometer EpicsXL-
MCL flow cytometer using Expo32 software (Beckman Coulter, Mijndrecht, the 




counts was used and for all other cell types 10000 counts. Quantification of cell 
concentrations was performed by using Flow-count fluorospheres.  
For the 24 hour cell viability assessment, CBSC were washed to remove the 
photosentizer and subsequently resuspended in autologous HES-plasma and kept 
overnight at 2-6°C. Cell viability was assayed using Annexin V and binding buffer. 
Unstained cells and cells labeled with isotype-matched mouse IgG2a-PE and IgG1-
FITC of irrelevant specificity were used as negative controls.  
HPC COLONY ASSAYS OF CBSC 
After PDT application and removal of the photosensitizer, CBSC were assayed in 
duplicate in semi-solid cultures for their number of CFU of granulocytes and 
monocytes (CFU-GM), burst forming units of erythrocytes (BFU-E), mix of those 
units (CFU-GEM) and CFU of megakaryocytes (CFU-Mk). For CFU-GM, CFU-GEM 
and BFU-E, 5.103 of leukocytes were plated and cultured in MethoCult GF H4434 
(StemCell technologies, Grenoble, France). Hematopoietic colonies were scored 
after 14 days of culture at 37°C, 5% CO2. Results are expressed as number of 
colonies per 5x103 of plated cells.  
For CFU-Mk, 1x105 of leukocytes were plated and cultured in MegaCult (StemCell 
technologies). Megakaryocyte colonies containing more than 3 cells were scored 
after 14 days at 37 °C, 5 % CO2. To differentiate the CFU-Mk to non-CFU-Mk, cells 
were dehydrated and stained immune-histochemically with anti-human CD41 
antibody and an alkaline phosphatase detection system (StemCell technologies). 
Results are expressed as number of colonies per 1x105 of plated cells. 
CD34+ EXPANSION AND DIFFERENTIATION INTO MEGAKARYOCYTES 
After PDT application and removal of the photosensitizer, CBSC were resuspended 
in autologous HES-plasma and kept overnight at 2-6°C. The next day, CD34+ cells 
were isolated and expanded. Therefore  mononuclear cells (MNC) were isolated 
by centrifugation on Ficoll density gradient and subsequently, CD34+ cells were 
isolated using MS separation columns (MiniMacs, MiltenyivBiotec, Amsterdam, 
NL) and StemSep CD34 positive selection kit according manufacturer instructions. 
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Cell concentration in the CD34 positive fraction was determined using a counting 
chamber. The purity of the CD34+ cell suspension was 90 % ± 5 % as determined 
by flow cytometry. The cells were then subsequently cultured at 1x105 cells per 
mL in IMDM supplemented with 20% (v/v) AB heparin plasma, 0.34% (v/v) human 
serum albumin Cealb®, 0.5 mg per mL human transferring saturated with 
FeCl3.H2O, 1% (v/v) penicillin and streptomycin and 50 ng per mL Thrombopoietin. 
Cultures were performed in 24-well plates (Greiner, Alphen a/d Rhijn, the 
Netherlands) for 10 days at 37°C, 5% CO2. Cell concentrations were determined at 
day 3, 7 and 9 of culture using a counting chamber. Culture medium was 
refreshed with TPO at day 7, without TPO at day 9. At day 10 the expansion rate 
was determined as follows:  
Total number of harvested cells 
Expansion rate = 
Total number of CD34+ cells seeded. 
The differentiation potential of the progenitor cells into megakaryocytes was 
evaluated by flow cytometric measurements of stem cells (CD34+, CD61-), 
megakaryocyte progenitors (CD61+) and megakaryocyte activation state (CD41+, 
CD62p+). 
CBSC TRANSPLANTATION  
Human CBSC were transplanted into NOD-CB17-Scid (NOD-scid) mice to assay 
bone marrow (BM) reconstitution after PDT. 
Female 5-6 weeks old mice were obtained from Charles River (France) and were 
maintained in animal facility of the LUMC (Leiden, the Netherlands). Animals were 
housed in micro-isolator cages in laminar flow racks and were given autoclaved 
food and acidified water containing 0.07 mg per mL Polymixin-B, 0.09 mg per mL 
cipoxin and 0.1 mg per mL Fungizone. All animal experiments were approved by 
the animal committee of the LUMC. 
Seven to 10 weeks old mice were treated with whole body irradiation with a 
single sub-lethal dose of 3.5 Gy, 4-24 hours before transplantation. The irradiated 
recipients were divided into 2 groups. Each group of 3 mice received CBSC from 




Before transplantation, samples were washed and kept overnight as described 
above. The next day, red cells were lysed with sterile IOTest3 lysis solution for 10 
min at room temperature. Subsequently, the leukocytes were washed twice with 
PBS and resuspended in PBS until a viable CD34+ cell concentration of 5x105 cells 
per mL. Mice were transplanted by intravenous injection in the tail with 
approximately 100.000 of CD34+ cells [range: 71250 - 112500 cells]. The total 
number of CD45+ cells injected was in average 40.4 x 106 cells [range: 0.92 x 106 – 
73.1 x 106 cells]. To avoid clotting, 0.13 mg per mL of DNAse was added to the 
syringe. 
After 7 weeks, mice were sacrificed with CO2 and BM was flushed from the 
femurs.  The level of chimerism in recipient mice was determined by flow 
cytometric assessment of the percentage of human-CD45+ cells in murine BM and 
peripheral blood. Therefore, after red cell lysis, suspensions of BM cells were 
incubated with FITC-conjugated anti-human CD45 or mouse IgG1 monoclonal 
antibodies and PE-conjugated rat anti-mouse CD45 and rat IgG2b (PharMingen, 
San Diego, CA, USA) for 30 min at room temperature.  Within the human-CD45 
positive population, the proportion of myeloid cells was determined by using anti-
human CD34, CD33 and CD41 while the proportion of lymphoid cells was 
determined by using anti-human CD3 and CD19.  
STATISTICAL ANALYSIS  
For statistical analysis of the differences in cell viability one-way Analysis of 
Variance (ANOVA) was used. To determine differences in Log inactivation of 
microorganisms and to compare quantitative measurements between light 
controls and PDT samples in HPC cultures and transplanted mice, paired 
Student’s-t-test or Mann-Whitney test was used. All data are depicted as Mean ± 
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RESULTS 
EFFECT OF PDT ON VSV INACTIVATION 
PDT of CBSC products with 25 μM Tri-P(4) for 60 min resulted in a 3.6 log10 ± 1.3 
inactivation of VSV. With 50 μM Tri-P(4), the reduction was 5.4 ± 0.3  log10 (Fig. 1). 
In light and dark controls, no reduction in viral load was observed during the 
treatment (data not shown). 
A proper decontamination procedure should inactivate at least 5 log10 of the 
added microorganism, therefore all other experiments were performed with 50 
μM Tri-P(4). 
 
Figure 1. Inactivation kinetic of 
VSV in CBSC with PDT using 
25μM ( ) and 50μM ( ) Tri-
P(4).  
Results are expressed as % of 
viral survival (logarithmic 
scale). 10% less survival 
corresponds to 1 log10 
inactivation. Mean ± SD of 3 
independent experiments are 
shown. Asterisks indicate 
statically significant differences 
(P < 0.001) between the two 
concentrations tested after 60 
min of treatment as calculated 
with the student’s-t-test. 
 
EFFECT OF PDT ON BACTERIAL INACTIVATION 
High load spike experiments (107 CFU/mL) were performed to determine the 
kinetics of Tri-P(4)-mediated PDT to inactivate G- and G+ bacteria (Fig. 2). The 
bacterial load of the studied bacteria decreased with increasing illumination time. 
After 60 min of treatment, S. aureus (G+) load was reduced by 3.3 log10 ± 1.1 and 
P. aeruginosa (G-) load by 4.2 log10 ± 0.8. S. agalactiae (G-) was shown to be very 




















sensitive to PDT as within 30 min of illumination a 6.5 log10 ± 0.2 reduction was 
obtained. In light and dark controls, no reduction in bacterial load was observed 
during the treatment (data not shown). Low load spike experiments of CBSCs 
were performed to determine the presence of residual bacteria in the treated 
products (table 1). All CBSC treated with PDT were found negative up to 7 days of 
culture. All samples treated with light only (no Tri-P(4)), became positive within 24 
hours of culture, confirming the microbial contamination of the samples.  
 
Figure 2.Inactivation kine- 
tic of bacteria in high load 
spiked CBSC using 50 μM 
Tri-P(4).  
( ) S. aureus; ( ) P. aeru-
ginosa, ( ) S. agalactiae. 
Results are expressed as 
percentage of bacterial 
survival (logarithmic 
scale). Mean ± SD of 3 to 
5 independent experi-
ments are shown. At 




Table 1: Inactivation of low titer of bacteria in CBSC by PDT using 50μM Tri-P(4). 
Bacteria N Mean initial titer  
Status of duplicated hemo-cultures in Bact-alert  
(culture duration ± sd) 
    CFU/ mL (range) Light control PDT 
P. aeruginosa 5 7,52 (0,9 - 17,5) 
positive  
(18,5 h ± 1,92) 
negative 
(7 days) 
S. aureus 3 1,93 (0,1 - 3,7) 
positive  
(15,67 h ± 0,29) 
negative  
(7 days) 
S. agalactiae 4 3,96 (0,4 - 10,6) 
positive  
(17,12 h ± 2,81) 
negative  
(7 days) 
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EFFECT OF PDT ON CELL VIABILITY  
The effect of PDT on the viability of the various cell types in the CBSC was 
analyzed 24 hours after treatment. As can be seen from Fig. 3, PDT has no effect 
on the viability of the hematopoietic precursor cells (CD34+). Also for the other 
leukocyte subsets present in the CBSC product, no increase in the number of 
apoptotic cells was observed after PDT. 
 
Figure 3. Apoptosis of 
leukocytes in CBSC 24 hours 
after PDT.  
Light controls (black bars), dark 
controls (hatched bars), PDT 
(gray bars). Results are given as 
% of Annexin V positive cells 
within the indicated cell 
population. Mean +/- SD of 7 
independent experiments are 
showed. Statistics differences 
were analyzed using one-way 




EFFECT OF PDT ON IN-VITRO HPC DIFFERENTIATION  
To examine the effect of PDT on the in-vitro growth of myeloid and 
megakaryocytic progenitor cells, semi-solid HPC colony assays were performed. As 
can be seen from Fig. 4, PDT did not affect the formation of erythroid colonies 





Figure 4. Effect of PDT on HPC differentiation in colony assays.  
Results are expressed in total numbers of BFU-E, CFU-GM and CFU-GEM per 
5.103 cells plated and numbers of CFU-MK per 1.105 cells plated. Statistic 
differences between light controls and PDT samples were determined using 
the paired student’s-t-tests. All p values were > 0.05. 
EFFECT OF PDT ON EX-VIVO  EXPANSION AND DIFFERENTIATION OF 
CD34+ CELLS INTO MEGAKARYOCYTES 
Since photodynamic treatment may in particular be considered for ex-vivo 
expansion of CBSC, we examined the effect of PDT on this assay. As shown in Fig. 
5A, there were no difference in expansion rate between cells treated with PDT 
and cells treated with light only (p = 0,78). To determine the effect of the HPC 
differentiation into megakaryocytes, different subsets of the expanded population 
were examined (Fig. 5B). The proportion of progenitor megakaryocytes, as 
determined by labeling with CD61, was similar for light controls and treated cells. 
Also the remaining number of progenitor stem cells CD34+ / CD61- after 
differentiation was the same in both groups. In addition, the activation state of 
the megakaryocytes in the expanded cultures as determined by the double 
expression of CD41 and CD62p+ on the cells after differentiation was not affected 
by PDT (Fig. 5C). 





























Figure 5. Effect of PDT on ex-vivo HPC expansion and differentiation into 
megakaryocytes.  
(A)  Ex-vivo expansion; (B) Differentiation of CD34+ into megakaryocytes. Results 
give the % of progenitor stem cells (CD34+, CD61- cells) and of progenitor 
megakaryocytes (CD61+) from the total number of cells in expanded culture. Light 
controls (black bars), PDT (gray bars). Mean ± SD of 5 independent experiments are 
shown. Statistic differences between light controls and PDT samples were 
determined using the paired student’s-t-test; all p values were > 0.05; (C) Activation 
state of megakaryocytes in expanded cultures: pictures representatives of 5 
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EFFECT OF PDT ON IN-VIVO  ENGRAFTMENT  
As the results from all in-vitro assays did not show a negative effect of PDT on 
CBSC, we tested in-vivo the effect of PDT on the CBSC engraftment potential (Fig. 
6). Only 50% (6 out of 12) of the mice from the PDT group engrafted against 67% 
(8 out of 12) in the control group (p=0.68). In addition, in engrafting mice, the 
percentage of human CD45+ cells detected in murine BM was significantly lower 
in the PDT group than in the control group. The reduction in CD45+ cells is 
accompanied by a dramatic loss in the number of CD19+ cells. No significant 
change was observed in the proportion of other lymphoid cells (CD3+ cells) or 
myeloid cells (CD34+, CD33+ and CD41+ cells). 
Figure 6. Effect of PDT on BM reconstitution after transplantation of human-CBSCs in 
NOD-scid mice. 
Results showed the percentage (and means) of human-derived cells in the murine 
BM from engrafted mice (>10% Hu-CD45+ cells) 7 weeks after transplantation of 4 
independent cord blood donors. In the light control group ( ) 8 mice from 12 
engrafted, in the PDT group ( ) 6 mice from 12 engrafted (p=0.68; Fisher Exact test). 
Means are indicated by horizontal lines, light controls by dotted lines, PDT by plain 
lines. ¥P values were determined using paired student-t-test or Mann Whitney test. 
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DISCUSSION 
We investigated the potential of Tri-P(4)-mediated PDT to decontaminate CBSC in 
order to overcome the risks due to pathogenic contamination in ex-vivo and in-
vitro applications.  
Our results showed that model virus VSV and bacteria could be inactivated in 
CBSC (Fig. 1 and 2). However, in comparison with application in RBCC11,12, the 
treatment required a 2-fold higher Tri-P(4) concentration. The need for increase in 
Tri-P(4) concentration may be explained by the difference in product contents. 
CBSC contains plasma proteins which are nearly absent in the tested SAG-M 
containing RBCC. These proteins, in particularly albumin, quench most of the 
singlet oxygen generated by the action of light on the photosensitizer.15 HES, 
which is also present in CBSC had only a dilution effect in plasma and did not 
affect the PDT efficacy (data not shown).  
Surprisingly, G+ S. aureus appeared to be more resistant to PDT inactivation as 
compared to the G- bacteria tested. This result is in contrast with the high 
sensitivity of the G+ bacteria found after PDT with porphyrins in saline solutions 
and RBCC.11,12,16,17 Thereby, interesting suggestions can be made about the 
binding site of Tri-P(4) on bacteria. Indeed, macrophages and platelets, which are 
present in high amounts in CBSC products can bind to bacteria via negatively 
charged teichoic acid components which are very abundant on the G+ bacterial 
wall.18,19 The cells may compete with the positively charged photosensitizer Tri-
P(4) for binding to bacteria through the teichoic acids, thereby reducing the 
efficacy of Tri-P(4) to inactivate G+ bacteria in CBSC. However, despite these 
limitations, we showed that pathogen inactivation in CBSC using PDT is feasible 
for low dose of contaminants, more representative for the actual contamination 
of CB (table 1).6 
In our studies, results from all in-vitro assays demonstrated that PDT did not 
affect HPC functions. Growth of myeloid and megakaryocytic progenitor cells and 
HPC expansion after PDT did not differ from the light controls. These results 




transplant to reconstitute the BM. Therefore, to determine the effect of PDT on 
the CBSC engraftment and the recovery of hematopoietic cell system in-vivo, we 
performed xeno-transplantation experiments in NOD-scid mice.20  
To our surprise, PDT application of CBSC products resulted in a reduced number of 
engrafted mice and a lower number of human-CD45+ in their BM as compared to 
the light control group. The reduction in engraftment was accompanied by a 
dramatic reduction in the number of CD19+ cells and a tendency to a lower 
number of myeloid cells, although the latter being not statically significant. From 
these results, it is clear that PDT application of CBSC impaired the HPC 
engraftment and hematopoietic recovery in NOD/Scid mice.  
The diminished engraftment observed 42-49 days after transplantation could be 
the result of an impaired homing of the photodynamically treated cells (Fig. 6). 
Possibly, the cells may need an elongated recovery time to regain their migratory 
capacity, to settle into the BM microenvironment, or to proliferate and 
differentiate properly.21 Moreover, measurements up to 120 days after 
transplantation in the BM, spleen and peripheral blood would give more insights 
in the level of PDT-induced engraftment inhibition. 
Although the mechanism of human HPC homing and engraftment in NOD/Scid 
mice is still not completely understood22, it is well accepted to observe skewing in 
B-cell development in the mouse BM after transplantation of cord blood-derived 
HPC in NOD/Scid models.23-27 Correspondingly, we found this predominance in B 
cell development in the mouse BM from our light control group. It has been 
shown by Fibbe et al. and Hogan et al. that the preferential B-cell engraftment 
was not related to the presence of committed or relatively mature B cells in the 
graft.23,24 Therefore, it is unlikely that the dramatic decrease in B-cell numbers in 
mouse BM is explained by a selective effect of PDT on the B-cell precursors or 
committed stem cells. Many factors have been described to influence migration 
and engraftment of stem cells, such as cell cycle, cytokines, chemokines, 
expression of adhesion molecules and cell-cell interaction.21,28-33 Further research 
should reveal whether PDT interacts with one of these factors, thereby 
contributing to the reduced engraftment potential. In conclusion, PDT with Tri-
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P(4) is able to decontaminate CBSC without affecting in-vitro cell viability and 
growth. Engraftment capabilities are however altered. 
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After transfusion, the presence of contaminating white blood cells (WBC) in blood 
components may result in either deleterious or positive immunological responses. 
We have previously reported that PDT with meso-substituted mono-phenyl-tri-(N-
methyl-4-pyridyl)-porphyrin (Tri-P(4)) and red light can inactivate pathogens in 
RBC products. The present study explored the effect of PDT on contaminating 
WBC in RBC products with varying hematocrit (Hct). After PDT, we evaluated 
adaptive and innate immunomodulation through allogeneic and mitogenic 
stimulation. PDT resulted in decreased T cell proliferation which was more 
pronounced with lower Hct. Dark effect of porphyrin Tri-P(4) was remarkable on 
antigen-presenting cells affecting expression of co-stimulatory molecules 
CD80/CD86. Finally, cytokine profile after PDT revealed a mixed Th1/Th2 type 
response while surface antigen expression supported the development of 
alternatively activated macrophages (AAM  or type 2 macrophages) instead of 
dendritic cells. In conclusion, PDT with Tri-P(4) altered proliferation, allo-
stimulation, cell surface antigen expression and cytokine profiles of the cells. 
These results suggest that PDT may be potentially useful in preventing transfusion 
associated Graft-versus-Host Disease and alloimmunisation. It seems worthwhile 
to further explore PDT-induced immunomodulation to optimize conditions which 
may result in allo-tolerance by AAM .   
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INTRODUCTION 
Risks associated with blood transfusion has dramatically decreased since the 
implementation of careful donor selection and the development of sensitive 
diagnostic tests, however a certain risk for complications by contaminating 
pathogens still remains.1,2 
Not only are viruses, bacteria and protozoa considered as pathogenic, allogeneic 
WBC present in blood components can also be recognized as pathogenic 
contaminants, inducing immune responses in the recipient, sometimes with 
deleterious effects. Such WBC-induced complications of blood transfusion include 
transfusion associated Graft-versus Host disease (GvHD), transfusion related 
immunosuppression, which can result in enhanced susceptibility to post-operative 
infection and multiple-organ-dysfunction syndrome, non-hemolytic febrile 
transfusion reactions (NHFTR) and immunization to Human leukocyte antigens 
(HLA).3 Although the mechanism is yet to be unraveled, the presence of allogeneic 
WBC in transfusion products can be beneficial reducing the risk of allograft 
rejection and of spontaneous recurrent abortion.3 
A number of approaches have been implemented to minimize the pathogenic role 
of contaminating WBC. Leukodepletion of blood components by filtration has 
resulted in a reduction in the frequency of NHFTR’s and HLA immunisation.2 
Gamma irradiation is effective in preventing WBC proliferation but does not 
impair the stimulatory capabilities of these cells.4 Some of these techniques, 
aimed to inactivate pathogen in blood products, such as Mirasol-Pathogen-
Reduction technology5 and Inactine technology using Pen 1106 have been shown 
to also reduce the proliferative capacity of the WBC as well as their ability to 
present antigens. Furthermore, it has been shown that photodynamic treatment 
(PDT) can have immunomodulatory effects in various experimental systems. In-
vivo studies showed that PDT with verteporfin was effective in alleviating immune 
pathology in murine models of arthritis, contact hypersensitivity, experimental 
allergic encephalomyelitis and retention of allogeneic skin grafts.7,8 PDT of 
peripheral blood mononuclear cells with a rhodamine derivative TH9402 may 




therapy using 8-methoxypsoralen was found to reverse GvHD.10 Investigations in 
the mechanism involved in immunomodulatory PDT have shown that PDT 
selectively eliminate certain cell populations, disrupt T cell response by affecting 
APCs by lowering expression of key cell surface molecules, including MHC I and II, 
CD80, CD86 and CD54 and modulate the cytokine network.11-13 
PDT utilizes mainly porphyrin and phthalocyanine-based photosensitizers which 
accumulates somewhat selectively in rapidly dividing cells such as activated cells 
of the immune system.14-16 Exposure to sub-lethal doses of PDT may result in the 
modification of cell surface receptor expression levels and cytokine release and 
consequently influence cell behaviour.8  
Mono-phenyl-tri-(N-methyl-4-pyridyl)-porphyrin chloride (Tri-P(4)) is a positively 
charged amphiphilic porphyrin that can be activated with red light to generate 
singlet oxygen responsible for oxidative damage to vicinal molecules. We have 
previously demonstrated that this photosensitizer was superior to other similar 
porphyrin photosensitizers in its action to efficiently inactivate a wide range of 
viruses and bacteria with limited damage to RBC.17,18 PDT with Tri-P(4) was also 
shown to have limited effects on cord blood derived stem cells and progenitor 
cells.19 These observations raised the question as to whether this treatment may 
be able to modulate WBC present in RBC product to reduce immunological post-
transfusion reactions or to enhance beneficial tolerizing effects of blood 
transfusion. 
We therefore explored the potential immunological effects of PDT with Tri-P(4) on 
contaminating WBC in RBC products with varying Hct. For this, we evaluated the 
effect of the treatment on in-vitro adaptive and innate immunological 
parameters, such as proliferation in response to mitogens and to allogeneic 
stimulator cells, the ability to stimulate proliferation of healthy untreated 
responder cells, survival, expression of constitutive and inducible cell surface 
antigens and production of soluble mediators (cytokines). 
 
 
Impact of PDT with porphyrins on WBC-containing RBC 
139 
MATERIALS AND METHODS 
MATERIALS  
Photosensitizer Tri-P(4) (mono-phenyl-tri-(N-methyl-4-pyridyl)-porphyrin chloride) 
was kindly provided by Buchem b.v., Apeldoorn, the Netherlands. Stock solutions 
of 1 mM were prepared in PBS and stored in the dark at 2-6°C. PBS (pH 7.4) and 
Ficoll gradient were provided by the Leiden University Medical Center (LUMC) 
Pharmacy, Leiden, the Netherlands. SAG-M is a red cell storage solution 
containing 150 mM NaCl, 1.25 mM adenine, 50 mM glucose and 29 mM mannitol 
(Fresenius Hemocare, Emmer-Compascuum, the Netherlands). IMDM and RPMI-
glutamine was purchased from Invitrogen, Breda, the Netherlands. Penicillin and 
streptomycin (pen/strep) were purchased from Bio-Whittaker (Verviers, Belgium). 
Pools of 40 individual AB sera, screened for the absence of HLA antibodies and 
disturbance in mixed lymphocyte reaction (MLR), were obtained from Sanquin 
Blood Bank Southwest (Rotterdam, the Netherlands). Phytohemagluttin (PHA), 
-mercapto-ethanol were purchased from Sigma-
Aldrich (Zwijndrecht, the Netherlands). Phycoerythrin (PE)-conjugated anti-human 
CD14, CD16, CD33, CD54, CD80, CD83, CD86, HLA-DR monoclonal antibodies 
(MoAb), PE-conjugated isotype-matched mouse IgG2a MoAb, fluorescein (FITC)-
conjugated anti-human CD45 MoAb, FITC-conjugated isotype-matched mouse 
IgG1 MoAb, propidium iodine (PI), IOTest3 lysis solution and the Flow-count 
fluorospheres were purchased from Beckman Coulter (Mijdrecht, the 
Netherlands). 
BLOOD PRODUCTS AND PROCESSING  
Whole blood derived buffy coats were provided by healthy HLA-typed donors 
from Sanquin Blood bank supply (Leiden, the Netherlands). The buffy coats were 
washed twice at 5000 gmin with SAG-M to remove plasma. After the last wash, 
the supernatant and the WBC layer were transferred into a new tube and 
centrifuged at 8500 gmin. The WBC pellet was resuspended in 10 mL SAG-M for 




obtain a final product with a WBC concentration 20.106 cell / mL and a Hct of 20% 
 4% or 55% 5%. Hct and cell concentrations were measured by Act 10 blood 
analyzer (Beckman Coulter, Mijdrecht, the Netherlands).  
The final product obtained is referred to as WBC-enriched RBC (WBC-RBC). All 
samples were DNA typed at low resolution for the loci HLA-A, -B, -C, -DRB1 and -
DQB1 by polymerase chain reaction /sequence-specific oligonucleotide using a 
reverse dot-blot method.20 HLA typing was performed at the national reference 
laboratory for histocompatibility testing (LUMC, the Netherlands).  
LIGHT SOURCE  
For all illuminations, the light source was a 300 W halogen lamp (Philips, 
Eindhoven, the Netherlands) combined with a cut-off filter (Kodak, wratten nr. 
23A, Rochester, NY) only transmitting light > 600 nm. The fluence rate at the level 
of the Petri dish was adjusted to 100 W per m2, as measured with an IL1400A 
radiometer with a SEL033 detector (International Light, Newburyport, MA). To 
avoid heating of the samples, the light was passed through a 1-cm thick water 
layer. The temperature did never exceed 25°C. 
PHOTODYNAMIC TREATMENT 
Tri-P(4) was added to the blood components to a final concentration of 25 μM. 
The WBC-RBC suspensions were thoroughly mixed. Subsequently 3 mL samples 
were transferred into 6 cm diameter petri dishes (tissue culture grade, Greiner, 
Alphen a/d Rhijn, the Netherlands), resulting in a cell layer thickness of 1 mm. The 
dishes were agitated at room temperature on a horizontal circular shaker (75 
rpm) for 5 min in the dark and subsequently illuminated under continuous 
agitation for 30 min corresponding to a light of 180 kJ/m2. The light control 
corresponded to WBC-RBC illuminated without addition of photosensitizer. The 
dark control corresponded to WBC-RBC spiked with photosensitizer but kept in 
the dark during the whole procedure (including preincubation and illumination 
time). 
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MITOGENIC STIMULATION  
To study proliferation, mononuclear cells (MNC) were isolated from WBC-RBC 
immediately after PDT by centrifugation on Ficoll density gradient and 
subsequently, the cells were resuspended in culture medium containing RMPI-
Glutamine supplemented with 10% human serum and 100 μg/mL Pen/strep. The 
cells (106 cell/mL) were stimulated with 1 μg/mL PHA in U-bottom 96-well plates. 
Cell proliferation was quantified by incubating the cells during the last 18 h of 4-
3H]thymidine. Before being pulsed, supernatants were 
collected and stored at – 3H]thymidine 
incorporation by liquid scintillation spectroscopy using a beta plate (Wallac, 
Turku, Finland). Results are expressed as % of light control. 
MIXED LYMPHOCYTE REACTION 
 To study allo-reactivity, MNC isolated from WBC-RBC after PDT by Ficoll isolation, 
as described above, were co-cultured with MNC isolated from a completely HLA-
mismatched buffy coat (allogeneic cells). Equal numbers of responder and 
stimulator cells (100 μL of 106 cells/mL) were cultured in U-bottom 96-well plates 
(Costar, Cambridge, MA, USA). Stimulator cells were obtained by irradiation at 
3000 Rad. Tri-P(4)-treated cells, controls and allogeneic cells were used both as 
responders and as stimulators.  As a control for spontaneous proliferation, the 
responder and stimulator cells were cultured in medium only. Cell proliferation 
was quantified by incubating the cells during the last 18 h of 5-day cultures with 1 
3H]thymidine (Amersham International, Amersham, UK). Assays were 
performed in triplicate. Before being pulsed, supernatants were collected and 
stored at –40°C. Proliferation was measured as described above. Results are 
expressed as % of light control. 
LPS STIMULATION 
After PDT, WBC-RBC was washed 4 times at 5000 gmin to remove the 
photosensitizer and, subsequently diluted 10-fold with IMDM supplemented with 




cell suspension (150 μl/well) were plated in triplicate in plate-bottom plate 
(Costar, Cambridge, MA, USA) and 50 μl of LPS (final concentration 250 pg/mL) or 
culture medium was added. After 20 h of incubation at 37°C, 5% CO2, samples 
were pooled then centrifuged at 2700 gmin. Supernatant was harvested and 
frozen at -40°C until use. Supernatant from non-LPS treated cell suspensions were 
harvested and frozen to be used as reference values before stimulation. 
CYTOKINE ANALYSIS 
Harvested supernatants from MLR and LPS stimulation assays were tested for a 
total of 17 cytokines at once (Interleukin-1beta (IL- -2, IL-4, IL-5, IL-6, IL-7, IL-
8, IL-10, IL-12p70, IL-13, IL-17, Granulocyte-colony stimulating factor (G-CSF), 
Granulocyte-monocyte-CSF (GM-CSF), Interferon-gamma (IFN-
chemoattractant protein-1 (MCP-1), macrophage inflammatory protein- -
-alpha (TNF- -Plex human Cytokine 
panel following the manufacturer’s description. Samples were analyzed using a 
Bio-Plex array reader equipped with Bio-Plex software (Bio-Rad Laboratories, 
Veenendaal, the Netherlands). 
IMMUNOPHENOTYPING  
After PDT application of WBC-RBC, samples were washed 4 times with PBS at 
1500 gmin to remove the photosensitizer. Cells were incubated with anti-human 
MoAb for 20 min at room temperature. After red cell lysis with lysis solution 
IOTest3, samples were analyzed on a four-laser cytometer EpicsXL-MCL flow 
cytometer using Expo32 software (Beckman Coulter, Mijndrecht, the 
Netherlands).  
CELL VIABILITY 
Using PI labeling and flow cytometry, cell viability was assayed in cell cultures 
from MLR at day 1, 4 and 6; day 0 being the day of input. Unstained cells and cells 
labeled with PE-conjugated isotype-matched mouse IgG2a and FITC-conjugated 
IgG1 of irrelevant specificity were used as negative controls.  
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STATISTICS 
For statistical analysis, Repeated measured Analysis of Variance (ANOVA) or 
Friedman test were used when appropriate, depending on the type of 
distribution. P values are from comparison with light controls and determined by 
Tukey’s or Newman-Keuls post-tests as indicated in legends. P values < 0.05 were 
considered as statistically significant. All data are expressed as Mean ± Standard 
Deviation (sd).  
RESULTS 
EFFECT OF PDT ON PROLIFERATION 
After PDT application, MNC were tested for their capacity to proliferate in 
response to PHA (Fig.1A), and to allogeneic stimulation (Fig.1B). PDT induced a 
significant reduction in proliferation when samples were treated in low Hct level. 
After stimulation with PHA, no significant difference was observed between light 
and dark controls. However, after PDT at low Hct level and allogeneic stimulation, 
we observed a significant increase in proliferation in dark controls as compared to 
light controls. The spontaneous proliferation of the photo-treated cells and dark 
control cells did not differ from the light controls (not shown).  
EFFECT OF PDT ON THE ABILITY OF MNC TO PRESENT ANTIGEN 
After PDT application, MNC were tested for their capacity to present antigen and 
thereby stimulate a 
proliferative response in untreated HLA-mismatched allogeneic cells. As can be 
seen from Fig.1C, the proliferative response induced by photodynamically treated 
stimulator cells was significantly reduced by approximately 50% of the light 
controls when the cells were treated in low Hct level. In high Hct level, no 
difference between the samples was seen. In the dark samples, no difference in 
the proliferative response was seen as compared to light controls. The 
spontaneous proliferation of the irradiated stimulator cells did not differ between 









Figure 1. Proliferation capacity of MNC after 
PHA stimulation (A), and allogeneic 
stimulation (B) after PDT of WBC-RBC in low (  
20%) and high (  50%). (C) Capacity of photo-
treated MNC to stimulate proliferation in 
MLR.  
Proliferation is expressed as % of light control. 
Mean with standard deviation are shown. 
Light controls (black bars), Dark samples (gray 
bars), PDT samples (white bars).  Statistic 
differences between the three groups of 
samples within each Hct level were performed 
using ANOVA and Tukey-post tests. 
Comparisons of each group between the two 
Hct levels were performed using student’s t-
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THE EFFECT OF PDT ON CELL VIABILITY  
Immediately after PDT of WBC-RBC, MNC were isolated by Ficoll centrifugation. 
Cell viability was determined during MLR at day 1, day 4 and day 6 of culture to 
check that the proliferation inhibition induced by PDT may not be due to excessive 
apoptosis induction. PDT did not affect the overall cell viability. The % of PI-
positive cells was 10-15% at day 1 and increased to 25-30% at day 6 of the MLR 
culture and was similar to untreated controls. There was no difference in non-
viable cells in cultures where photodynamically treated cells were used as 
responders or in cultures where the treated cells were used as stimulator cells. In 
addition, no difference was seen between light controls and dark controls (data 
not shown). 
EFFECT OF PDT ON THE RELEASE OF CYTOKINES BY ALLO-ACTIVATED 
PHOTO-TREATED RESPONDER CELLS IN MLR  
The cytokine pattern produced in MLR by photodynamically treated MNC used as 
responders was determined. As the effect of PDT on the proliferation was 
dependent on the Hct level of the treated product, a similar relationship was 
observed with the cytokines released during the cultures. When MNC were 
treated in low Hct level (<30), a significant negative correlation was observed 
between proliferation and the release of IL-4, IL-10, IL-13, IL-12, TNF- , MIP-
and INF-  (Fig.2); the lower the proliferation, the more cytokines were released. In 
contrast, the release of IL-2 was positively correlated with proliferation; the lower 
the proliferation, the lower IL-2 was released. In high Hct level (>50), no significant 
change in cytokine release in PDT samples was seen as compared with light 
controls. Moreover, for IL- -5, IL-6, IL-7, IL-8, IL-17, G-CSF, GM-CSF, MCP-1, no 
significant difference with light controls was observed at both Hct levels (data not 
shown). Finally, no difference in cytokine pattern between dark and light controls 





Figure 2.Correlation between proliferation and cytokine release in MLR wherein MNC 
were used as responders after PDT of WBC-RBC in Hct <30 (circles) or in Hct > 50 (squares). 
Both level of released cytokine and proliferation rate are expressed as % of light control. 
Only PDT samples are represented. Results shown are mean of triplicates of 6 independent 
experiments, each one represented by one dot. Correlations were indicated by Pearson r 
and p value. Fit lines were established by linear regression. 
EFFECT OF PDT ON THE RELEASE OF CYTOKINES BY TRI-P(4)-TREATED 
STIMULATOR CELLS IN MLR 
The cytokine pattern produced in MLR by allogeneic cells after antigen 
presentation by Tri-P(4)-treated MNC was determined. In concordance with the 
proliferation results, the level of cytokine released did not correlate with the Hct 
level of the product during PDT. However, as can be seen from Fig.3, significant 
negative correlations between proliferation and the release of IL- -6, INF- , 
TNF- , MIP-1  and GM-CSF were observed. Striking was that the cytokine levels 
mostly exceeded the levels of light controls (> 100%) when proliferation was the 
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most inhibited, except for IL-2 showing a significant positive correlation with 
proliferation. In addition, no difference in cytokine pattern between dark and light 
controls was seen (data not shown). 
 
Figure 3. Correlation between proliferation and cytokine release in MLR wherein MNC were 
used as stimulators after PDT of WBC-RBC. 
Both level of released cytokine and proliferation rate are expressed as % of light control. 
Only PDT samples are represented. Results shown are mean of triplicates of 5 or 6 
independent experiments, each one represented by one dot. Correlations were indicated by 










EFFECT OF PDT ON LPS-STIMULATED CELLS  
After PDT application, WBC-RBCs were stimulated with LPS for 20 hours, after 
which cytokine production and antigen expression were determined. As can be 
seen in Fig.4, in dark and PDT samples, a significant reduction of nearly 50% in 
release of IL-8 and MIP-
Fig.4) whereas for the other cytokines tested no difference with the light controls 
was observed (frame in Fig.4).  
The proportion of cells expressing surface antigen were determined and given in 
Fig.5. PDT induced an increase in numbers of CD14, HLA-DR and CD83 expressing 
cells as compared to light and dark controls. The increased in the amount of HLA-
DR and CD83 positive cells was only observed after LPS stimulation, while the 
increased in the amount of CD14 positive cells was LPS independent. Moreover, 
four hours after PDT application and before LPS stimulation, the amount of CD80 
and CD86 expressing cells decreased significantly as compared to light controls as 
well in the dark samples as in PDT samples. No PDT effect and LPS effect was 
observed in the amounts of CD33, CD54 and CD16 expressing cells (Fig.5). 
Moreover, alteration in the stimulation capabilities of APC was associated with 
increased production of cytokines suggestive of active inhibition. Investigation of 
the innate immunity of WBC in treated RBC products using LPS showed that Tri-
P(4) alone affect the APC response.  
Changes in cellular expression of cell surface markers were determined by 
measuring mean fluorescence intensities (MFI) of each marker and given in Table 
1. The MFI of CD14 and HLA-DR expressions increased upon PDT as compared to 
light and dark controls and both were LPS independent. In contrast, MFI of CD83 
expression increased upon PDT only without LPS, while after LPS stimulation, MFI 
remained similar between the three groups of samples. No significant change in 
MFI of CD33, CD16, CD54, CD80 and CD86 expressions were observed after PDT as 












Figure 4. Effect of PDT on the release 
of cytokines in LPS-stimulated cells. 
Cytokine releases are expressed in 
pg/mL. Mean ± sd of 6 independent 
experiments are shown. Asterisks 
indicates statistical differences with 
the light controls as determined by 
ANOVA and Tukey post-test (*) p 
values < 0.05; (**) p values < 0.01. 
Graph legend: Light controls (black 
bars), dark controls (gray bars); PDT 






PDT with Tri-P(4) and red light has been shown to inactivate a number of 
pathogens including viruses and bacteria in RBCC18 and cord blood products.19 As 
contaminating WBC in RBCC are implicated as a causative factor for an immune 
response after transfusion3,21, we were interested to determine the effect of Tri-
P(4)-mediated PDT on these cells.  
 Light control Dark PDT 
IL-  568 ± 699 566 ± 644 568 ± 642 
IL-2 23 ± 18 23 ± 14 20 ± 10 
IL-4 56 ± 47 45 ± 29 41 ± 23 
IL-6 6578 ± 3734 6780 ± 5186 7123 ± 2896 
IL-7 3.1 ± 1.9 2.8 ± 1.8 2.6 ± 0.9 
IL-10 119 ± 102 137 ± 162 133 ± 119 
IL-12 3.1 ± 2.5 4.2 ± 3.7 3.0 ± 1.6 
IL-17 27 ± 9.0 25 ± 9.4 23 ± 6.2 
INF-g 150 ± 116 175 ± 113 161 ± 88 
TNF-a 203 ± 217 214 ± 204 210 ± 127 
MCP-1 856 ± 984 716 ± 538 1190 ± 906 
G-CSF 1004 ± 922 687 ± 474 778 ± 446 




PDT with Tri-P(4) had no effect on the spontaneous proliferation and cell viability 
of the treated WBCs. However, photodynamically treated WBCs showed impaired 
proliferation after stimulation with PHA and upon co-culture with allogeneic 
stimulator cells. The degree of impairment of proliferative capacity was increasing 
when WBC had been exposed to PDT in lower Hct.  Although cytokine production 
was reduced at a certain level of proliferation inhibition, stronger proliferation 
inhibition resulted in less decrease of cytokine production (Fig.2). PDT also 
impaired the capacity of antigen-presenting cells (APC) to stimulate the T-cell 
proliferation in MLR, however, this effect was less influenced by Hct. Moreover, 
the reduction in the stimulation capabilities of APC was associated with increased 
production of cytokines suggestive of active inhibition. We also found by using LPS 
that the APC response was affected by the presence of Tri-P(4) only, in the 
absence of light. 
 
Table 1: Intensities of cell surface marker expression (MFI) on WBC after PDT 
Data indicated are Mean Fluorescence Intensity (MFI) ± SD of 8 independent experiments.  
Statistic differences were determined with ANOVA and Newman-Keuls post tests or with Friedman 
test depending on the type of distribution. Tests were performed in respective medium. Superscript 
symbols shown indicate a significant difference with light controls (p < 0.05): (*) from ANOVA and 




 Medium  LPS 
 Light control Dark PDT  Light control Dark PDT 
HLA-DR 107 ± 89 114 ± 63 210 ± 139*  136 ± 129 99 ± 73 208 ± 157* 
CD83 30 ± 12 33 ± 7.6 41 ± 6.7*  26 ± 12 26 ± 11 28 ± 8.7 
CD14 729 ± 234 886 ± 271 1016 ± 404†  773 ± 187 709 ± 249 1174 ± 411† 
CD33 39 ± 12 39 ± 17 35 ± 16  52 ± 24 49 ± 29 48 ± 20 
CD16 32 ± 12 31 ± 7.4 31 ± 6.6  32 ± 8.4 31 ± 12 40 ± 23 
CD54 87 ± 95 106 ± 130 76 ± 57  215 ± 272 147 ± 178 166 ± 160 
CD80 62 ± 98 42 ± 29 45 ± 19  34 ± 3.7 27 ± 6.7 41 ± 7.4 
CD86 69 ± 29 97 ± 73 110 ± 55  59 ± 48 52 ± 27 66 ± 24 




Figure 5. Effect of PDT on the cell surface expression on LPS-stimulated WBC-RBC. 
Cell surface antigen expression is expressed as percentage of positive cells from the CD45+ 
population. Day 0 corresponds to un-stimulated WBC-RBC 4 hours after PDT. Medium and LPS 
corresponded to WBC-RBC cultured after PDT without and with LPS respectively for 20 hours. 
Light controls (black bars), Dark controls (gray bars), PDT (white bars). Mean ± sd of 8 independent 
experiments are shown. Asterisks indicates statistical differences with the light controls in their 
respective culture media as determined by ANOVA and Tukey post-test; (*) p values < 0.05; (**) p 
values < 0.01; n.d. not detectable.  
The dark effect of the photosensitizer Tri-P(4) on APCs was compatible with our 
observations that Tri-P(4) binds non covalently but differentially to leukocytes 
with a preference for monocytes/macrophages and granulocytes (L.L. Trannoy, 
unpublished). We observed that release of both chemoattractants IL-8 and MIP-




the release of these cytokines have in common a signaling pathway.22,23 Further 
studies are required to identify the membrane receptor which may interact with 
Tri-P(4) disrupting simultaneously the release of IL-8 and MIP- , the 
expression of co-stimulatory molecules CD80 and CD86 on APC were also reduced 
both in dark and PDT samples (Fig.5). These results suggest that Tri-P(4) affects 
the antigen presentation functionality of APC by interacting directly with 
monocytes / macrophages in the absence of light.  
The Hct of the blood product influences the photodynamic effect on T cells. 
Increasing the Hct caused higher pigmentation of the blood product and may 
hinder proper light penetration to the WBC. Thereby PDT may affect differently 
the WBCs. High doses and low doses PDT has been shown to generate different 
results as high doses resulted in necrotic or apoptotic cells, while low doses PDT 
or sublethal doses PDT may result in the modification of cell surface receptor 
expression and consequently influence cell activities.8,24 
Another possible explanation is the capacity of RBC to scavenge reactive oxygen 
species (ROS).25 Tri-P(4) is a porphyrin that remains extracellular by binding 
exclusively to cell membrane of living and resting cells (unpublished results, L.L. 
Trannoy). Illumination of porphyrin Tri-P(4) at appropriate wavelength generates 
ROS, in particularly singlet oxygen (1O2) which reacts with substances in close 
vicinity. ROS is also a natural product, produced by neutrophils in host defense to 
kill invading pathogens and involved in intercellular and intracellular signaling of 
homeostasis, cell proliferation and differentiation and inflammatory and immune 
responses.26 Generation of ROS by light activation of Tri-P(4) can cause lipid and 
amino-acid peroxidation, affecting cell membrane associated targets, and may 
produce a number of effects on the immune cells. RBC may play a protective role 
by scavenging PDT-generated extracellular ROS and varying the Hct of RBC may 
affect the degree of photo-damage induced by ROS. Further research would 
determine whether illumination with a lower light dose in the absence of RBC may 
show the same effects on WBC after PDT with Tri-P(4).  
In our study, T-cell response and IL-2 release correlated with the Hct level of the 
photodynamically treated WBC-RBC products, as seen after PDT when Tri-P(4)-
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treated cells were used as responders in MLR and after PHA stimulation. This 
indicated that T-cells are target for ROS-mediated PDT and that the presence of 
RBC during PDT application may protect the T cells against the damaging effect of 
singlet oxygen. Possible targets of PDT may be the TCR and CD28 signaling 
pathways which were found to be sensitive to oxidative stress induced e.g. by BSO 
(DL-buthionine-(S,R)-sulfoximine) depleting intracellular antioxidant reduced 
glutathione 27 and after PUVA treatment.28 Both treatments result in T-cell 
hyporesponsiveness.  
Our results showed that PDT with Tri-P(4) act both on APCs and on T cells, on one 
hand through a dark effect of Tri-P(4) down-regulating the costimulatory 
molecules CD80 and CD86 and on the other hand through a photodynamic effect 
inhibiting the responder and stimulatory potentials of WBC in MLR. Therefore we 
suggest that the immunomodulatory effect of PDT may result in an impaired 
interaction between T-cells and APC. Blockage of the CD80/CD86-CD28 co-
stimulation was shown to result in T cell hyporesponsiveness and in generation of 
alternatively activated macrophages (AAM ), also referred to as type 2 
macrophages 29-31 The induction of this type of macrophages is supported on one 
hand by the PDT-induced increase in cell number and cellular expression of HLA-
DR and CD14 on APC, and on the other hand by the refractoriness of CD80 / CD86 
up-regulation to LPS stimulation (Table 1). These cellular events are partly 
characteristic of AAM  as demonstrated by Xu 32 and Verreck.30 As these cells are 
unable to prime T-cells, they may contribute to the PDT-induced T-cell 
hyporesponsiveness.31,33 An additional indication pointing toward the involvement 
of APC after PDT is the fact that un-stimulated WBC-RBC cultures of photo-treated 
cells showed an up-regulation of CD83 which was refractory to LPS stimulation 
(Table 1). Indeed, monocytes are precursors of dendritic cells (DC) and 
macrophages, with each cell type having the capability to convert into the other 
until late in differentiation / maturation process.34 Hence, PDT seems to activate 
monocytes to differentiate into DC as suggested by the high expression of CD83 
and HLA-DR (Table 1); however, LPS stimulation skews this polarization favoring 
type 2 macrophage development (lower CD83, higher CD14 expression).30  
Finally, at a level of PDT-induced proliferation reduction up to 40%, it appeared 




the degree of inhibition of proliferation; cytokine levels exceeding even these in 
light control cultures (Fig.3). These results strongly suggest an immunomodulatory 
event. Moreover, the cytokine profile revealing a mixed Th1/Th2 type response, 
suggests that several types of APC may be synergically or simultaneously involved.  
 
In conclusion, in addition to inactivating pathogens, PDT with Tri-P(4) may be able 
to steer the immune response to T-cell hyporesponsiveness by functionally 
affecting both T cells and APC. These dual effects may present an advantage on 
gamma irradiation which was shown to inhibit proliferation of the MNC without 
affecting the antigen-presenting capabilities of the irradiated cells.35 
Consequently, we may consider the possibility of using PDT with Tri-P(4) to 
deviate an immune response towards tolerance or to prevent undesired 
transfusion related immunological reactions.  
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Blood transfusions in developed countries are generally considered to be safe, 
however recent events illustrated that blood transfusions still need a maximum of 
vigilance and that considerable efforts are required to maintain optimal safety of 
blood transfusion practices. The emergence of new virus, such as the WNV in the 
North American continent or TTV in Asia,1,2 the potential risk of transmission of 
variant PrPsc 3,4, the bacterial contamination of blood products responsible for 
sepsis,5,6 the reduction but not the elimination of the window-periods despite the 
increased sensitivity of the tests,7,8 promote the development of new strategies to 
increase the safety of the blood products. Chemical and photodynamic pathogen 
inactivation technologies are the most recent developments for the reduction of 
pathogen transmission via transfusion of cellular blood products. 
This thesis describes the potential of PDT to decontaminate RBCC and CBSC. 
Besides the inactivation of pathogens, the viability and functions of RBCs and 
leukocytes, including hematopoietic progenitor stem cells, were evaluated.  
FINDING A SUITABLE PATHOGEN PHOTOINACTIVATION METHOD 
The original idea to inactivate pathogens in blood products is to add and activate 
an agent that targets pathogens but leaves the RBCs unharmed. Since RBCs 
contain no nucleic acids, photosensitizers binding to DNA or RNA were, at least in 
theory, the most promising photosensitizers to investigate. Photosensitization 
reaction resulting from the impact of light on the chemical agent leads to 




reproduce and infect new cells. Theoretically, RBCs lacking nucleic acids remain 
therefore unaffected.  
However, all photosensitizers tested so far for pathogen photoinactivation also 
induce damage to RBCs. Since a photosensitizer needs to bind to a target to 
induce damage, it is obvious, that the binding of the photosensitizers is not 
restricted to nucleic acids, but that binding to membranes also occurs. Minimizing 
photodamage to RBCs can be achieved by using more pathogen-specific 
photosensitizers or by specific protection of the cells. For this latter, more inside 
in the molecular mechanisms behind photodynamically induced damage is 
needed. A possible mechanism of photodamage and the specific protection of 
RBCs are described in chapters 2 and 3. The quest for more pathogen-specific 
photosensitizers is described in chapters 4 and 5.  
PROTECTION OF RED BLOOD CELLS  
Upon activation of the photosensitizer with visible light, various reactive oxygen 
species (ROS) are formed. ROS can inactivate a broad range of pathogens. 
However, as ROS are not selective and can be generated in all locations where 
sensitizer molecules are present, phototreatment can also damage RBCs.  
A better understanding of the molecular mechanisms behind photodynamically-
induced damage is needed to improve the selectivity of the photodynamic 
decontamination technique and to avoid damage to RBCs. Increased permeability 
of the membrane to cations, as measured by K+ leakage, is one of the first events 
that appear after photosensitization of RBCs. This damage results subsequently in 
delayed RBC hemolysis. In chapter 2, we used the photosensitizer DMMB to get 
more insight behind the PDT-mediated potassium leakage. As it is likely that 
damage to a membrane protein could be involved in K+ leakage, the kinetics of 
photodynamically induced K+ leakage and inhibition of several transport systems 
were investigated. Inhibition of band 3 activity by DMMB-mediated PDT showed a 
comparable light dose dependency as PDT-induced K+ leakage, whereas glycerol 
transport activity was inhibited only at higher light doses. Glucose transport was 
not affected by DMMB-mediated PDT. Dipyridamole (DIP), an inhibitor of anion 
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transport, protected band 3 against DMMB-induced damage, and prevented the 
increase in cation permeability of the membrane. These results suggest that there 
is a direct correlation between DMMB-mediated photodamage to band 3 and K+ 
leakage. 
Band 3 constitutes the anion transporter of the RBC and, with about a million 
copies per cell, it is the most abundant protein on the RBC membrane. DIP binds 
non-covalently, with high affinity to band 3 and has been reported to possess 
activity as a scavenger of various ROS. An obvious way to minimize the damage to 
RBCs induced by photodynamic pathogen inactivation would be to use DIP during 
PDT. In chapter 3, we showed that DIP can react with 1O2 which is the main ROS 
formed by PDT. The presence of DIP during PDT with photosensitizers DMMB and 
AlPCS4 resulted in a significant protection of the RBCs detected by decreased K+ 
leakage and hemolysis. In contrast to the strong protection of RBCs by DIP, hardly 
any effect on the photoinactivation of the model virus VSV was observed (chapter 
3). This indicates that DIP has the potential to increase the specificity of the 
pathogen inactivation of RBC concentrates, thereby increasing the practical 
applicability of this treatment.  However, the results were obtained under 
experimental conditions illuminating a model virus in diluted RBC suspension. 
Further research should focus in the effect of DIP on the photoinactivation of 
other viruses, including HIV, HCV, in a more concentrated RBC suspension. In 
addition, the effect of DIP on the self-life of phototreated RBC concentrates needs 
further investigation. 
Another way to protect RBC from PDT-induced hemolysis is to choose the optimal 
RBC suspension media. In this case the protection is indirect: the damaging agent 
is not inactivated but the effect of damage is suppressed. Studies have shown that 
solution in which phototreatment was performed could influence the amount of 
hemolysis induced by PDT.9,10 Less hemolysis was found when illumination was 
performed solutions with high osmotic strength as SAG-M. The solution in which 
the RBCs are stored after PDT has a much more pronounced effect on hemolysis. 
As shown in chapter 4, RBC hemolysis was reduced in SAG-S, SAG-D and AS-3 as 
compared to the standard RBC additive solution SAG-M. The presence of 




(AS-3) prevented RBC hemolysis after PDT by counterbalancing the osmotic 
activity of hemoglobin. RBC integrity was best maintained when illumination was 
performed in the high osmotic additive solution SAG-M followed by storage in AS-
3. 
PATHOGEN INACTIVATION WITH TRI-P(4) IN RBC PRODUCT: 
ADVANTAGES AND DRAWBACKS  
In our search to find a photosensitizer that efficiently inactivates pathogens 
without inducing RBC damage, we focused on a series of meso-substituted 
positively charged porphyrins. These photosensitizers have been shown to have a 
strong bactericidal potential.11,12 From this series photosensitizer Tri-P(4) stood 
out as the best porphyrin suitable for pathogen inactivation in RBCC (chapter 4). 
Our preliminary studies have shown that PDT of RBC with the amphiphilic 
photosensitizer Tri-P(4) gives the most satisfactory results combining low 
hemolysis with efficient virus kill. In contrast, hydrophobic cationic porphyrins 
such as Trans-P(4), Cis-P(4) and mono-P(4) were supposed, like DMMB, to bind to 
RBC and were found to induce a rapid potassium efflux. Hydrophilic porphyrin 
derivatives tetra-P(4), TAP, TNH-P(4) and AlPcS4  (chapter 3) may not bind to RBCs 
but showed a moderate cell lysis.  
When illuminated in SAG-M and stored in AS-3, parameters for RBC quality after 
PDT with Tri-P(4) were satisfactory as shown by in-vitro measurements and in-vivo 
autologous RBC survival experiments in Rhesus monkeys. To extent the study, we 
investigated the pathogen-inactivating capacity of PDT with Tri-P(4) for a broader 
range of pathogens (chapter 5). From this study, it became clear that for a >5 log 
inactivation of various enveloped viruses, and gram positive and gram negative 
bacteria, a light dose of 360 kJ/m2 was required. This implies a four times longer 
illumination time than required for the inactivation of VSV (chapter 5). These 
more rigid illumination conditions clearly increased RBC damage.  
Despite these promising results, pathogen inactivation with Tri-P(4) presents 
many drawbacks. Firstly, the efficacy of PDT with Tri-P(4) to inactivate the non-
enveloped CPV is low. Non-enveloped viruses are known to be very resistant to 
   Conclusion 
163 
chemical and photochemical treatments. However, as discussed in chapter 5, 
there is a remarkable difference in sensitivity to PDT within the parvoviridae 
families. Possibly, by using CPV as a model for human parvovirus B19, the 
inactivation of parvovirus B19 after PDT with Tri-P(4) is underestimated. Further 
testing evaluating the inactivation of human parvo B19 and of other non-
enveloped viruses such as Hepatitis A virus in RBC using PDT with Tri-P(4) may 
clarify this issue. 
More worrying is that Tri-P(4) is unable to inactivate intracellular viruses (chapter 
5). In contrast to neutral photosensitizers, cationic dyes do not penetrate the 
membrane bilayer as shown by the low cytotoxic effects of PDT with Tri-P(4) on 
WBC (chapter 6). Recently, Lambrechts et al. have demonstrated that under 
hypotonic conditions the influx of the photosensitizer into the yeast Candida 
albicans was enhanced, thereby potentiating the photosensitizing effect of Tri-
P(4).13 it remains to be elucidated whether there are conditions upon which 
bacteria, viruses and infected leukocytes, but not the RBCs, become permeable to 
the photosensitizer, thereby increasing the Tri-P(4) photoinactivation efficiency. 
Furthermore, a broader range of pathogen to inactivate in RBCC including fungi, 
parasites, and antibiotic resistant bacterial strains remain to be investigated. 
Studies with skin infection models have shown that fungi as well fungal spores are 
sensitive to PDT with Tri-P(4).14,15 This raises the question whether RBCC 
environment provides the satisfactory conditions for an efficient fungicidal effect. 
Moreover, besides bacteria, bacterial endotoxins can also be responsible for fatal 
post-transfusion reactions.16 The impact of PDT on endotoxin release from 
photoinactivated bacteria need also to be investigated.  
Another major concern about the suitability Tri-P(4) for photodecontamination of 
RBCC is the increase of IgG binding to the RBC membrane upon PDT. This is a 
problem also observed with other photosensitizer a.o DMMB and AlPcS4, and so 
far only observed with human cells (chapter 4). Binding of IgG is normally a sign of 
senescence of RBC which are subsequently removed from the circulation by 
macrophages. It can be speculated that PDT-induced IgG binding was the cause of 




mechanism behind the process of PDT-induced IgG binding and whether these 
coated cells are phagocytized is still unknown. We have found that photodamage 
of both plasma proteins and RBC membrane is required to induce this IgG binding. 
This suggests a more complex phenomenon than simply the induction of a 
senescence process exposing phosphatidyl serine onto the RBC membrane. To 
circumvent interference with transfusion-related diagnostic tests, it is of great 
importance to prevent IgG binding to RBCs during pathogen inactivation 
application. A possibility to do this is the addition of GSH to the RBC suspensions. 
GSH can prevent IgG binding by preventing the formation of sulfur bridges 
between cysteine amino acids. GSH has an advantage over other scavengers as it 
is a natural constituent of the blood and therefore might not have to be removed 
before transfusion. However, when considering the up-scaling of the photo-
treatment from small blood aliquots, as used in our studies, to full RBCC units, 
questions raise regarding the transfusion safety of photo-treated RBCs. With 
higher RBC volume, a greater amount of GSH would be required. The toxicity of 
large amount of GSH transfused intravenously needs to be determined. This is a 
subject of highest importance because the development of antibodies against 
RBCs treated with pathogen inactivation techniques is a major project killer. 
Despite the satisfactory in-vitro results and the in-vivo survival of treated RBCs in 
animals, Phase III clinical studies with S-303 and Pen 110 systems were halted 
because of the formation of antibodies against neo-antigens on the treated RBCs. 
Therefore, the future of these pathogen inactivation methods, including Tri-P(4)-
mediated PDT, is uncertain until the immunogenicity is completely understood 
and resolved. 
OTHER PERSPECTIVES FOR PDT WITH PORPHYRIN TRI-P(4)   
The amphiphilic character of photosensitizers was reported to promote cell 
uptake and better intracellular targeting.17 However, the cytotoxicity studies 
performed with such photosensitizers were often conducted with tumor cell lines 
cells while relatively little detailed information exists regarding non-transformed 
cells, especially cells of the immune system.18  
   Conclusion 
165 
Although porphyrin Tri-P(4) is amphiphilic and was reported to bind to DNA19,20, 
there seems to be very limited uptake of Tri-P(4) by intact cells. As mentioned 
above, Tri-P(4) is unable to inactivate intracellular virus, most likely because the 
porphyrin is not taken up by the cells. We also observed no cytototoxic effect 
upon PDT with Tri-P(4) of leukocytes present in treated RBCs. This observation 
had lead to conduct photoinactivation studies in CBSC products (chapter 6) and to 
investigate potential immunomodulating effects of PDT with Tri-P(4) (chapter 7). 
Bacterial contamination of CBSC is a major problem. It has been reported that up 
to 13% of CBSC products have been found positive in bacterial cultures.21,22 
Recently, the FDA guidelines and Netcord FACT standards requested the release 
of pathogen-free CBSC products for transplantation.  All contaminated products 
have to be discarded. Because of the low number of stem cells, protocols for ex-
vivo expansion of CBSC are developed. The presence of contaminants is a critical 
issue for such cultures which present ideal conditions for bacterial growth. 
PDT with Tri-P(4) of CBSC resulted in the inactivation of spiked virus (VSV), the G+ 
S. aureus and, the  G- P. aeruginosa and S. agalactiae (chapter 6). However, in 
comparison with application in RBCs, the treatment required a twofold higher Tri-
P(4) concentration. This may be explained by the difference in product 
composition. CBSC contains plasma proteins which are nearly absent in RBCs. 
These proteins, in particularly albumin, quench most of the singlet oxygen 
generated by the action of light on the photosensitizer. Also the presence of high 
number of macrophages and platelets may influence the bacterial inactivation. G+ 
bacteria are known to be readily sensitive to PDT when treated in saline or in 
RBCC containing SAG-M. However when treated in CBSC, the sensitivity of G+ 
bacteria to PDT decreased and became even lower than this of G- bacteria. 
Macrophages and platelets, which are abundant in CBSC, can bind to G+ bacteria 
via the teichoic acid components. The cells may compete with Tri-P(4) for binding 
to bacteria through the teichoic acid, thereby reducing the efficacy of Tri-P(4) to 
inactivate G+ bacteria.  
PDT with Tri-P(4) had no effect on the viability of hematopoietic progenitor stem 
cells nor on their ability to differentiate and form colonies in-vitro. Also the ex-
vivo expansion and differentiation of CD34-positive cells isolated from 




these excellent in-vitro results apparently not affecting lineage-committed cells, 
transplantation of photo-treated stem cells in NOD/scid mice showed a lower 
engraftment and hematopoietic recovery as compared to untreated cells. The 
diminished engraftment could be the result of an impaired homing of the 
photodynamically treated cells. Many factors have been described to influence 
migration and engraftment of stem cells, such as cell cycle, cytokines, 
chemokines, expression of adhesion molecules and cell-cell interaction.23-29 
Further research is needed to reveal whether PDT interacts with one of these 
critical factors, thereby contributing to the reduced engraftment potential. 
As in CBSCs, PDT with Tri-P(4) had no effect on the viability of leukocytes in RBC 
products (chapter 7). However, PDT does affect their functions. Alterations in 
proliferation, in allo-stimulation, in cell surface antigen expression and cytokine 
profiles are critical events in Tri-P(4)-phototreated cells. These changes result in 
an interesting issue, which is steering the immune response to T-cell 
hyporesponsiveness. For this, a combined effect of dark properties of Tri-P(4) 
which is binding to antigen-presenting cells (APC) and the effect of 
photodynamically-generated ROS on T cells was required. Binding of Tri-P(4) 
resulted in down-regulation of CD80/CD86, up-regulation of HLA-DR and CD14 
and in lower release of chemoattractants IL-8 and MIP-1beta. These results may 
support the formation of alternatively-activated macrophages capable of inducing 
T-cell hyporesponsiveness. In addition, impairment of the T cell response to allo-
antigens upon PDT with Tri-P(4) was strongly dependent on the amount of RBC. 
The lesser RBCs were present, the more the T cell proliferation was inhibited. The 
reason of this correlation may be that the increased RBC concentration reduces 
the amount of light that reached the leukocytes during PDT. Therefore, by 
adapting the light dose, PDT can modulate the interaction between T-cells and 
APC. Such modulation can have advantages in establishing appropriate treatment 
conditions for prevention of transfusion-associated Graft-versus-Host disease and 
alloimmunization, or for induction of tolerance in a recipient. However, it has 
been suggested that RBCs have a role as modulators of T-cell growth and survival 
and thereby may contribute to immunomodulating effects of transfusion.30,31 
Therefore the effect of the presence of RBC during PDT with Tri-P(4) of leukocyte 
products may not be underestimated. Further research is required to establish if 
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adjusting the light dose may result in same immunomodulating effects as a 
variation in concentration of RBC.  
In conclusion, due to the particular properties of porphyrin Tri-P(4), many 
purposes are conceivable for PDT with Tri-P(4) from pathogen inactivation to 
immunomodulation. The great advantage of this cationic amphiphilic dye is the 
modulation of its effect by adjusting the environment. PDT with Tri-P(4) can then 
be applied for various goals.  
At first, PDT with Tri-P(4) appeared to be a good method for pathogen inactivation 
in stem cell containing products, including those derived from à priori 
contaminated areas, for development of hematopoietic as well as regenerative 
therapies. Besides cord blood products, PDT with Tri-P(4) may be applied to 
decontaminate other sources of hematopoietic progenitor cells (e.g. bone marrow 
or menstrual blood).32,33  
However, the original purpose to apply photodynamic treatment to enhance 
safety of RBCs is hampered by the photodynamically-induced damage to RBC. This 
can only be solved by providing adequate protection to RBC and this led to too 
many concerns regarding the therapeutic quality of the treated blood products. 
Therefore, it is unlikely that PDT with Tri-P(4) will be used for pathogen 
inactivation in RBC. Nevertheless, the studies with RBC revealed another potential 
of PDT with Tri-P(4) for dividing cell populations and for modulation of allo-
immune responses, including tolerance induction.  
REFERENCES 
 1.  Charrel RN, de Lamballerie X, Durand JP, Gallian P, Attoui H, Biagini P, de Micco P. 
Prevalence of antibody against West Nile virus in volunteer blood donors living in 
southeastern France. Transfusion 2001;41(10):1320-1. 
 2.  Dai CY, Yu ML, Chuang WL, Wang CS, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF, 
Chang WY. The molecular epidemiology and clinical significance of TT virus (TTV) 
infection in healthy blood donors from southern Taiwan. Transfus. Apher. Sci. 
2001;24(1):9-15. 
 3.  Roddie PH, Turner ML, Williamson LM. Leucocyte depletion of blood components. 




 4.  Moor AC, Dubbelman TM, VanSteveninck J, Brand A. Transfusion-transmitted 
diseases: risks, prevention and perspectives. Eur. J. Haemotol. 1999;62(1):1-18. 
 5.  Kuehnert MJ, Roth VR, Haley NR, Gregory KR, Elder KV, Schreiber GB, Arduino MJ, 
Holt SC, Carson LA, Banerjee SN, et al. Transfusion-transmitted bacterial infection in 
the United States, 1998 through 2000. Transfusion 2001;41(12):1493-9. 
 6.  Perez P, Bruneau C, Chassaigne M, Salmi LR, Noel L, Allouch P, Audurier A, Gulian C, 
Janus G, Boulard G, et al. Multivariate analysis of determinants of bacterial 
contamination of whole-blood donations. Vox Sang. 2002;82(2):55-60. 
 7.  Ruzzenenti MR, De Luigi MC, Bruni R, Giannini G, Bo A, Valbonesi M, Barresi R, 
Torretta F, Gianotti P, Bruzzone B. PCR testing for HCV in anti-HCV negative blood 
donors involved in the so called HCV +ve post-transfusion hepatitis. Transfus. Sci. 
2000;22(3):161-4. 
 8.  Liu H, Shah M, Stramer SL, Chen W, Weiblen BJ, Murphy EL. Sensitivity and 
specificity of human T-lymphotropic virus (HTLV) types I and II polymerase chain 
reaction and several serologic assays in screening a population with a high 
prevalence of HTLV-II. Transfusion 1999;39(11-12):1185-93. 
 9.  Besselink GA, Ebbing IG, Hilarius PM, De_Korte D, Verhoeven AJ, Lagerberg JW. 
Composition of the additive solution affects red blood cell integrity after 
photodynamic treatment. Vox Sang. 2003;85(3):183-9. 
 10.  Wagner SJ, Skripchenko A, Thompson-Montgomery D. Use of a flow-cell system to 
investigate virucidal dimethylmethylene blue phototreatment in two RBC additive 
solutions. Transfusion 2002;42(9):1200-5. 
 11.  Merchat M, Spikes JD, Bertoloni G, Jori G. Studies on the mechanism of bacteria 
photosensitization by meso- substituted cationic porphyrins. J. Photochem. 
Photobiol. B 1996;35(3):149-57. 
 12.  Minnock A, Vernon DI, Schofield J, Griffiths J, Parish JH, Brown ST. Photoinactivation 
of bacteria. Use of a cationic water-soluble zinc phthalocyanine to photoinactivate 
both gram-negative and gram-positive bacteria. J. Photochem. Photobiol. B 1996 
Feb;32(3):159-64. 
 13.  Lambrechts SA, Aalders MC, Van Marle J. Mechanistic study of photodynamic 
inactivation of Candida albicans by a cationic porphyrin. Antimicrob Agents 
Chemother 2005 May;49(5):2026-34. 
   Conclusion 
169 
 14.  Smijs TG, Van Der Haas RN, Lugtenburg J, Liu Y, De Jong RL, Schuitmaker HJ. 
Photodynamic Treatment of the Dermatophyte Trichophyton Rubrum and its 
Microconidia with Porphyrin Photosensitizers. Photochem.Photobiol. 2004 Apr 1. 
 15.  Smijs TG, Schuitmaker HJ. Photodynamic inactivation of the dermatophyte 
Trichophyton rubrum. Photochem. Photobiol. 2003;77(5):556-60. 
 16.  Vasconcelos E, Seghatchian J. Bacterial contamination in blood components and 
preventative strategies: an overview. Transfus. Apher. Sci. 2004 Oct;31(2):155-63. 
 17.  Paquette B, Boyle RW, Ali H, MacLennan AH, Truscott TG, van Lier JE. Sulfonated 
phthalimidomethyl aluminum phthalocyanine: the effect of hydrophobic 
substituents on the in vitro phototoxicity of phthalocyanines. Photochem. 
Photobiol. 1991 Mar;53(3):323-7. 
 18.  Hunt DW, Chan AH. Influence of photodynamic therapy on immunological aspects 
of disease - an update. Expert Opin. Investig. Drugs 2000;9(4):807-17. 
 19.  Munson BR, Fiel RJ. DNA intercalation and photosensitization by cationic meso 
substituted porphyrins. Nucleic Acids Research 1992;20(6):1315-9. 
 20.  Sari MA, Battioni JP, Dupre D, Mansuy D, Le_Pecq JB. Interaction of cationic 
porphyrins with DNA: importance of the number and position of the charges and 
minimum structural requirements for intercalation. Biochemistry 1990;29(17):4205-
15. 
 21.  Honohan A, Olthuis H, Bernards AT, van Beckhoven JM, Brand A. Microbial 
contamination of cord blood stem cells. Vox Sang. 2002;82(1):32-8. 
 22.  Kogler G, Callejas J, Hakenberg P, Enczmann J, Adams O, Daubener W, Krempe C, 
Gobel U, Somville T, Wernet P. Hematopoietic transplant potential of unrelated 
cord blood: critical issues. J. Hematother. 1996;5(2):105-16. 
 23.  Guenechea G, Segovia JC, Albella B, Lamana M, Ramirez M, Regidor C, Fernandez 
MN, Bueren JA. Delayed engraftment of nonobese diabetic/severe combined 
immunodeficient mice transplanted with ex vivo-expanded human CD34(+) cord 
blood cells. Blood 1999 Feb 1;93(3):1097-105. 
 24.  Ahmed F, Ings SJ, Pizzey AR, Blundell MP, Thrasher AJ, Ye HT, Fahey A, Linch DC, 
Yong KL. Impaired bone marrow homing of cytokine-activated CD34+ cells in the 




 25.  Zhai QL, Qiu LG, Li Q, Meng HX, Han JL, Herzig RH, Han ZC. Short-term ex vivo 
expansion sustains the homing-related properties of umbilical cord blood 
hematopoietic stem and progenitor cells. Haematologica 2004 Mar;89(3):265-73. 
 26.  Graf T. Differentiation plasticity of hematopoietic cells. Blood 2002 May 
1;99(9):3089-101. 
 27.  Gothot A, van der Loo JC, Clapp DW, Srour EF. Cell cycle-related changes in 
repopulating capacity of human mobilized peripheral blood CD34(+) cells in non-
obese diabetic/severe combined immune-deficient mice. Blood 1998 Oct 
15;92(8):2641-9. 
 28.  Springer TA. Traffic signals on endothelium for lymphocyte recirculation and 
leukocyte emigration. Annu. Rev. Physiol 1995;57:827-72. 
 29.  Peled A, Kollet O, Ponomaryov T, Petit I, Franitza S, Grabovsky V, Slav MM, Nagler A, 
Lider O, Alon R, et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and 
VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration 
and engraftment of NOD/SCID mice. Blood 2000 Jun 1;95(11):3289-96. 
 30.  Fonseca AM, Porto G, Uchida K, Arosa FA. Red blood cells inhibit activation-induced 
cell death and oxidative stress in human peripheral blood T lymphocytes. Blood 
2001;97(10):3152-60. 
 31.  Arosa FA, Pereira CF, Fonseca AM. Red blood cells as modulators of T cell growth 
and survival. Curr. Pharm. Des 2004;10(2):191-201. 
 32.  Padley D, Koontz F, Trigg ME, Gingrich R, Strauss RG. Bacterial contamination rates 
following processing of bone marrow and peripheral blood progenitor cell 
preparations. Transfusion 1996;36(1):53-6. 
 33.  Patel AN, Park E, Kuzman M, Benetti F, Silva FJ, Allickson JG. Multipotent menstrual 






HET INACTIVEREN VAN PATHOGENEN IN 
CELLULAIRE BLOED PRODUCTEN MET 
FOTODYNAMISCHE BEHANDELING 
INTRODUCTIE: BLOEDPRODUCTEN EN ZIEKTEVERWEKKERS 
De veiligheid van bloedtransfusie is een van de prioriteit van de bloedbank. Om 
veiligheid te garanderen is een reeks procedures geïmplementeerd. Ten eerste 
dient het doneren van bloed een vrijwillige, onbetaalde activiteit te zijn. Het 
donorbloed wordt vervolgens getest op de aanwezigheid van belangrijke 
ziekteverwekkers, zoals Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human 
Immunodeficiency Virus (HIV), Human T-cell leucemia virus (HTLV) en Treponema 
pallidum.  
In geindustrialiseerde landen bedraagt de frequentie van geïnfecteerde 
bloeddonaties ongeveer 1 op 270.000 voor HCV, 1 op 205.000 voor HBV en 1 op 
3,1 miljoen voor HIV. De frequenties zijn nog veel lager voor HTLV en Treponema 
palladium. 
Ondanks deze lage frequenties, kan het risico dat een geïnfecteerde bloeddonatie 
aan een patiënt wordt overgedragen niet uitgesloten worden. Ten eerste komt 
het voor dat, wanneer een donor zeer recentelijk geïnfecteerd is, de 
ziekteverwekker nog niet detecteerbaar is in zijn bloed omdat de concentratie van 
het pathogeen of de hoeveelheid antilichamen tegen de ziekteverwekker nog te 
laag is. Ten tweede wordt de bloedvoorziening voortdurend bedreigd door 
nieuwe opkomende ziekteverwekkers, bijvoorbeeld het vogelgriep virus (H5N1) 
en het West-Nijl virus. Mensen reizen steeds meer en gaan steeds vaker naar 
tropische landen waar infecties zeer vaak voorkomen met parasieten, 
verantwoordelijk voor malaria of Chagas ziekte. Bovendien duurt het testen van 




transfusie, op te merken. Ten slotte is er niet voor alle bekende ziekteverwekkers 
een test beschikbaar.  
Gezien het brede scala aan ziekteverwekkers is het niet realistisch om alle 
bloeddonaties op alle micro-organismen te testen. Dit zou leiden tot hogere 
kosten en langere verwerking van het bloed, wat uiteindelijk enorme gevolgen 
zou hebben voor de bloedvoorziening in ziekenhuizen. 
Om de veiligheid van de bloedtransfusie te vergroten, zijn technieken ontwikkeld 
om ziekteverwekkers te inactiveren zonder dat de kwaliteit van het bloedproduct 
achteruit gaat. Zulke technieken worden “Pathogene Inactivatie Technieken” 
genoemd. Deze zijn vergelijkbaar met sterilisatietechnieken, met het grote 
verschil dat, bij sterilisatieprocessen alle componenten, inclusief de cellen, 
geïnactiveerd of vernietigd worden. Deze totale vernietiging is niet toepasbaar op 
cellulaire bloedproducten, omdat de bloedcellen noodzakelijk zijn voor het 
therapeutische effect van een bloedtransfusie. Om deze reden is binnen dit 
promotieonderzoek gewerkt aan een methode, waarmee met behulp van 
fotodynamische behandeling, specifiek de ziekteverwekkers in cellulaire 
producten worden geïnactiveerd.  
HET PRINCIPE VAN FOTODYNAMISCHE BEHANDELING OM 
PATHOGENEN TE INACTIVEREN 
De fotodynamische reactie betreft de activering van een lichtgevoelige molecuul 
(fotosensitizer) door belichting met rood licht in de aanwezigheid van zuurstof. Als 
de fotosensitizer eenmaal is geactiveerd, dan gaat deze chemische reacties aan 
met andere moleculen, waardoor zich zeer reactieve deeltjes vormen. Deze zeer 
reactieve toxische deeltjes zijn verantwoordelijk voor oxidatieve schade aan 
talloze moleculen die aanwezig zijn op virussen, bacteriën en bloedcellen. De 
eigenschappen van de fotosensitizer bepalen de effectiviteit en de selectiviteit 
van de fotodynamische behandeling (PDT voor PhotoDynamic Treatment).  
DOEL VAN HET ONDERZOEK 
In het onderzoek beschreven in dit proefschrift richtte onze pathogene inactivatie 
techniek zich voornamelijk op bloedproducten die rode bloedcellen bevatten 
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zoals rode bloedcel concentraten (RBC) en navelstrengbloed. Het doel van het 
onderzoek was een fotosensitizer te vinden waarmee micro-organismen 
geïnactiveerd worden zonder de bloedcellen te beschadigen. Alle bekende 
fotosensitizers die in staat waren om verschillende pathogenen te inactiveren, 
waren ook schadelijk voor de rode bloedcellen. In hoofdstukken 2 en 3 hebben 
wij studies uitgevoerd met als doel meer inzicht te krijgen in het mechanisme 
achter de fotodynamische schade aan rode bloedcellen, wat vervolgens moest 
leiden tot het beter beschermen van deze cellen. De zoektocht naar meer 
specifieke fotosensitizers is beschreven in hoofdstukken 4 en 5. In hoofdstukken 
6 en 7 beschreven wij de toepassing van pathogene inactivering op 
navelstrengbloed en op witte bloedcellen. 
SCHADE AAN RBC MEMBRAAN DOOR PDT MET DMMB EN SELECTIEVE 
BESCHERMING 
In hoofdstuk 2 wordt een studie beschreven naar het schadelijke effect van PDT 
met dimethyl-methylene blauw (DMMB) op de rode bloedcellen. DMMB is een 
fotosensitizer die bindt aan rode bloedcellen, waardoor de cellen direct 
blootgesteld worden aan de schadelijke effecten van de oxidatieve deeltjes. We 
hebben een eiwit, zogenaamd Band 3, geïdentificeerd waarop fotodynamische 
schade plaatstvindt. Band 3 transporteert anionen door het rode 
bloedcelmembraan. Als de activiteit van Band 3 verstoord is, kan de rode bloedcel 
zijn osmotische regulatie niet meer garanderen. De cellen zwellen op, waardoor 
ze vervolgens kapot gaan. Die wordt hemolyse genoemd.  
In hoofdstuk 3 hebben wij een manier gevonden om Band 3 selectief te 
beschermen tegen fotodynamische schade door PDT met DMMB. Als 
Dipyridamole toegevoegd wordt aan het bloedproduct, is Band 3 beschermd 
tegen het schadelijke effect van PDT met DMMB. Dipyridamole is een molecuul 
dat aan Band 3 bindt en de schadelijke oxidatieve deeltjes vangt. Dipyridamole 
werkt eigenlijk als een schild en beschermt Band 3 zonder de inactivatie van 
virussen door PDT met DMMB te verminderen.  
Helaas bleek echter dat PDT met DMMB ook op andere plekken van de rode 




moeilijk in stand te houden bleek. Vandaar dat wij op zoek zijn gegaan naar 
andere fotosensitizers.  
DE ZOEKTOCHT NAAR EEN NIEUWE FOTOSENSITIZER: TRI-P(4) 
In hoofdstuk 4 is een reeks nieuwe fotosensitizers getest en geëvalueerd op hun 
potentieel om virussen te inactiveren. Tevens zijn hun effecten op de kwaliteit van 
de rode bloedcellen geëvalueerd. De nieuwe fotosensitizers bestaan uit derivaten 
van porfyrines. Porphyrines zijn macrocyclische molecules (zeer grote cyclus) met 
vier pyrrole moleculen (fig.1). Van de 7 verschillende geteste porfyrines, was Tri-
P(4) de  fotosensitizer die virussen het beste kon doden met beperkte schade aan 
rode bloedcellen. Tests in resusapen wezen uit dat de PDT-benhandelde rode 
bloecellen na transfusie net zoveel kans op overleving hadden als de 
onbehandelde cellen. Het vervolgonderzoek hierop is beschreven in hoofdstuk 5, 
waar PDT met Tri-P(4) getest werd op een breed scala aan micro-organismen die 
voornamelijk relevant zijn bij bloed transfusie. Deze studie heeft laten zien dat 
modelvirussen voor HCV, HBV en HIV geïnactiveerd konden worden. Echter PDT 
met Tri-P(4) scoorde onvoldoende bij het inactiveren van intracellulaire virussen 
en Parvo-virussen (waarvan de menselijke variant B19 veroorzaakt de vijfde 
ziekte, of anders genoemd erythema infectiosum). Parvo-virussen zijn bekend om 
hun hoge resistentie tegen chemische behandelingen. Bacteriën, vaak betrokken 
bij rode bloedcel contaminatie zoals Yersinia enterolitica, 
waren ook gevoelig voor PDT met Tri-P(4). In vergelijking 
met DMMB, brengt Tri-P(4) minder schade toe aan rode 
bloedcellen. Desalniettemin leidt fotodynamische schade 
door Tri-P(4) toch tot een vermindering van de 
therapeutische kwaliteit van het bloedproduct.  
Vanwege de al geringe kans op overdracht van micro-
organismen via bloedtransfusie, blijkt de ontsmetting 
methode via PDT met Tri-P(4) geen toegevoegde waarde 
te hebben in het toenemen van de transfusionelle 
veiligheid. Dit vanwege de beperking van de behandeling 
om alle virussen te kunnen inactiveren en de schade, desondanks niet te 
verwaarlozen, aan de rode bloed cellen. Daarom is het besloten om deze techniek 
Figure 1: basische 
vorm van 
porphyrine 
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van pathogen inactivatie niet in te voeren voor de ontsmetting van rode bloed cel 
concentraten.  
ONTSMETTING VAN NAVELSTRENGBLOED 
Het gebruik van navelstrengbloed berust op een hoge concentratie 
bloedstamcellen, waardoor het een geschikt alternatief is voor 
beenmergtransplantatie, voornamelijk bij kinderen. De bloedstamcellen worden 
ook gekweekt voor nieuwe therapeutische doeleinden. Bij afname van het 
navelstrengbloed wordt het product vaak vervuild met bacteriën, wat gevaarlijk 
kan zijn voor de getransplanteerde patiënt en het kweken van de stamcellen zelf 
kan belemmeren.  
Zoals beschreven in hoofdstuk 6 inactiveert PDT met Tri-P(4) alle bacteriën in 
vervuilde navelstrengbloedproducten. De stamcellen overleven deze 
ontsmettingsbehandeling. Helaas bleek uit studies in muizen dat de kwaliteit van 
het navelstrengbloed als transplantaat vermindert, waarschijnlijk doordat er toch 
fotodynamische schade aan de cellen plaatsvindt, die de cel migratie naar de 
beenmerg zou hebben aangetast. De stamcellen konden echter wel verder 
gekweekt worden tot andere bloedcellen, zoals thrombocyten. Doordat tijdens 
het kweken van deze cellen, het gebruik van antibiotica steeds bemoeilijkt wordt 
omdat bacteriën resistentie ontwikkelen tegen antibiotica, zou PDT met Tri-P(4) 
een interessante alternatieve behandeling zijn voor de ontsmetting van overige 
stamcel bevattende producten zoals de beenmerg en het menstruatiebloed. Met 
deze andere bronnen van stamcellen wordt onderzoek gedaan naar het herstel 
van weefsels en organen.  
DE MODULATIE VAN HET IMMUUNSYSTEEM MET PDT EN TRI-P(4) 
In hoofdstuk 7 is een studie beschreven naar het effect van PDT met Tri-P(4) op 
de witte bloedcellen die aanwezig zijn in rode bloedcelconcentraten. De transfusie 
van witte bloedcellen geeft bijwerkingen doordat het lichaam van de 
getransfuseerde patiënt als “vreemd” wordt herkend en aangevallen wordt door 
de witte bloedcellen van de donor. Een andere bijwerking is de aanmaak van 
antilichamen door de patiënt tegen de getransfuseerde witte bloedcellen. Zulke 




Daarentegen, na een transplantatie (in het bijzonder niertransplantatie) bevordert 
de transfusie van witte bloedcellen de acceptatie van het transplantaat door het 
lichaam van de getransplanteerde patiënt. 
Deze studie richtte zich op de bestudering van het effect van PDT met Tri-P(4) op 
het modulatiepotentieel van de witte bloedcellen. Onze resultaten laten zien dat 
PDT met Tri-P(4) het opwekken van de ontstekingsreacties remt. De sterkte van 
de remming is afhankelijk van de hoeveelheid rode bloedcellen die aanwezig zijn 
in het bloedproduct. De cellen werken als een schild tegen fotodynamische 
schade aan witte bloedcellen. De resultaten gaven sterke aanwijzingen dat de 
immune respons van donor witte bloedcellen gemoduleerd kon worden met PDT 
en Tri-P(4). Verder onderzoek is nodig om te bepalen of PDT met Tri-P(4) nieuwe 
ontwikkelingen zal brengen in het voorkomen van afstotingsreacties na 
orgaantransplantatie of het aanmaken van antilichamen na bloedtransfusie. 
CONCLUSIE 
Onze studies hebben laten zien dat de fotosensitizer Tri-P(4) veel beter is dan alle 
andere geteste fotosensitizers om pathogenen te inactiveren in rode 
bloedcelproducten. Echter, ondanks de veelbelovende resultaten van 
fotodynamische ontsmetting van rode bloedcelproducten, zou de resulterende 
therapeutische kwaliteit van het bloedproduct toch te veel reden voor 
bezorgdheid opleveren bij transfusiespecialisten. Vandaar dat verder onderzoek 
naar het gebruik van PDT met Tri-P(4) voor pathogene inactivatie in rode bloedcel 
concentraten niet voortgezet zal worden. Desalniettemin hebben onze studies 
verschillende toepassingen voor de fotodynamische behandeling met Tri-P(4) op 
bloed producten naar voren gebracht. De pathogeen inactiverende werking van 
Tri-P(4) zou wel gebruikt kunnen worden in andere bronnen van stamcellen zoals 
menstruatiebloed en beenmerg, gezien het geringe effect op stamcellen. 
Daarnaast zouden de effecten van de behandeling op de witte bloed cellen 
gunstig kunnen zijn om transfusiegerelateerde immune reacties te voorkomen of 




RÉSUMÉ EN FRANÇAIS 
INACTIVATION PAR LE TRAITEMENT 
PHOTODYNAMIQUE DES AGENTS 
PATHOGENIQUES CONTENUS DANS LES 
PRODUITS SANGUINS CELLULAIRES 
INTRODUCTION : LES DONS SANGUINS ET LES AGENTS INFECTIEUX 
La production de produits sanguins sains est l'une des priorités des banques de 
sang. Cela passe par une série de procédures qui commence par le don de sang 
volontaire et non-rémunéré. Le don sanguin est ensuite testé, entre autres, pour 
la présence d’agents infectieux tels que les virus d’hépatite B et C (VHB, VHC), le 
virus d’immunodéficience acquise (VIH), le virus T-lymphotropique humain (HTLV) 
causant divers cancers et la bactérie Treponema pallidum responsable de la 
syphilis.  
Dans les pays industrialisés, le nombre de dons infectieux est actuellement très 
faible, de   l’ordre de 1 sur 205.000 pour le VHB, 1 sur 270.000 pour le VHC, 1 sur 
3.1 million pour le VIH. La fréquence est encore plus faible pour le HTLV et le 
Treponema pallidum. Bien que ces chiffres soient très faibles, le danger de 
transfuser un don sanguin infecté par un agent pathogène persiste.  
Tout d’abord, un individu récemment infecté peut faire un don de sang contaminé 
alors que la présence de l’agent infectieux n’est pas encore détectable, la 
concentration de l'agent pathogène ou d'anticorps dans le sang étant encore trop 
faible. Ensuite, les banques de sang sont confrontées à une menace permanente 
de nouvelles infections, comme par exemple l’émergence de nouveaux virus tels 
que celui de la grippe aviaire (H5N1) ou du virus du Nil occidental. Par ailleurs, les 
gens voyagent de plus en plus dans les pays tropicaux, s’exposant à des infections 
parasitaires responsables des maladies comme la malaria ou la maladie de 
Chagas. Il y a encore trop de contaminations bactériennes des produits sanguins 




Pour finir, il n’y a pas de tests de dépistage disponibles pour tous les agents 
pathogéniques connus. Au regard de la gamme d’agents infectieux susceptibles de 
contaminer le sang, il serait inconcevable que chaque don soit testé pour tous les 
agents pathogéniques. Ceci générerait une hausse des coûts de production et un 
processus de préparation plus long, ayant des conséquences énormes sur 
l’approvisionnement des dons sanguins aux centres hospitaliers.  
Afin d’assurer la sécurité des transfusions sanguines, de nouvelles technologies 
ont été développées. Elles ont pour but d’inactiver les agents pathogéniques sans 
que la qualité du produit sanguin ne soit altérée. Ces techniques sont appelées 
« Techniques d’inactivation pathogénique ». Elles sont comparables à des 
techniques de stérilisation, avec la grande différence que, dans le processus de 
stérilisation, tous les composants, incluant les cellules sanguines, sont détruits, 
alors que ceci n’est pas envisageable pour les produits sanguins cellulaires. Les 
cellules sanguines sont en effet indispensables à l’effet thérapeutique de la 
transfusion sanguine. C’est pour cette raison qu’au cours de ces travaux de 
recherche, nous avons travaillé à une méthode, basée sur le traitement 
photodynamique, qui inactive spécifiquement les agents pathogéniques dans les 
produits sanguins cellulaires.  
LE PRINCIPE DU TRAITEMENT PHOTODYNAMIQUE POUR INACTIVER 
LES AGENTS PATHOGENIQUES 
Le traitement photodynamique (TPD) implique l’excitation par la lumière rouge 
d’une molécule photosensible (photosensibilisateur) en présence d’oxygène. Le 
photosensibilisateur excité réagit avec d’autres molécules, produisant ainsi des 
espèces chimiques toxiques qui oxydent de nombreuses molécules présentes sur 
les agents pathogéniques ou les cellules sanguines. Les propriétés du 
photosensibilisateur déterminent l’efficacité et la sélectivité du TPD. 
BUT DE LA RECHERCHE 
Le développement de notre technique de photo-décontamination se concentrait 
essentiellement sur les produits sanguins labiles tels les concentrés de globules 
rouges et le sang placentaire. Notre objectif était de trouver un 
photosensibilisateur capable d’inactiver les agents pathogéniques sans 
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endommager les cellules sanguines. Jusqu’alors, tous les photosensibilisateurs 
susceptibles d’avoir une bonne activité anti-pathogénique endommageaient aussi 
les globules rouges. Les chapitres 2 et 3 décrivent les travaux effectués pour 
mieux comprendre les mécanismes impliqués dans l’endommagement des 
globules rouges par le TPD afin de pouvoir mieux les protéger. Les chapitres 4 et 5 
décrivent la découverte d’un nouveau photosensibilisateur qui serait plus 
spécifique pour les agents pathogéniques que pour les globules rouges. Enfin, les 
chapitres 6 et 7 décrivent l’application du TPD pour la décontamination du sang 
placentaire et ses effets sur les globules blancs. 
L’ENDOMMAGEMENT DES GLOBULES ROUGES PAR TPD AVEC LE 
PHOTOSENSIBILISATEUR DMMB ET PROTECTION SELECTIVE. 
Le photosensibilisateur DMMB (di-méthyle-méthylène bleu) est un agent 
chimique capable d’inactiver une grande gamme d’agents viraux, bactériens et 
parasitaires. Cependant le DMMB se fixe sur les globules rouges, exposant 
directement les cellules aux effets néfastes des espèces chimiques oxydantes. 
Nous avons identifié une protéine, appelée Bande 3, comme étant la molécule à 
laquelle le DMMB se fixe et qui serait endommagée par le TPD (chapitre 2). La 
protéine Bande 3 assure l’échange de molécules tel que le chlorure et le 
bicarbonate à travers la membrane plasmique des globules rouges. Quand 
l’activité de Bande 3 est perturbée, voire inhibée, le globule rouge n’est plus en 
état de réguler son état osmotique. Il finit alors par éclater. C’est le phénomène 
d’hémolyse. Dans le chapitre 3, nous décrivons une manière de protéger la 
protéine Bande 3 contre les dommages photodynamiques causés par le TPD avec 
le DMMB. Pour cela, du dipyridamole est ajouté aux produits sanguins. Cet agent 
chimique se fixe sur la protéine Bande 3 et la protège en contrant les espèces 
chimiques oxydantes générées par le TPD. Tout cela se fait sans réduction de 
l’efficacité du DMMB à inactiver les agents viraux.  
Cependant, les dommages causés aux globules rouges par le TPD avec le DMMB 
sont très étendus. La qualité des globules rouges est très difficile à maintenir en 





TRI-P(4), UN NOUVEAU PHOTOSENSIBILISATEUR, TRES PROMETTEUR 
Comme décrit dans le chapitre 4, de nouveaux photosensibilisateurs ont été 
testés. Ils sont tous dérivés de porphyrines, des molécules macrocycliques (cycle 
de grande taille) tétra-pyrroliques (formées de quatre molécules de pyrrole) 
(fig.1).  Ces dérivés de porphyrines ont été testés pour déterminer leur potentiel à 
inactiver les agents viraux et bactériens. Parallèlement, leurs effets sur les 
globules rouges ont été étudiés. Parmi les 7 molécules différentes testées, la 
porphyrine Tri-P(4) s’est avérée être supérieure aux autres par sa plus grande 
efficacité à inactiver le virus tout en causant le moins de dommages aux globules 
rouges. Des globules rouges de singes Rhésus ont été sujets au TPD avec le Tri-
P(4) puis re-transfusés aux animaux. La chance de survie des cellules traitées au 
Tri-P(4) était comparable à celles des cellules non traitées. La suite des études est 
décrite dans le chapitre 5, où une gamme plus large d’agents pathogéniques a été 
traitée avec le TPD et le Tri-P(4). L’étude a montré que les agents particulièrement 
importants en transfusion sanguine comme le VHB, VHC et le VIH étaient 
sensibles au traitement et pouvaient être rendus inactifs mais cela nécessitait une 
durée de traitement 4 fois plus longue. Cependant, le TPD avec le Tri-P(4) n’était 
pas capable d’inactiver les virus intracellulaires (ceux qui ont infecté des globules 
blancs), ni les Parvovirus (dont la variante humain B19 est responsable de 
l’érythème infectieux aigu, autrement dit la cinquième maladie). Ces virus sont 
connus pour être les plus résistants aux traitements chimiques. En revanche, les 
bactéries se sont avérées être très sensibles au TPD avec le Tri-P(4). Comparé au 
DMMB, le Tri-P(4) cause moins de dommages aux globules 
rouges. Néanmoins, ces dommages contribuent à une 
diminution de la qualité thérapeutique du produit sanguin.  
Compte tenu de la faible fréquence de transfusion de sang 
contaminé, la technique de décontamination utilisant le 
TPD avec le Tri-P(4) ne semble pas apporter de valeur 
ajoutée à l’accroissement de la sécurité transfusionnelle, de 
par sa capacité limitée à inactiver tous les virus et aux 
dégâts, malgré tout non négligeables, causés aux globules 
rouges. Par conséquent, il a été décidé que le traitement d’inactivation 
Figure 1: Squelette 
de base de 
porphyrine 
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pathogénique par le TPD avec le Tri-P(4) ne serait pas appliqué dans les banques 
de sang. 
DECONTAMINATION DU SANG PLACENTAIRE 
Le sang placentaire provient du cordon ombilical après la naissance du nouveau-
né. Ce produit contient une quantité importante de cellules souches (cellules de 
sang primitives encore indifférenciées) capable de restituer un système 
immunitaire après transplantation chez un patient. Les cellules souches issues du 
sang placentaire sont aussi mises en culture pour développer de nouveaux 
intérêts thérapeutiques. Cependant, pendant la récolte du sang placentaire, le 
produit est souvent contaminé par des bactéries. D’une part, celles-ci peuvent 
être dangereuses pour le patient qui reçoit le produit transplanté. D’autre part, 
les bactéries trouvent dans les cultures cellulaires les conditions idéales pour leur 
croissance, empêchant la culture saine des cellules souches. 
Comme décrit dans le chapitre 6, le TPD avec Tri-P(4) est capable d’inactiver les 
bactéries contaminantes sans affecter la survie des cellules souches. 
Malheureusement, des études chez les souris ont montré que les cellules souches 
traitées au TPD ont une capacité réduite à reconstituer un système immunitaire 
après transplantation. Ceci est probablement dû aux effets photodynamiques qui 
ont malgré tout causé quelques dommages aux cellules souches affectant leur 
migration vers la moelle osseuse. Cependant, les cellules souches traitées au TPD 
avec Tri-P(4) pouvaient être mises en culture pour produire d’autres cellules 
sanguines. Comme pendant leurs cultures, l’utilisation d’antibiotiques devient de 
plus en plus limitée à cause du développement de souches bactériennes 
résistantes, le TPD avec le Tri-P(4) pourrait être une méthode intéressante pour la 
décontamination des autres sources de cellules souches comme la moelle osseuse 
et les menstrues. Ces autres sources de cellules souches contribuent à la 







LA MODULATION DU SYSTEME IMMUNITAIRE PAR LE TPD AVEC TRI-
P(4) 
Dans le chapitre 7, nous décrivons une étude effectuée pour étudier l’effet du 
TPD avec le Tri-P(4) sur les globules blancs restés dans les concentrés de globules 
rouges obtenus après centrifugation. La transfusion des globules blancs peut avoir 
des effets néfastes chez le patient. Par exemple, après transfusion sanguine, les 
globules blancs contenus dans le don sanguin reconnaissent les tissus du patient 
comme étrangers et les attaquent. Ou encore, le patient produit des anticorps 
dirigés contre les globules blancs transfusés. Ces anticorps peuvent présenter des 
problèmes de compatibilité aux cours des prochaines transfusions sanguines. En 
revanche, il a été démontré que la transfusion des globules blancs à un patient 
transplanté peut favoriser l’acceptation de la greffe. 
Nous avons étudié le potentiel du TPD avec le Tri-P(4) à moduler la fonction des 
globules blancs. Nos résultats ont montré que ce traitement inhibait les réactions 
inflammatoires et que le niveau d’inhibition était fortement dépendant de la 
quantité de globules rouges présents pendant le TPD. Les globules rouges 
agissaient en fait comme un bouclier contre les effets néfastes du TPD. Les effets 
induits par le TPD sur les fonctions immunitaires des globules blancs se 
produisaient par un mécanisme complexe qui affecte toutes les sortes de cellules 
(celles qui initient l’inflammation et celles qui répondent aux stimuli). Des 
recherches plus approfondies permettraient de déterminer si le TPD avec le Tri-
P(4) serait efficace pour empêcher des réactions de rejet après transplantation ou 
pour empêcher la formation d’anticorps après transfusion. 
CONCLUSION 
Nos études ont montré que le photosensibilisateur Tri-P(4) est supérieur à tous les 
autres photosensibilisateurs testés pour inactiver les agents pathogéniques dans 
les produits sanguins de globules rouges. Cependant, malgré les résultats très 
prometteurs concernant la décontamination des concentrés de globules rouges, la 
qualité thérapeutique du produit sanguin après le traitement photodynamique 
reste préoccupante. C’est la raison pour laquelle les recherches de 
développement du TPD avec la porphyrine Tri-P(4) pour l’inactivation 
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pathogénique dans les concentrés de globules rouges ne seront pas poursuivies. 
Néanmoins, les études effectuées avec le photosensibilisateur Tri-P(4) ont permis 
de découvrir d’autres potentiels. Grace à sa capacité à inactiver les bactéries, tout 
en épargnant les cellules souches, le TPD avec le Tri-P(4) pourrait être fortement 
utile pour la décontamination d’autres sources de cellules souches comme celles 
des menstrues ou de la moelle osseuse. Par ailleurs, ses effets sur les globules 
blancs pourraient permettre la prévention des effets néfastes liés à la transfusion 
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